data_1gxe_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1gxe _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.471 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.491 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.427 HG12 ' HB3' ' A' ' 120' ' ' ASP . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.9 t60 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.521 HD12 HG12 ' A' ' 33' ' ' ILE . 6.8 mt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.526 HG12 ' CE2' ' A' ' 96' ' ' PHE . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HB ' HD21 ' A' ' 27' ' ' LEU . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.414 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 21' ' ' VAL . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.451 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.403 ' CG2' ' OG ' ' A' ' 94' ' ' SER . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.405 ' O ' HG12 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 15' ' ' ILE . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.588 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.3 tttt . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 110.45 -0.635 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.431 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.16 0.505 . . . . 0.0 110.085 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.404 HG21 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.52 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.439 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.526 ' CE2' HG12 ' A' ' 19' ' ' ILE . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.282 0.563 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.422 ' HB2' ' CD2' ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.588 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.491 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . 0.413 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.471 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.427 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.469 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.484 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.414 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 120.65 0.262 . . . . 0.0 110.927 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.545 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.414 ' O ' ' N ' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.548 ' HA ' HG21 ' A' ' 33' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.414 ' N ' ' O ' ' A' ' 6' ' ' LYS . 12.0 t60 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.447 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 8.5 mt . . . . . 0 N--CA 1.493 1.712 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.491 ' N ' ' O ' ' A' ' 16' ' ' PRO . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.438 HG13 HD12 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.402 HG11 ' HA ' ' A' ' 128' ' ' VAL . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.42 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.438 HD12 HG13 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.476 ' HA ' ' HB ' ' A' ' 97' ' ' THR . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.558 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.402 ' O ' HG21 ' A' ' 31' ' ' VAL . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.548 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.476 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.653 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.447 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.433 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.223 0.535 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.402 ' OG ' ' NE1' ' A' ' 43' ' ' TRP . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.41 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.558 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 . . . . . 0 N--CA 1.494 1.766 0 CA-C-O 121.239 0.542 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.461 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.653 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.447 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.545 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.521 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . 0.43 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.463 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.42 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 129' ' ' ILE . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.455 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.509 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.515 HG21 ' CD1' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.443 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 1.8 t60 . . . . . 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.515 ' CD1' HG21 ' A' ' 7' ' ' ILE . 7.6 mt . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 120.857 0.361 . . . . 0.0 110.126 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.52 ' HB2' HD11 ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.462 ' N ' ' O ' ' A' ' 16' ' ' PRO . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.447 ' CG1' ' CD1' ' A' ' 27' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.447 ' CD1' ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.461 ' HA ' ' HB ' ' A' ' 97' ' ' THR . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.408 HG12 HD12 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 34' ' ' SER . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.471 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.614 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.484 0.949 0 N-CA-C 110.393 -0.657 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' N ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.219 0.533 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.44 ' CG2' ' HB3' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.44 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.42 ' OG ' ' NE1' ' A' ' 43' ' ' TRP . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.545 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.461 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.251 0.548 . . . . 0.0 110.406 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.47 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.412 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.614 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.437 ' CG2' HD13 ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.509 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.455 ' CG1' ' HA ' ' A' ' 4' ' ' PRO . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.51 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.499 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.507 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HA ' HG21 ' A' ' 33' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.2 p-80 . . . . . 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.444 HD12 HG12 ' A' ' 33' ' ' ILE . 2.2 mt . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.441 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.441 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 4.3 t30 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.439 ' CD2' HG13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.553 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.473 HG22 HD11 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.449 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 42' ' ' ILE . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.572 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.483 0.891 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.167 0.508 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.422 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.422 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.402 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.553 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.449 ' HB3' HG21 ' A' ' 128' ' ' VAL . 0.9 OUTLIER . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.76 0.314 . . . . 0.0 111.52 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' CE2' ' A' ' 109' ' ' TYR . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.463 ' O ' ' N ' ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.572 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.446 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.507 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.499 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.468 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.463 ' N ' ' O ' ' A' ' 109' ' ' TYR . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.426 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.433 ' CB ' ' CE1' ' A' ' 8' ' ' HIS . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.482 ' HA ' ' CG2' ' A' ' 33' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.433 ' CE1' ' CB ' ' A' ' 6' ' ' LYS . 3.3 p-80 . . . . . 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.418 HD12 HG12 ' A' ' 33' ' ' ILE . 6.7 mt . . . . . 0 N--CA 1.493 1.713 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' N ' ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.458 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.476 HG12 ' CE2' ' A' ' 96' ' ' PHE . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.427 ' HB ' HD21 ' A' ' 27' ' ' LEU . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.432 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.425 ' HA3' ' HA3' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.432 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.452 ' CD1' ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.452 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.448 ' O ' HG21 ' A' ' 31' ' ' VAL . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.482 ' CG2' ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HA ' ' O ' ' A' ' 91' ' ' LYS . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.42 ' HA ' ' OD1' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.48 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.601 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.447 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.424 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.982 0 N-CA-C 110.471 -0.626 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.286 0.565 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.443 ' CG2' ' CB ' ' A' ' 93' ' ' ARG . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 38' ' ' ALA . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.443 ' CB ' ' CG2' ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.414 ' CB ' HG22 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.497 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . 0.425 ' HA3' ' HA3' ' A' ' 24' ' ' GLY . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.465 ' HB3' ' CG2' ' A' ' 128' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 121.446 0.641 . . . . 0.0 110.162 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.424 ' CE2' ' HB3' ' A' ' 45' ' ' LYS . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.447 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.601 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.426 ' CG1' ' HA ' ' A' ' 4' ' ' PRO . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.493 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.472 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.557 0.218 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.5 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.544 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.476 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.408 HG21 ' CD1' ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.476 ' CD2' ' HB3' ' A' ' 6' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.408 ' CD1' HG21 ' A' ' 7' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.495 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.52 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.474 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.426 ' CD1' ' N ' ' A' ' 28' ' ' ARG . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.426 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 96' ' ' PHE . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.407 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.413 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.479 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.611 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.933 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.209 0.528 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.431 ' HB2' HG12 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.481 ' CE2' HG12 ' A' ' 19' ' ' ILE . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.506 ' HB3' ' CG2' ' A' ' 128' ' ' VAL . 0.8 OUTLIER . . . . . 0 N--CA 1.504 2.234 0 CA-C-O 121.027 0.442 . . . . 0.0 111.821 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.46 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.611 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.438 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.544 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . 0.42 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.5 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . 0.408 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.476 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.506 ' CG2' ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.443 HG23 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.677 0.275 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.623 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.512 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.4 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.41 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 3.8 t60 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.4 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 3.9 mt . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.412 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.414 ' CD2' HG13 ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.496 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.427 HD11 HG22 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.511 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.624 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.484 0.938 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.442 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 . . . . . 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.325 0.583 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.496 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.222 0.534 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.44 ' CE2' ' HG3' ' A' ' 45' ' ' LYS . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.624 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.512 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . 0.439 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.623 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . 0.424 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.473 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.478 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.41 ' N ' HG22 ' A' ' 117' ' ' VAL . 18.6 mt-10 . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.44 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.496 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HB2' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.536 ' HA ' HG21 ' A' ' 33' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.467 ' CD2' ' HB2' ' A' ' 6' ' ' LYS . 0.7 OUTLIER . . . . . 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 33' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.411 ' CG1' ' CG2' ' A' ' 128' ' ' VAL . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' A' ' 129' ' ' ILE . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.416 ' HA ' HG12 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.405 HD22 HD11 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.589 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.407 ' HA ' HG13 ' A' ' 95' ' ' ILE . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.437 ' O ' HG21 ' A' ' 31' ' ' VAL . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.536 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.41 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.459 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.579 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.429 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt . . . . . 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 N--CA 1.483 0.905 0 N-CA-C 110.281 -0.699 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.434 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 . . . . . 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.229 0.538 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.405 ' CG2' ' CB ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.405 ' CB ' ' CG2' ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.413 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.589 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.231 0.538 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.43 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.411 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.451 ' CG1' ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.496 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.458 ' HB ' ' HD3' ' A' ' 5' ' ' PRO . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.484 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . 0.407 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.473 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.56 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.416 HG12 ' HA ' ' A' ' 23' ' ' ALA . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.467 HG13 ' HA ' ' A' ' 22' ' ' VAL . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.564 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.499 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.419 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' LYS . 5.0 t60 . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.419 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 25.5 mt . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.581 ' HB2' HD11 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.447 HG11 ' HA ' ' A' ' 128' ' ' VAL . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.423 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.441 ' CD2' HG13 ' A' ' 19' ' ' ILE . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.403 ' N ' HD13 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.585 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.427 ' CG2' ' OG ' ' A' ' 94' ' ' SER . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.403 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.413 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.433 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.473 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.566 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 N--CA 1.483 0.908 0 N-CA-C 110.44 -0.639 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.203 0.525 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.448 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.427 ' OG ' ' CG2' ' A' ' 31' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.585 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.247 0.546 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.566 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.499 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . 0.416 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.564 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . 0.452 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.472 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.581 HD11 ' HB2' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.447 ' HA ' HG11 ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.435 HG21 HD11 ' A' ' 129' ' ' ILE . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 120.667 0.27 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.547 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.56 ' HA ' HG21 ' A' ' 33' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.46 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.7 p-80 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.425 HG11 ' HA ' ' A' ' 128' ' ' VAL . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.442 ' CD2' HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.479 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.454 ' O ' HG21 ' A' ' 31' ' ' VAL . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.56 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.481 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.53 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.466 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.415 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 110.442 -0.638 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.296 0.57 . . . . 0.0 109.919 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.443 ' CG2' ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' CG ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.475 ' CG ' ' CG2' ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.433 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.507 ' CE2' HG12 ' A' ' 19' ' ' ILE . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 . . . . . 0 N--CA 1.495 1.792 0 CA-C-O 121.297 0.57 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.415 ' CE2' ' HB3' ' A' ' 45' ' ' LYS . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.466 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.53 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.438 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.547 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . 0.47 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.425 ' HA ' HG11 ' A' ' 21' ' ' VAL . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 16.4 mtt-85 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.244 0.545 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.508 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 5.7 pt20 -145.11 -132.9 0.08 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.814 . . . . 0.0 109.866 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -116.4 148.14 41.08 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.118 . . . . 0.0 110.305 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.471 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.491 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.427 HG12 ' HB3' ' A' ' 120' ' ' ASP . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.569 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 12.9 t60 -125.27 164.5 20.19 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.569 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.1 OUTLIER -119.38 -92.48 0.54 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.236 -0.915 . . . . 0.0 110.897 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 13.7 t70 -120.1 -12.69 9.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.955 -1.09 . . . . 0.0 111.758 -178.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.488 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER -170.19 -61.77 0.0 OUTLIER Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.714 -1.241 . . . . 0.0 112.422 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.488 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 40.4 Cg_endo -67.32 -11.79 33.48 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.196 1.103 . . . . 0.0 111.434 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 8' ' ' HIS . . . 44.74 48.4 9.09 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.8 ttm180 -128.03 99.2 5.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.208 -1.172 . . . . 0.0 110.516 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.521 HD12 HG12 ' A' ' 33' ' ' ILE . 6.8 mt -81.6 119.92 76.69 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.382 -0.824 . . . . 0.0 109.634 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.526 HG12 ' CE2' ' A' ' 96' ' ' PHE . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HB ' HD21 ' A' ' 27' ' ' LEU . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.414 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.619 HD21 ' HB ' ' A' ' 21' ' ' VAL . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.451 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.403 ' CG2' ' OG ' ' A' ' 94' ' ' SER . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.513 ' HG2' ' HB3' ' A' ' 9' ' ' LEU . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 15' ' ' ILE . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.588 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.3 tttt -109.15 151.46 26.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.81 129.97 33.26 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.356 -0.84 . . . . 0.0 110.138 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.9 mm -104.98 -1.09 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.301 -0.874 . . . . 0.0 110.605 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 66.1 p 44.29 59.25 3.34 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.415 -0.803 . . . . 0.0 110.913 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -97.54 -73.63 0.6 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 110.152 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 174.75 98.97 0.11 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -154.66 -158.39 0.85 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.365 -1.079 . . . . 0.0 110.164 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.1 -159.96 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.35 -0.844 . . . . 0.0 110.437 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -51.59 173.23 0.13 Allowed Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.61 -0.682 . . . . 0.0 110.526 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.56 166.91 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.816 1.429 . . . . 0.0 110.505 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -158.93 149.07 19.4 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.845 . . . . 0.0 110.206 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.6 73.85 16.78 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.388 -0.82 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.0 -170.74 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.992 1.522 . . . . 0.0 110.456 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -89.42 138.93 28.28 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.199 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.09 96.31 0.94 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.684 1.36 . . . . 0.0 110.45 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.431 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.88 30.73 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.25 -37.78 37.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.35 -0.844 . . . . 0.0 110.186 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -86.31 -167.27 1.81 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.35 -0.844 . . . . 0.0 110.142 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.39 -167.03 2.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.399 -0.813 . . . . 0.0 110.224 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.0 t-105 -104.69 74.5 1.15 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.439 -0.788 . . . . 0.0 110.151 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.423 ' O ' ' N ' ' A' ' 74' ' ' ASP . 57.6 t -67.4 -18.03 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.336 -0.852 . . . . 0.0 110.36 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 21.2 t80 52.89 -90.33 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.415 -0.803 . . . . 0.0 110.439 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 72' ' ' VAL . 2.5 p30 -69.35 -163.99 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.091 -1.006 . . . . 0.0 110.147 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -97.97 128.39 44.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.281 -0.887 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.29 99.75 0.15 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.319 -0.863 . . . . 0.0 110.18 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -84.18 -35.03 23.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.825 . . . . 0.0 110.148 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.68 84.09 6.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 110.149 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 3.8 m -83.32 -72.74 0.44 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.381 -0.825 . . . . 0.0 110.225 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -69.47 105.73 2.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.378 -0.826 . . . . 0.0 110.289 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.67 -162.42 0.13 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.327 -0.858 . . . . 0.0 110.025 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -82.69 -27.91 30.93 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.361 -0.837 . . . . 0.0 110.246 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -159.11 38.6 0.5 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 13.4 ttt-85 -111.89 -62.5 1.55 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.347 -1.09 . . . . 0.0 110.191 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.97 138.16 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.355 -0.84 . . . . 0.0 110.176 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.28 106.91 10.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.327 -0.858 . . . . 0.0 110.085 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.404 HG21 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.52 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.439 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.526 ' CE2' HG12 ' A' ' 19' ' ' ILE . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -173.48 28.07 0.09 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.467 ' O ' HG12 ' A' ' 21' ' ' VAL . . . -70.89 84.31 0.67 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.529 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -87.86 -173.7 4.4 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -0.861 . . . . 0.0 110.581 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -28.96 19.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.466 -0.771 . . . . 0.0 110.324 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -64.33 -28.63 69.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.378 -0.826 . . . . 0.0 109.809 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -32.36 18.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.452 -0.78 . . . . 0.0 110.014 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -50.59 163.23 0.19 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.415 -0.803 . . . . 0.0 110.554 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.422 ' HB2' ' CD2' ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.588 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.491 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.413 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.508 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.427 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.469 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.484 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.414 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.6 mtm-85 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.208 0.527 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.526 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.6 OUTLIER -61.38 -159.89 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.318 -0.864 . . . . 0.0 110.354 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -81.46 150.46 67.1 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.209 -0.932 . . . . 0.0 110.927 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.521 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.545 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.414 ' O ' ' N ' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.548 ' HA ' HG21 ' A' ' 33' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 12.0 t60 -125.43 161.32 27.33 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.537 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -124.11 -98.23 0.43 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.413 -0.804 . . . . 0.0 110.357 179.434 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.434 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 12.5 t70 -109.62 -20.8 12.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.761 -1.212 . . . . 0.0 111.21 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.504 ' HB3' ' CD ' ' A' ' 12' ' ' PRO . 1.8 t -153.66 -66.8 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 120.891 -1.131 . . . . 0.0 111.846 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.504 ' CD ' ' HB3' ' A' ' 11' ' ' CYS . 41.6 Cg_endo -68.51 -87.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 122.833 0.912 . . . . 0.0 110.828 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.508 ' N ' HD13 ' A' ' 9' ' ' LEU . . . 121.73 49.9 0.26 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.6 OUTLIER -118.3 93.84 4.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.575 -0.956 . . . . 0.0 109.33 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.447 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 8.5 mt -79.37 113.02 33.15 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.491 ' N ' ' O ' ' A' ' 16' ' ' PRO . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.438 HG13 HD12 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.425 ' CG1' ' CB ' ' A' ' 101' ' ' ALA . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.42 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.438 HD12 HG13 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.476 ' HA ' ' HB ' ' A' ' 97' ' ' THR . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.558 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.402 ' O ' HG21 ' A' ' 31' ' ' VAL . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.548 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.476 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.435 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.653 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.447 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER -120.88 147.69 45.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.08 119.05 16.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.396 -0.815 . . . . 0.0 110.085 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.0 mt -103.45 -19.97 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.387 -0.821 . . . . 0.0 110.397 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.403 HG21 ' N ' ' A' ' 49' ' ' GLN . 6.1 t -54.53 -30.75 54.68 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.27 -0.894 . . . . 0.0 110.535 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.403 ' N ' HG21 ' A' ' 48' ' ' THR . 1.1 tt0 51.17 38.76 21.91 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.365 -0.834 . . . . 0.0 110.593 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -138.23 -110.06 0.92 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -129.51 -68.76 0.71 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.331 -1.099 . . . . 0.0 110.241 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.91 -160.38 0.99 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.862 . . . . 0.0 110.221 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -92.66 166.71 16.16 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.562 -0.711 . . . . 0.0 110.257 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.91 167.09 26.86 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.862 1.454 . . . . 0.0 110.403 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.06 109.36 18.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 110.154 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.1 ttt-85 -118.43 73.8 11.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.457 -0.777 . . . . 0.0 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.88 155.55 53.28 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.005 1.529 . . . . 0.0 110.437 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.71 149.84 71.53 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.305 -0.872 . . . . 0.0 110.198 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.64 116.33 4.64 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.709 1.373 . . . . 0.0 110.435 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.433 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -152.02 74.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 70' ' ' GLU . 1.4 t 52.77 70.05 0.62 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.383 -0.823 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.0 t70 55.4 -87.04 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.481 -0.762 . . . . 0.0 110.602 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 68' ' ' SER . 3.0 mm-40 -65.21 -170.24 0.06 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.015 -1.053 . . . . 0.0 110.19 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.3 t-105 -111.42 77.38 1.04 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.3 -0.875 . . . . 0.0 110.232 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' A' ' 73' ' ' PHE . 60.2 t -79.82 -8.37 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.38 -0.825 . . . . 0.0 110.536 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.493 ' CG ' ' O ' ' A' ' 72' ' ' VAL . 39.2 p90 37.52 -164.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 CA-C-O 121.341 0.591 . . . . 0.0 111.871 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -149.08 -161.98 1.46 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.188 -0.945 . . . . 0.0 110.332 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 mttt -53.77 177.96 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.35 -0.844 . . . . 0.0 110.382 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.9 tptm 60.51 156.44 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.445 -0.785 . . . . 0.0 110.279 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.4 pp -170.41 -177.16 2.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.241 -0.912 . . . . 0.0 110.315 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 127.57 36.36 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.414 -0.804 . . . . 0.0 110.183 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.49 -176.73 0.25 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.4 -0.813 . . . . 0.0 110.203 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -119.2 -175.97 3.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.39 -0.819 . . . . 0.0 110.243 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.8 t -172.77 -156.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 0.0 110.027 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.423 ' N ' ' OG1' ' A' ' 81' ' ' THR . 3.3 tt0 66.5 -66.06 0.19 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.445 -0.785 . . . . 0.0 109.401 -179.191 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -102.45 -21.08 10.95 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.082 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 11.1 mtt85 -91.85 -79.7 0.37 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.337 -1.096 . . . . 0.0 110.312 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.7 p -122.13 121.01 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.145 -0.972 . . . . 0.0 110.206 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.19 115.69 29.67 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.402 ' OG ' ' NE1' ' A' ' 43' ' ' TRP . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.41 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.558 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.9 28.33 0.1 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.425 ' CB ' ' CG1' ' A' ' 21' ' ' VAL . . . -69.2 85.77 0.38 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.348 -1.089 . . . . 0.0 109.662 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -90.11 174.64 7.52 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.405 -0.809 . . . . 0.0 110.449 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.21 -29.72 23.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.339 -0.851 . . . . 0.0 110.362 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -70.94 -21.0 62.4 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.424 -0.797 . . . . 0.0 110.127 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -87.17 -33.05 19.52 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.375 -0.828 . . . . 0.0 110.032 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.8 tt0 -52.76 165.68 0.26 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.359 -0.838 . . . . 0.0 110.456 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.461 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.653 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.447 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.545 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.526 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.43 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.463 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.42 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.422 HG21 HD11 ' A' ' 129' ' ' ILE . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.232 0.539 . . . . 0.0 110.178 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.486 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 8.5 pt20 -85.91 -142.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.385 -0.822 . . . . 0.0 110.219 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -117.92 150.35 47.06 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.101 -0.999 . . . . 0.0 110.299 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.455 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.509 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.515 HG21 ' CD1' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.56 ' CD2' ' O ' ' A' ' 9' ' ' LEU . 1.8 t60 -126.95 157.85 38.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.56 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -120.25 -115.98 0.32 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.227 -0.92 . . . . 0.0 110.776 179.695 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.41 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 2.3 t0 -73.74 -43.16 59.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.462 -1.399 . . . . 0.0 108.984 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.606 ' CB ' ' HD3' ' A' ' 12' ' ' PRO . 0.1 OUTLIER 175.44 -57.97 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.799 -0.563 . . . . 0.0 110.536 179.211 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.606 ' HD3' ' CB ' ' A' ' 11' ' ' CYS . 54.9 Cg_endo -88.48 154.0 6.5 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.352 1.185 . . . . 0.0 111.252 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.479 ' O ' ' C ' ' A' ' 14' ' ' ARG . . . 55.21 51.69 52.42 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 178.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.484 ' O ' HD22 ' A' ' 9' ' ' LEU . 1.4 ptp85 -32.15 -93.22 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.571 -0.958 . . . . 0.0 111.531 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.515 ' CD1' HG21 ' A' ' 7' ' ' ILE . 7.6 mt -140.47 86.52 12.4 Favored Pre-proline 0 N--CA 1.488 1.435 0 O-C-N 120.324 -1.485 . . . . 0.0 110.126 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.52 ' HB2' HD11 ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.462 ' N ' ' O ' ' A' ' 16' ' ' PRO . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.447 ' CG1' ' CD1' ' A' ' 27' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.4 ' CG1' ' CB ' ' A' ' 101' ' ' ALA . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.447 ' CD1' ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.461 ' HA ' ' HB ' ' A' ' 97' ' ' THR . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.545 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.408 HG12 HD12 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.401 ' HB3' ' HB2' ' A' ' 2' ' ' GLN . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 34' ' ' SER . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.471 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.614 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt -127.31 156.45 41.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.5 150.27 49.73 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 76.0 mt -101.51 25.5 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.477 -0.764 . . . . 0.0 109.971 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 67.3 p -74.74 -4.77 39.48 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.368 -0.833 . . . . 0.0 110.567 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 54.68 -151.51 0.37 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.201 -0.937 . . . . 0.0 110.219 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -53.75 -85.05 0.03 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 51.91 -167.52 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.307 -1.113 . . . . 0.0 110.329 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.86 -160.94 0.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.245 -0.909 . . . . 0.0 110.412 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.73 168.96 4.76 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.53 -0.731 . . . . 0.0 110.123 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.75 166.85 28.71 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.799 1.421 . . . . 0.0 110.457 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -116.95 143.74 45.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.08 86.14 13.39 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.366 -0.834 . . . . 0.0 110.351 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.03 169.19 22.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.834 1.439 . . . . 0.0 110.334 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -138.13 120.26 10.76 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 110.129 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.62 116.51 4.74 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.707 1.372 . . . . 0.0 110.393 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' N ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -159.11 32.62 0.21 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.41 97.26 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.402 -0.811 . . . . 0.0 110.46 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -86.69 53.35 2.79 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.272 -0.892 . . . . 0.0 110.329 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -123.58 -167.29 1.59 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.322 -0.861 . . . . 0.0 110.168 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.2 t-105 -103.24 127.66 50.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.258 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.5 t -110.73 162.14 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 110.202 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 31.7 p90 -141.68 -148.63 0.24 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.492 -0.755 . . . . 0.0 109.963 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -51.23 -63.07 1.25 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.106 -0.996 . . . . 0.0 110.724 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.01 96.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.276 -0.89 . . . . 0.0 110.215 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 37.9 tttp -74.15 119.18 18.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.387 -0.821 . . . . 0.0 110.272 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.26 67.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.327 -0.858 . . . . 0.0 110.239 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.8 pp -167.84 159.54 11.68 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.387 -0.821 . . . . 0.0 110.212 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.8 m -146.84 144.31 29.22 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 110.213 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -107.16 72.32 0.87 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 110.192 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.7 t -113.51 -162.56 0.81 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.365 -0.834 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -84.8 73.18 10.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.39 -0.819 . . . . 0.0 109.788 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 126.94 1.2 6.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.5 mmm180 53.28 88.02 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.106 -1.232 . . . . 0.0 110.434 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.5 p -157.34 149.98 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 110.088 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -133.03 94.87 3.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 110.286 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.44 ' CG2' ' HB3' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.44 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.42 ' OG ' ' NE1' ' A' ' 43' ' ' TRP . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.545 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.461 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 179.89 32.22 0.06 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.4 ' CB ' ' CG1' ' A' ' 21' ' ' VAL . . . -69.53 82.0 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.183 -1.187 . . . . 0.0 109.9 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -92.96 -169.75 2.25 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.46 -0.775 . . . . 0.0 110.295 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -54.07 -27.95 35.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.284 -0.885 . . . . 0.0 110.223 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -71.8 -25.72 62.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -0.816 . . . . 0.0 109.998 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -85.3 -37.86 19.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -52.64 153.42 3.16 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.29 -0.881 . . . . 0.0 110.406 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.47 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.412 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.614 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.437 ' CG2' HD13 ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.509 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.486 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.51 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 17' ' ' ASP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.188 0.518 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.471 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 7.3 pt20 -93.29 -142.64 0.22 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.434 -0.791 . . . . 0.0 110.129 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -116.87 150.37 45.72 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.103 -0.998 . . . . 0.0 110.221 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.499 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.507 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HA ' HG21 ' A' ' 33' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.518 ' HA ' ' HA3' ' A' ' 13' ' ' GLY . 2.2 p-80 -125.39 174.75 7.95 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.421 HD13 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -127.11 -98.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.372 -0.83 . . . . 0.0 110.934 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -120.09 -13.5 8.96 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.571 -1.331 . . . . 0.0 112.002 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.58 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.67 -70.51 0.02 OUTLIER Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 120.611 -1.306 . . . . 0.0 112.328 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.58 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 39.3 Cg_endo -66.7 -84.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.008 1.004 . . . . 0.0 110.803 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 8' ' ' HIS . . . 121.56 50.33 0.25 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -134.6 107.54 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.532 -0.981 . . . . 0.0 109.942 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.444 HD12 HG12 ' A' ' 33' ' ' ILE . 2.2 mt -79.38 132.73 61.55 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 0.0 109.527 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.441 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.441 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 4.3 t30 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.439 ' CD2' HG13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.553 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.41 ' HB ' ' CG2' ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.473 HG22 HD11 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.449 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 42' ' ' ILE . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.572 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER -95.44 153.65 17.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -134.88 143.6 47.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.355 -0.84 . . . . 0.0 110.325 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 47' ' ' ILE . 5.3 mp 53.35 26.81 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.439 -0.788 . . . . 0.0 110.317 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.4 p -98.68 -38.81 8.96 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.338 -0.851 . . . . 0.0 110.115 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -107.49 144.51 34.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.8 . . . . 0.0 110.1 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -116.32 -109.54 2.63 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -126.13 150.88 47.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -158.78 0.91 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.384 -0.823 . . . . 0.0 110.223 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.66 162.73 65.44 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.77 166.97 22.97 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.835 1.439 . . . . 0.0 110.595 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.75 -176.31 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.357 -0.84 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -139.47 76.33 31.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.075 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -76.02 -165.55 0.31 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.774 1.407 . . . . 0.0 110.54 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.2 152.68 29.35 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.386 -0.821 . . . . 0.0 110.269 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.06 102.25 1.43 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.745 1.392 . . . . 0.0 110.418 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.69 172.33 10.69 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.0 m -71.36 99.13 1.9 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -0.832 . . . . 0.0 110.149 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -68.16 -165.59 0.05 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.35 -0.844 . . . . 0.0 110.264 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -165.62 1.3 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.403 -0.81 . . . . 0.0 110.355 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.1 t-105 -103.48 131.69 50.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.462 -0.774 . . . . 0.0 110.15 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 98.2 t -113.89 -95.26 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.283 -0.886 . . . . 0.0 110.224 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.2 t80 -172.49 -64.37 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.006 -1.059 . . . . 0.0 110.257 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -85.08 122.56 29.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -167.69 31.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.348 -0.845 . . . . 0.0 110.185 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.3 ttpt -156.23 106.85 2.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.405 -0.809 . . . . 0.0 110.187 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -95.91 51.53 1.26 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.444 -0.785 . . . . 0.0 110.128 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.0 mt -59.66 138.83 57.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.359 -0.838 . . . . 0.0 110.288 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.7 p -60.3 133.01 55.69 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.354 -0.841 . . . . 0.0 110.405 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -83.54 -170.82 3.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.872 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.476 ' O ' ' N ' ' A' ' 83' ' ' GLY . 0.6 OUTLIER 179.99 -27.62 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.269 -0.894 . . . . 0.0 110.648 179.779 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -64.39 76.45 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.285 -0.884 . . . . 0.0 109.295 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 81' ' ' THR . . . 98.36 4.48 57.32 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -178.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -105.14 -78.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.176 -1.191 . . . . 0.0 110.609 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.7 p -84.84 134.31 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.965 . . . . 0.0 110.68 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.13 94.91 3.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.454 -0.779 . . . . 0.0 109.97 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.422 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.422 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.402 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.553 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.403 HG12 ' HB1' ' A' ' 101' ' ' ALA . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 118.63 45.52 0.47 Allowed Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.403 ' HB1' HG12 ' A' ' 98' ' ' VAL . . . -53.58 -82.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.287 -1.125 . . . . 0.0 109.369 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.45 ' HB3' ' N ' ' A' ' 106' ' ' GLU . 1.2 tm-20 -135.58 138.75 43.29 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.291 -0.881 . . . . 0.0 109.56 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.97 -63.23 1.15 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.167 -0.958 . . . . 0.0 111.533 -179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -97.11 -2.18 43.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.216 -0.927 . . . . 0.0 111.971 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.571 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -119.72 -8.88 9.85 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.899 -1.126 . . . . 0.0 111.8 -178.519 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.571 ' C ' ' O ' ' A' ' 105' ' ' ASP . 0.9 OUTLIER 24.01 -121.61 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.559 -0.713 . . . . 0.0 111.52 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.421 ' O ' ' CE2' ' A' ' 109' ' ' TYR . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.463 ' O ' ' N ' ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.572 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.446 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.507 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.499 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.468 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.463 ' N ' ' O ' ' A' ' 109' ' ' TYR . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.449 HG21 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.7 mtt-85 . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.182 0.515 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.436 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 15.8 pt20 -146.7 -155.55 0.63 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.361 -0.837 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -90.55 151.38 44.03 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.373 -0.829 . . . . 0.0 110.219 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.426 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.433 ' CB ' ' CE1' ' A' ' 8' ' ' HIS . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.482 ' HA ' ' CG2' ' A' ' 33' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.433 ' CE1' ' CB ' ' A' ' 6' ' ' LYS . 3.3 p-80 -100.79 175.16 5.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.45 HD13 ' N ' ' A' ' 13' ' ' GLY . 0.2 OUTLIER -116.58 -103.11 0.42 Allowed 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.243 -0.91 . . . . 0.0 110.892 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -102.07 -24.94 13.9 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.6 -1.313 . . . . 0.0 111.045 -179.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.563 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -147.12 -68.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.031 -1.043 . . . . 0.0 111.664 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.563 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 43.6 Cg_endo -70.04 -92.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 122.935 0.966 . . . . 0.0 110.692 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.45 ' N ' HD13 ' A' ' 9' ' ' LEU . . . 114.83 50.34 0.48 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 mtt-85 -106.43 87.4 2.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.374 -1.074 . . . . 0.0 110.435 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.418 HD12 HG12 ' A' ' 33' ' ' ILE . 6.7 mt -80.02 113.33 37.43 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.41 -0.806 . . . . 0.0 109.672 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' N ' ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.458 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.42 ' N ' ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.476 HG12 ' CE2' ' A' ' 96' ' ' PHE . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.427 ' HB ' HD21 ' A' ' 27' ' ' LEU . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.432 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.425 ' HA3' ' HA3' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.432 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.452 ' CD1' ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.452 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.448 ' O ' HG21 ' A' ' 31' ' ' VAL . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.482 ' CG2' ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HA ' ' O ' ' A' ' 91' ' ' LYS . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.42 ' HA ' ' OD1' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.48 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.601 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.447 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.424 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -111.85 145.94 38.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.14 138.12 41.67 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.422 -0.799 . . . . 0.0 110.113 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.3 tt -82.25 160.05 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.134 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 74.7 p -102.43 38.03 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.484 -0.76 . . . . 0.0 110.021 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -144.13 179.69 7.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 110.185 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.43 141.78 9.39 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 52.3 52.09 14.95 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.347 -1.09 . . . . 0.0 110.446 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.81 -158.65 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.428 -0.795 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -84.72 170.72 12.76 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.583 -0.698 . . . . 0.0 110.133 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.9 166.85 28.87 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.76 1.4 . . . . 0.0 110.478 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.16 -164.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 110.263 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.41 ' CG ' ' O ' ' A' ' 56' ' ' ARG . 2.0 ptp85 -137.32 87.88 17.71 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.432 -0.793 . . . . 0.0 110.281 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.61 177.73 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.778 1.409 . . . . 0.0 110.491 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -70.56 174.82 3.04 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.383 -0.823 . . . . 0.0 110.148 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 171.46 17.53 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.741 1.39 . . . . 0.0 110.471 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.424 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -166.03 135.61 3.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 55.2 p -79.7 74.36 6.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -72.17 133.4 45.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.826 . . . . 0.0 110.232 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.46 -166.53 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.297 -0.877 . . . . 0.0 110.197 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 73.6 t-105 -97.54 101.27 12.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.344 -0.847 . . . . 0.0 110.279 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.6 p -61.31 168.86 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.143 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -98.12 -60.01 1.64 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.54 -0.725 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t70 52.5 -168.97 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.427 -0.796 . . . . 0.0 110.503 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 91.42 0.06 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.362 -0.836 . . . . 0.0 110.164 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.64 144.26 57.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.398 -0.814 . . . . 0.0 110.029 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.6 tp -107.81 170.26 8.1 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -0.821 . . . . 0.0 110.26 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -138.68 45.86 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.424 -0.797 . . . . 0.0 110.288 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.6 m -153.57 125.0 7.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.863 . . . . 0.0 110.291 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -62.03 -61.82 2.21 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.32 -0.862 . . . . 0.0 110.246 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.29 -178.78 6.56 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 110.183 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -62.25 -31.92 72.55 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.175 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.88 38.95 0.09 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -100.18 -52.04 3.5 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.304 -1.115 . . . . 0.0 109.913 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.06 136.74 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.364 -0.835 . . . . 0.0 109.878 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.54 103.51 7.15 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.266 -0.896 . . . . 0.0 110.358 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.402 HG22 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.443 ' CG2' ' CB ' ' A' ' 93' ' ' ARG . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 38' ' ' ALA . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.443 ' CB ' ' CG2' ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.414 ' CB ' HG22 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.497 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . 0.425 ' HA3' ' HA3' ' A' ' 24' ' ' GLY . . . 125.98 41.28 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.48 -85.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.379 -1.071 . . . . 0.0 109.79 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.406 ' O ' HG23 ' A' ' 128' ' ' VAL . 1.2 mt-10 -134.37 151.1 51.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.736 179.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 8.3 mtmt -95.28 -62.96 1.21 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.125 -0.985 . . . . 0.0 109.887 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -97.63 -2.96 40.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.533 -0.729 . . . . 0.0 110.624 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 106' ' ' GLU . 0.5 OUTLIER -85.08 21.35 1.66 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.185 -0.947 . . . . 0.0 112.436 -178.225 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.465 ' HB3' ' CG2' ' A' ' 128' ' ' VAL . 0.7 OUTLIER -59.32 -148.82 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.888 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 179.407 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.424 ' CE2' ' HB3' ' A' ' 45' ' ' LYS . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.447 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.601 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.436 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.493 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.472 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.283 0.564 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.507 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 5.4 pt20 -102.23 -134.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.334 -0.854 . . . . 0.0 110.112 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -126.91 149.81 70.02 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 120.975 -1.078 . . . . 0.0 110.544 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.5 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.544 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.476 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.408 HG21 ' CD1' ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.476 ' CD2' ' HB3' ' A' ' 6' ' ' LYS . 0.4 OUTLIER -125.44 156.96 38.05 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.546 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -149.78 -157.5 0.82 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.212 -0.93 . . . . 0.0 109.989 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.61 -29.73 62.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.043 -1.036 . . . . 0.0 109.289 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 12.6 m -111.69 75.57 1.43 Allowed Pre-proline 0 C--N 1.304 -1.404 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.9 -176.97 0.66 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.905 1.476 . . . . 0.0 111.093 -179.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 36.65 1.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.841 -1.704 . . . . 0.0 108.841 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 64.03 145.06 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.528 -0.983 . . . . 0.0 110.356 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.408 ' CD1' HG21 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -79.0 149.08 73.02 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.429 -0.794 . . . . 0.0 109.05 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.495 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.52 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.474 ' HB ' ' CB ' ' A' ' 25' ' ' ASN . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.474 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.426 ' CD1' ' N ' ' A' ' 28' ' ' ARG . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.426 ' N ' ' CD1' ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 96' ' ' PHE . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.407 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.413 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.479 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.611 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp -110.35 119.43 39.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.36 113.49 26.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.394 -0.816 . . . . 0.0 110.18 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 3.6 mp -96.42 -23.44 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.403 -0.81 . . . . 0.0 110.167 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 71.9 p 43.82 54.79 5.5 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.629 -0.67 . . . . 0.0 111.004 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.54 -56.11 2.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.895 . . . . 0.0 110.156 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.13 93.75 1.54 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -65.92 -30.64 71.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.296 -1.12 . . . . 0.0 110.309 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.58 -161.09 0.11 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.296 -0.878 . . . . 0.0 110.412 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -127.64 173.63 5.2 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.604 -0.685 . . . . 0.0 110.173 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.53 166.48 29.73 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.855 1.45 . . . . 0.0 110.449 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -121.55 -176.13 3.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.39 -0.819 . . . . 0.0 110.286 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.87 81.22 22.75 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.462 -0.774 . . . . 0.0 110.247 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.7 160.34 31.31 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.907 1.478 . . . . 0.0 110.488 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.13 162.63 52.89 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.328 -0.858 . . . . 0.0 110.141 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.84 161.62 43.25 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.804 1.423 . . . . 0.0 110.467 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -168.8 161.04 10.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.0 t -62.49 102.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.339 -0.85 . . . . 0.0 110.123 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -54.82 -55.81 26.24 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.364 -0.835 . . . . 0.0 110.368 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -154.49 -168.53 2.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.336 -0.852 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 75.3 t-105 -141.28 165.93 26.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.397 -0.814 . . . . 0.0 110.129 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 74' ' ' ASP . 92.3 t -86.95 -83.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.844 . . . . 0.0 110.236 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.403 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 25.7 t80 51.36 -89.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.435 -0.791 . . . . 0.0 110.587 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.456 ' N ' ' O ' ' A' ' 72' ' ' VAL . 72.2 m-20 -53.36 137.67 34.71 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.071 -1.018 . . . . 0.0 110.507 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.85 -70.17 0.73 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.439 -0.788 . . . . 0.0 110.211 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -121.55 56.86 1.04 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 110.197 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 5.8 tt -142.57 84.24 1.85 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.317 -0.864 . . . . 0.0 110.397 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.1 mt -111.86 38.29 2.7 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.342 -0.849 . . . . 0.0 109.992 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.6 p -131.77 54.87 1.9 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 110.433 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -97.25 40.73 1.14 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.351 -0.843 . . . . 0.0 109.939 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.453 ' O ' ' C ' ' A' ' 82' ' ' GLU . 0.3 OUTLIER -89.95 48.68 1.61 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.383 -0.823 . . . . 0.0 110.283 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 81' ' ' THR . 9.1 pt-20 32.77 72.71 0.07 Allowed 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.692 -0.63 . . . . 0.0 111.612 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 127.97 4.34 5.6 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 54.42 87.98 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.969 -1.312 . . . . 0.0 110.522 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.6 p -74.91 145.51 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 110.142 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -115.31 94.77 4.86 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.431 ' HB2' HG12 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.481 ' CE2' HG12 ' A' ' 19' ' ' ILE . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 120.96 40.38 0.56 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.09 -84.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.235 -1.156 . . . . 0.0 109.751 179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.481 ' O ' HG23 ' A' ' 128' ' ' VAL . 1.7 mp0 -134.24 146.68 50.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.187 -0.945 . . . . 0.0 109.522 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 -63.31 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.152 -0.967 . . . . 0.0 110.396 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.26 -3.92 36.33 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.389 -0.819 . . . . 0.0 110.817 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.535 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.4 OUTLIER -76.51 -56.24 4.8 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.226 -0.921 . . . . 0.0 111.483 -178.696 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.535 ' C ' ' O ' ' A' ' 105' ' ' ASP . 0.8 OUTLIER 22.88 -138.37 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.815 -0.553 . . . . 0.0 111.821 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.46 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.611 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.438 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.544 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.42 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.507 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.408 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.476 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.506 ' CG2' ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.443 HG23 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 37.0 ptt85 . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.24 0.543 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.531 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -148.44 -161.08 1.26 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.391 -0.818 . . . . 0.0 110.359 -179.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -82.66 145.81 51.66 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.726 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.623 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.512 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.4 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.533 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.8 t60 -118.67 152.43 36.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.533 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -136.43 -121.22 0.15 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.339 -0.851 . . . . 0.0 110.729 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.432 ' N ' HD11 ' A' ' 9' ' ' LEU . 2.2 t70 -52.01 -30.9 27.31 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.682 -1.261 . . . . 0.0 111.007 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.45 ' O ' ' CE1' ' A' ' 8' ' ' HIS . 0.1 OUTLIER 179.98 -57.4 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.04 -1.037 . . . . 0.0 111.94 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.434 ' HD2' ' N ' ' A' ' 11' ' ' CYS . 38.7 Cg_endo -67.18 -64.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.208 1.109 . . . . 0.0 111.32 -178.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.439 ' HA3' ' HG ' ' A' ' 9' ' ' LEU . . . 120.54 47.8 0.32 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 20.3 mtt180 -106.26 85.31 2.17 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -1.088 . . . . 0.0 110.271 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.4 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 3.9 mt -79.5 121.85 83.17 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.314 -0.866 . . . . 0.0 109.338 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.447 ' CG1' ' O ' ' A' ' 101' ' ' ALA . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.412 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.414 ' CD2' HG13 ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.496 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.427 HD11 HG22 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.511 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.624 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt -112.96 86.03 2.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -69.84 143.29 52.91 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.41 -0.807 . . . . 0.0 109.94 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 50.1 mm -93.77 -52.17 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -0.934 . . . . 0.0 110.085 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 65.5 p 43.05 30.56 0.27 Allowed 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.857 -0.527 . . . . 0.0 110.873 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -117.05 -179.37 3.68 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.419 -0.801 . . . . 0.0 110.302 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 63.07 -89.31 0.06 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -165.78 122.16 1.36 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.363 -1.08 . . . . 0.0 110.165 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.8 -160.36 0.12 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.341 -0.849 . . . . 0.0 110.458 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -89.83 167.23 17.78 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.64 -0.662 . . . . 0.0 110.266 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.46 167.12 27.28 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.813 1.428 . . . . 0.0 110.395 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.05 91.47 0.8 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.391 -0.818 . . . . 0.0 110.171 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 56' ' ' ARG . 5.6 ptp85 -139.6 73.67 34.84 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.31 -0.869 . . . . 0.0 110.238 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.22 139.52 18.91 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.855 1.45 . . . . 0.0 110.436 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.09 128.92 17.78 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.328 -0.858 . . . . 0.0 110.174 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.28 94.93 0.83 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.699 1.368 . . . . 0.0 110.414 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.442 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -62.1 -174.9 0.06 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -109.15 43.05 1.32 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.289 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -75.69 147.19 39.59 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.379 -0.825 . . . . 0.0 110.153 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.18 -169.79 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.8 t-105 -93.5 146.16 23.98 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.432 -0.793 . . . . 0.0 110.203 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.95 161.6 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.376 -0.828 . . . . 0.0 110.173 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -97.85 -64.38 1.04 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -0.825 . . . . 0.0 110.219 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.92 -179.69 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.397 -0.814 . . . . 0.0 110.469 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.8 ttpt -124.65 -4.05 7.72 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.345 -0.847 . . . . 0.0 110.733 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 52.38 63.37 2.27 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.13 -0.981 . . . . 0.0 110.394 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -168.67 77.38 0.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.346 -0.847 . . . . 0.0 110.103 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.5 pp -167.8 -179.62 4.33 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.364 -0.835 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.0 p -132.01 137.37 47.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.352 -0.842 . . . . 0.0 110.22 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -109.94 41.48 1.7 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.347 -0.845 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -135.06 52.69 2.02 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.165 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 52.93 26.58 4.78 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.342 -0.849 . . . . 0.0 110.241 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 66.15 54.98 21.1 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.57 -60.44 1.66 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.428 -1.042 . . . . 0.0 110.384 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.42 ' HA ' ' CG2' ' A' ' 98' ' ' VAL . 7.7 p -106.83 144.9 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.332 -0.855 . . . . 0.0 110.505 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -129.06 97.76 4.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.417 -0.802 . . . . 0.0 109.989 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.496 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.42 ' CG2' ' HA ' ' A' ' 85' ' ' VAL . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -171.79 26.74 0.1 OUTLIER Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.447 ' O ' ' CG1' ' A' ' 21' ' ' VAL . . . -74.8 87.37 2.24 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.399 -1.059 . . . . 0.0 109.369 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -99.52 -169.7 1.79 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.9 tttt -54.57 -37.38 65.42 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.447 -0.783 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.407 ' HG3' ' N ' ' A' ' 105' ' ' ASP . 0.7 OUTLIER -59.67 -20.97 59.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.316 -0.865 . . . . 0.0 110.12 179.697 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . 0.407 ' N ' ' HG3' ' A' ' 104' ' ' GLU . 0.7 OUTLIER -93.37 -23.44 18.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.066 179.66 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -51.2 166.28 0.11 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.352 -0.842 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.44 ' CE2' ' HG3' ' A' ' 45' ' ' LYS . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.44 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.624 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.512 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.439 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.623 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.424 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.473 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.478 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.412 ' CG1' ' HA ' ' A' ' 23' ' ' ALA . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.22 0.534 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.505 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.5 OUTLIER -161.18 -102.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.41 ' N ' HG22 ' A' ' 117' ' ' VAL . 18.6 mt-10 -126.3 150.35 69.8 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.842 -1.161 . . . . 0.0 110.234 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.44 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.496 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HB2' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' HA ' HG21 ' A' ' 33' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.467 ' CD2' ' HB2' ' A' ' 6' ' ' LYS . 0.7 OUTLIER -125.72 167.3 15.34 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.551 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 0.0 OUTLIER -148.14 -153.31 0.48 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.373 -0.83 . . . . 0.0 109.864 -179.775 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -54.24 -31.44 53.41 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.008 -1.058 . . . . 0.0 108.998 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 4.6 t -111.73 76.87 1.71 Allowed Pre-proline 0 C--N 1.304 -1.397 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.81 -166.48 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 124.0 1.526 . . . . 0.0 111.141 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.45 ' O ' ' HB2' ' A' ' 14' ' ' ARG . . . 116.32 33.71 1.43 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 13' ' ' GLY . 4.7 mmt85 60.88 145.29 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.645 -0.915 . . . . 0.0 110.482 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.438 HD13 HG21 ' A' ' 33' ' ' ILE . 0.9 OUTLIER -79.17 139.88 56.74 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.276 -0.89 . . . . 0.0 109.196 179.839 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' CG1' ' O ' ' A' ' 101' ' ' ALA . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' A' ' 129' ' ' ILE . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.416 ' HA ' HG12 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.405 HD22 HD11 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.589 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.407 ' HA ' HG13 ' A' ' 95' ' ' ILE . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.437 ' O ' HG21 ' A' ' 31' ' ' VAL . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.536 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.414 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.41 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.459 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.579 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.429 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt -105.26 128.18 53.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -113.09 92.01 3.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.294 -0.879 . . . . 0.0 110.287 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.3 mt -103.56 -16.96 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.486 -0.759 . . . . 0.0 110.08 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.9 t -56.08 -23.15 32.02 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.345 -0.847 . . . . 0.0 110.571 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -128.64 -169.97 2.17 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.26 -0.9 . . . . 0.0 110.291 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.65 -34.68 4.89 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -166.44 -60.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.314 -1.109 . . . . 0.0 110.268 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -158.44 0.24 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.308 -0.87 . . . . 0.0 110.454 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -127.96 170.23 10.81 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.571 -0.706 . . . . 0.0 110.256 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.25 166.31 30.29 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.761 1.401 . . . . 0.0 110.402 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.32 92.48 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.347 -0.846 . . . . 0.0 110.537 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.3 ptm180 -125.16 73.8 66.68 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.402 -0.812 . . . . 0.0 110.247 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.92 140.87 20.76 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.881 1.464 . . . . 0.0 110.292 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.99 155.85 80.96 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.311 -0.868 . . . . 0.0 110.247 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.09 105.19 1.91 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.821 1.432 . . . . 0.0 110.281 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.434 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -104.37 -165.18 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.32 35.15 2.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.368 -0.832 . . . . 0.0 110.281 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -85.75 -179.05 6.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 110.166 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -124.29 -174.5 3.02 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.328 -0.857 . . . . 0.0 110.259 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 71.6 t-105 -102.03 141.99 34.0 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.395 -0.816 . . . . 0.0 110.276 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 60.3 t -94.34 166.91 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.415 -0.803 . . . . 0.0 110.13 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -49.99 14.76 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 0.0 110.101 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.9 p30 -133.4 63.36 1.63 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.345 -0.847 . . . . 0.0 110.258 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -159.3 88.38 0.87 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.256 -0.902 . . . . 0.0 110.181 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.23 32.41 3.98 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.358 -0.839 . . . . 0.0 110.252 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.21 85.63 1.81 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.368 -0.832 . . . . 0.0 110.132 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 6.9 mp -83.01 96.51 8.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.398 -0.814 . . . . 0.0 110.184 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 67.3 m -60.8 134.16 56.82 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.346 -0.846 . . . . 0.0 110.16 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -114.5 77.1 1.03 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.401 -0.812 . . . . 0.0 110.173 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.2 p -104.38 67.77 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.388 -0.82 . . . . 0.0 110.109 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 54.79 -87.74 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.502 -0.749 . . . . 0.0 110.597 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -103.76 27.09 21.13 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.7 ttt-85 62.17 127.54 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.363 -1.081 . . . . 0.0 110.423 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.453 ' HA ' ' CG2' ' A' ' 98' ' ' VAL . 7.4 p -60.73 127.16 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.297 -0.877 . . . . 0.0 110.19 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -109.9 102.89 11.62 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.328 -0.857 . . . . 0.0 110.27 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.405 ' CG2' ' CB ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.405 ' CB ' ' CG2' ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.413 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.589 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.453 ' CG2' ' HA ' ' A' ' 85' ' ' VAL . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.28 25.12 0.15 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' A' ' 21' ' ' VAL . . . -74.66 87.5 2.18 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.351 -1.087 . . . . 0.0 109.477 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -168.88 1.37 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.528 -0.732 . . . . 0.0 110.385 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.09 -29.74 22.91 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.377 -0.827 . . . . 0.0 110.299 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -74.35 -22.22 59.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.444 -0.785 . . . . 0.0 110.149 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -85.98 -28.23 24.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.345 -0.847 . . . . 0.0 110.25 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -49.68 169.31 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.329 -0.857 . . . . 0.0 110.722 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.43 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.411 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.579 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.451 ' CG1' ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.496 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.505 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.484 ' CG1' ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.407 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.473 HD12 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.56 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.416 HG12 ' HA ' ' A' ' 23' ' ' ALA . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.467 HG13 ' HA ' ' A' ' 22' ' ' VAL . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.152 0.501 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.485 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 5.0 pt20 -65.7 -144.45 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.446 -0.784 . . . . 0.0 110.079 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -114.11 147.84 38.73 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.087 -1.008 . . . . 0.0 110.262 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.564 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.499 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.419 ' CG2' ' CD1' ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.525 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 5.0 t60 -119.11 152.21 36.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.525 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -137.07 -120.78 0.15 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.219 -0.926 . . . . 0.0 110.968 179.947 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.403 ' H ' ' HB2' ' A' ' 9' ' ' LEU . 6.6 t70 -54.62 -31.6 57.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 111.306 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.446 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 0.1 OUTLIER -175.09 -58.84 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.789 0 C-N-CA 119.084 -1.046 . . . . 0.0 112.023 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 38.1 Cg_endo -66.0 -71.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.21 1.111 . . . . 0.0 111.106 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.429 ' HA3' ' HA ' ' A' ' 8' ' ' HIS . . . 120.64 49.95 0.28 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.474 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.1 OUTLIER -113.89 87.83 2.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.503 -0.998 . . . . 0.0 109.743 179.502 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.419 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 25.5 mt -79.31 110.82 16.45 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.474 ' HD3' ' O ' ' A' ' 14' ' ' ARG . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.581 ' HB2' HD11 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.447 HG11 ' HA ' ' A' ' 128' ' ' VAL . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.423 ' HA ' ' CG1' ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.441 ' CD2' HG13 ' A' ' 19' ' ' ILE . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.403 ' N ' HD13 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.585 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.427 ' CG2' ' OG ' ' A' ' 94' ' ' SER . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.403 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.413 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.433 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.473 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.566 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -117.09 163.45 16.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.37 91.83 2.71 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.455 -0.778 . . . . 0.0 110.126 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.0 mt -138.38 26.95 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.586 -0.696 . . . . 0.0 109.402 179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.2 t -125.4 39.41 3.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.46 -0.775 . . . . 0.0 110.188 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -62.16 146.78 49.65 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -150.3 -78.66 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -143.19 78.89 1.62 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.373 -1.074 . . . . 0.0 110.232 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.58 -157.68 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.461 -0.774 . . . . 0.0 110.283 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.11 174.06 0.26 Allowed Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.632 -0.667 . . . . 0.0 110.407 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.7 167.24 27.06 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.788 1.415 . . . . 0.0 110.453 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 59.93 106.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.439 -0.788 . . . . 0.0 110.249 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.91 88.42 36.02 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.854 . . . . 0.0 110.329 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.88 165.6 28.24 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.821 1.432 . . . . 0.0 110.458 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.29 87.43 56.39 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.387 -0.821 . . . . 0.0 110.202 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.58 143.03 37.35 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.761 1.401 . . . . 0.0 110.44 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -169.39 -162.43 0.35 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 p 49.19 31.23 3.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.431 -0.793 . . . . 0.0 110.702 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -60.42 -68.73 0.27 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.381 -0.824 . . . . 0.0 110.214 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -77.43 -172.08 2.37 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.324 -0.86 . . . . 0.0 110.075 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.5 t-105 -99.58 96.48 7.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.283 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.3 p -62.37 168.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.356 -0.84 . . . . 0.0 110.311 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -112.19 -165.73 1.02 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.557 -0.715 . . . . 0.0 110.078 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 53.2 p-10 -156.29 -170.72 3.45 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 110.374 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.7 mttm 52.95 -165.91 0.07 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.301 -0.875 . . . . 0.0 110.423 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.67 28.29 7.84 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.358 -0.839 . . . . 0.0 110.468 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -94.7 142.47 27.42 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 110.109 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mp -73.13 -53.18 11.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.169 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 4.7 m -80.6 -9.36 59.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.379 -0.826 . . . . 0.0 110.543 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 55.67 47.71 20.02 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.178 -0.951 . . . . 0.0 110.293 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.6 p -130.05 -78.1 0.54 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.367 -0.833 . . . . 0.0 110.184 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -173.23 38.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 110.027 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 118.38 36.87 0.89 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 52.18 85.45 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.356 -1.084 . . . . 0.0 110.42 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.442 ' HA ' ' CG2' ' A' ' 98' ' ' VAL . 10.1 p -127.26 130.87 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 110.406 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -114.74 110.89 20.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.381 -0.824 . . . . 0.0 110.043 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.448 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.427 ' OG ' ' CG2' ' A' ' 31' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.4 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.585 ' HB3' ' HB3' ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.442 ' CG2' ' HA ' ' A' ' 85' ' ' VAL . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -167.17 24.75 0.13 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.417 ' O ' HG12 ' A' ' 21' ' ' VAL . . . -69.47 86.86 0.45 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.305 -1.115 . . . . 0.0 109.552 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -95.34 -175.99 3.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 0.0 110.456 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -52.81 -32.98 46.93 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -0.856 . . . . 0.0 110.185 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.64 -20.63 66.4 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.431 -0.793 . . . . 0.0 110.08 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.78 -32.19 17.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -0.867 . . . . 0.0 109.908 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -51.71 169.13 0.07 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.38 -0.825 . . . . 0.0 110.412 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.522 ' HB2' ' HB3' ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.566 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.499 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.416 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.564 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.452 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.472 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.581 HD11 ' HB2' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.447 ' HA ' HG11 ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.435 HG21 HD11 ' A' ' 129' ' ' ILE . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 8.0 ptt180 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.279 0.561 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.524 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -145.69 -165.77 2.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.889 . . . . 0.0 110.404 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -79.64 150.95 73.73 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.229 -0.919 . . . . 0.0 110.754 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.547 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.56 ' HA ' HG21 ' A' ' 33' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.46 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.7 p-80 -118.47 174.84 6.02 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.479 HD13 ' N ' ' A' ' 13' ' ' GLY . 0.2 OUTLIER -122.85 -102.77 0.39 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.319 -0.863 . . . . 0.0 110.756 -179.762 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -101.92 -24.38 14.02 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.627 -1.296 . . . . 0.0 111.159 -179.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.544 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.45 -67.23 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 120.992 -1.068 . . . . 0.0 111.758 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.544 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 44.0 Cg_endo -69.66 -93.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.032 1.017 . . . . 0.0 110.568 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.479 ' N ' HD13 ' A' ' 9' ' ' LEU . . . 119.98 50.04 0.29 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 5.2 mtt180 -109.56 91.46 3.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.411 -1.053 . . . . 0.0 110.089 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 2.0 mt -79.57 114.81 48.68 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 126' ' ' VAL . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.499 HG12 ' O ' ' A' ' 101' ' ' ALA . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.442 ' CD2' HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.479 ' HB3' ' HB3' ' A' ' 96' ' ' PHE . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.454 ' O ' HG21 ' A' ' 31' ' ' VAL . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.56 HG21 ' HA ' ' A' ' 7' ' ' ILE . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.481 ' CG2' ' CG2' ' A' ' 111' ' ' VAL . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.53 ' CE3' ' HB ' ' A' ' 111' ' ' VAL . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.466 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.415 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt -124.58 159.12 31.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -131.89 91.43 2.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.526 -0.733 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.1 mt -133.72 28.02 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.574 -0.704 . . . . 0.0 109.364 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.8 t -117.44 30.54 7.23 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.495 -0.753 . . . . 0.0 110.278 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 61.6 mm-40 -101.11 -34.07 9.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.346 -0.847 . . . . 0.0 110.07 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -162.4 146.4 11.88 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -138.45 -64.11 0.53 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.329 -1.101 . . . . 0.0 110.209 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.33 -160.56 0.74 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.234 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -86.2 171.35 10.51 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.59 -0.694 . . . . 0.0 110.269 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.34 166.78 28.75 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.695 1.366 . . . . 0.0 110.389 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -163.45 74.61 0.35 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.373 -0.829 . . . . 0.0 110.34 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.6 ttt180 -119.31 73.75 14.79 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.858 . . . . 0.0 109.96 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.26 -166.49 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.012 1.533 . . . . 0.0 110.556 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -61.6 171.15 1.46 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 110.213 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.06 110.75 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.702 1.37 . . . . 0.0 110.442 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' HD3' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -90.17 157.09 17.89 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.2 t -70.69 78.16 0.6 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.169 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.52 173.25 2.8 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.422 -0.798 . . . . 0.0 110.262 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -121.51 -166.19 1.34 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.418 -0.802 . . . . 0.0 110.168 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 67.2 t-105 -73.7 174.86 7.78 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.335 -0.853 . . . . 0.0 109.914 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 49.6 t -86.86 14.32 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.16 -0.962 . . . . 0.0 110.838 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -56.11 -173.08 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.063 -1.023 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -129.69 140.7 51.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.369 -0.832 . . . . 0.0 110.272 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.4 tptp -168.74 -47.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.441 -0.787 . . . . 0.0 110.132 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 154.77 32.34 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.352 -0.842 . . . . 0.0 110.201 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.13 177.59 8.94 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -0.873 . . . . 0.0 110.166 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -114.83 43.02 2.04 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.367 -0.833 . . . . 0.0 110.208 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -141.93 50.39 1.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.324 -0.86 . . . . 0.0 110.357 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.04 67.24 3.84 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 25.82 10.47 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.42 -0.8 . . . . 0.0 110.286 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 51.11 82.36 0.06 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.298 -0.876 . . . . 0.0 110.505 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.81 9.62 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 59.64 107.8 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.266 -1.138 . . . . 0.0 110.224 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.415 ' CG1' HG22 ' A' ' 98' ' ' VAL . 3.3 m -68.61 144.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.274 -0.891 . . . . 0.0 109.954 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -97.42 94.74 7.21 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.211 -0.93 . . . . 0.0 109.919 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.443 ' CG2' ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' CG ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.475 ' CG ' ' CG2' ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.433 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.507 ' CE2' HG12 ' A' ' 19' ' ' ILE . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.415 HG22 ' CG1' ' A' ' 85' ' ' VAL . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -177.82 31.53 0.07 OUTLIER Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.499 ' O ' HG12 ' A' ' 21' ' ' VAL . . . -70.23 83.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.333 -1.098 . . . . 0.0 109.699 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -92.51 -169.57 2.25 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.261 -0.899 . . . . 0.0 110.519 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 2.2 mmtt -52.76 -34.35 52.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 110.198 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -60.29 -25.0 65.4 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.361 -0.837 . . . . 0.0 109.799 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -91.27 -32.17 15.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.434 -0.791 . . . . 0.0 109.824 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -52.32 166.34 0.18 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.366 -0.834 . . . . 0.0 110.359 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.415 ' CE2' ' HB3' ' A' ' 45' ' ' LYS . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.466 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.53 ' HB ' ' CE3' ' A' ' 43' ' ' TRP . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.438 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.547 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . 0.47 HG11 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 17' ' ' ASP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.425 ' HA ' HG11 ' A' ' 21' ' ' VAL . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.479 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.428 ' O ' HG22 ' A' ' 33' ' ' ILE . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.943 ' CG2' HD12 ' A' ' 15' ' ' ILE . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.943 HD12 ' CG2' ' A' ' 7' ' ' ILE . 6.8 mt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.805 ' CD1' HD21 ' A' ' 27' ' ' LEU . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 27' ' ' LEU . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 22' ' ' VAL . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.417 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.876 HD12 ' N ' ' A' ' 28' ' ' ARG . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.876 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.727 HD23 ' HB3' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.798 ' HB ' HG23 ' A' ' 15' ' ' ILE . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.422 ' O ' HG12 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.606 HG21 HG11 ' A' ' 113' ' ' VAL . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.854 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.682 HG22 HG22 ' A' ' 112' ' ' THR . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.97 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 109' ' ' TYR . 18.3 tttt . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 110.45 -0.635 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.424 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.16 0.505 . . . . 0.0 110.085 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.484 ' CG2' HG12 ' A' ' 41' ' ' VAL . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.854 ' HB3' HG11 ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.462 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.411 HG22 ' H ' ' A' ' 100' ' ' GLY . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.282 0.563 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.73 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.682 HG22 HG22 ' A' ' 42' ' ' ILE . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.606 HG11 HG21 ' A' ' 33' ' ' ILE . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.498 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.425 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.479 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.429 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.443 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.97 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.417 HG12 ' HB2' ' A' ' 23' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 120.65 0.262 . . . . 0.0 110.927 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.527 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.563 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.964 HG23 HD12 ' A' ' 15' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.418 ' HB3' ' HG3' ' A' ' 6' ' ' LYS . 12.4 t-80 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 33' ' ' ILE . 8.5 mt . . . . . 0 N--CA 1.493 1.712 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.74 ' OD1' HG11 ' A' ' 31' ' ' VAL . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.642 HG23 ' HB ' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.895 HD11 HD11 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.777 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.542 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.895 HD11 HD11 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.714 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.763 HD13 HD13 ' A' ' 19' ' ' ILE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.74 HG11 ' OD1' ' A' ' 17' ' ' ASP . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.489 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.965 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.749 HG11 ' HB2' ' A' ' 94' ' ' SER . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.961 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.425 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 65' ' ' THR . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.223 0.535 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.404 HG23 ' HA ' ' A' ' 94' ' ' SER . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.749 ' HB2' HG11 ' A' ' 41' ' ' VAL . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.488 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 100' ' ' GLY . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.401 ' CG ' ' HA ' ' A' ' 127' ' ' LYS . 2.8 tt0 . . . . . 0 N--CA 1.494 1.766 0 CA-C-O 121.239 0.542 . . . . 0.0 110.456 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.782 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.925 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.66 HG23 ' HG3' ' A' ' 121' ' ' GLN . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 33' ' ' ILE . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.563 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.464 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.66 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.925 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.961 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.642 ' HB ' HG23 ' A' ' 18' ' ' THR . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.495 HG11 ' HE1' ' A' ' 109' ' ' TYR . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.401 ' HA ' ' CG ' ' A' ' 106' ' ' GLU . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.463 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.532 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.698 HG22 ' HB ' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 . . . . . 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.902 ' CD1' HG23 ' A' ' 33' ' ' ILE . 7.6 mt . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 120.857 0.361 . . . . 0.0 110.126 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.647 HG23 ' HB ' ' A' ' 125' ' ' THR . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.991 HD13 HD13 ' A' ' 29' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG22 ' HB3' ' A' ' 127' ' ' LYS . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.599 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' H ' HG22 ' A' ' 22' ' ' VAL . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.9 HD11 ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.691 ' H ' HD12 ' A' ' 27' ' ' LEU . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.991 HD13 HD13 ' A' ' 19' ' ' ILE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 94' ' ' SER . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.446 ' O ' HD11 ' A' ' 15' ' ' ILE . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.902 HG23 ' CD1' ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.665 HG13 ' O ' ' A' ' 41' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.941 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.484 0.949 0 N-CA-C 110.393 -0.657 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' N ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.219 0.533 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.528 HG21 HG12 ' A' ' 41' ' ' VAL . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.895 HG22 ' O ' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.895 ' O ' HG22 ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.648 ' HB2' HG11 ' A' ' 41' ' ' VAL . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.685 ' HB3' HD23 ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.506 ' HA ' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.251 0.548 . . . . 0.0 110.406 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.799 ' HB2' HD23 ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.412 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.949 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 114' ' ' LYS . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.648 HG21 ' CD1' ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.432 ' HD2' HG22 ' A' ' 112' ' ' THR . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.532 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.479 ' HB ' ' HD3' ' A' ' 5' ' ' PRO . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.949 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 71.2 m-20 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.941 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.647 ' HB ' HG23 ' A' ' 18' ' ' THR . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.506 HG13 ' HA ' ' A' ' 106' ' ' GLU . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.622 ' HB3' HG22 ' A' ' 20' ' ' VAL . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 130' ' ' ASP . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.443 ' N ' HG22 ' A' ' 129' ' ' ILE . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.501 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.514 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 1.058 HG23 HD12 ' A' ' 15' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.475 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.2 p-80 . . . . . 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.058 HD12 HG23 ' A' ' 7' ' ' ILE . 2.2 mt . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.491 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.834 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.914 ' O ' HD13 ' A' ' 27' ' ' LEU . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.641 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 22' ' ' VAL . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.452 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 25.6 t-20 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.914 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.754 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.575 HD23 ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.586 ' OD2' HD11 ' A' ' 95' ' ' ILE . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.706 ' HB ' HG23 ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.66 HG23 HD11 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 91' ' ' LYS . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.836 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.875 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.483 0.891 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.167 0.508 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.432 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.836 ' HB3' HG11 ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.586 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.468 ' CG1' HD23 ' A' ' 27' ' ' LEU . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.629 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.9 OUTLIER . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.76 0.314 . . . . 0.0 111.52 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.594 ' O ' HG11 ' A' ' 126' ' ' VAL . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.558 ' HB2' HD23 ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.891 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.514 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.501 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.438 ' C ' HG12 ' A' ' 122' ' ' VAL . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.891 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.875 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.594 HG11 ' O ' ' A' ' 107' ' ' GLY . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.445 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 129' ' ' ILE . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.42 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.615 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.847 ' CG2' HD12 ' A' ' 15' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.615 ' CD2' ' HB3' ' A' ' 6' ' ' LYS . 5.4 p80 . . . . . 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.896 HD11 HG23 ' A' ' 33' ' ' ILE . 6.7 mt . . . . . 0 N--CA 1.493 1.713 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.672 ' O ' HG22 ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.772 ' CA ' HD12 ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.672 HG22 ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.808 ' CG2' HD21 ' A' ' 124' ' ' LEU . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.759 ' O ' HD22 ' A' ' 27' ' ' LEU . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 22' ' ' VAL . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.443 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.887 HD12 ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.887 ' N ' HD12 ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.651 HD23 ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.844 ' HB ' HG23 ' A' ' 15' ' ' ILE . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.896 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.824 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.948 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.439 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.982 0 N-CA-C 110.471 -0.626 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.421 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.286 0.565 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 96' ' ' PHE . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' H ' ' A' ' 92' ' ' ASP . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.561 ' H ' HG23 ' A' ' 90' ' ' THR . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.824 ' HB3' HG11 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.456 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.651 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 27' ' ' LEU . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 24' ' ' GLY . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.926 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 121.446 0.641 . . . . 0.0 110.162 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' HG13 ' A' ' 126' ' ' VAL . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.745 ' HB2' HD23 ' A' ' 124' ' ' LEU . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.956 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 41' ' ' VAL . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.624 HG21 ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.42 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.426 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.4 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.956 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.948 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.568 HG11 ' HE1' ' A' ' 109' ' ' TYR . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.419 ' O ' HG13 ' A' ' 20' ' ' VAL . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.926 HG23 ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.463 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.557 0.218 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.504 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.558 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.546 ' HE2' ' CE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.986 HG23 HD12 ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.546 ' CE1' ' HE2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.986 HD12 HG23 ' A' ' 7' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.703 ' HG2' HG12 ' A' ' 31' ' ' VAL . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.813 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 18' ' ' THR . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.813 ' CG1' HD21 ' A' ' 27' ' ' LEU . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.863 ' O ' HD13 ' A' ' 27' ' ' LEU . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.561 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.431 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.863 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.849 ' N ' HD12 ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.856 HD21 HD11 ' A' ' 124' ' ' LEU . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.703 HG12 ' HG2' ' A' ' 16' ' ' PRO . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.531 ' O ' HD11 ' A' ' 15' ' ' ILE . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.512 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.945 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.933 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.209 0.528 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.747 HG22 ' CD1' ' A' ' 96' ' ' PHE . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.451 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.747 ' CD1' HG22 ' A' ' 87' ' ' VAL . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.913 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.8 OUTLIER . . . . . 0 N--CA 1.504 2.234 0 CA-C-O 121.027 0.442 . . . . 0.0 111.821 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.629 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.68 ' HB2' HD23 ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.874 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.478 HG11 HG21 ' A' ' 33' ' ' ILE . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.558 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.504 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.444 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.874 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.945 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 107' ' ' GLY . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.913 HG23 ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.677 0.275 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.636 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 1.037 HG23 HD12 ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.037 HD12 HG23 ' A' ' 7' ' ' ILE . 3.9 mt . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.664 ' O ' HG22 ' A' ' 18' ' ' THR . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.806 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.664 HG22 ' O ' ' A' ' 16' ' ' PRO . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.866 ' CD1' HD11 ' A' ' 27' ' ' LEU . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.501 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.894 ' CG1' HG22 ' A' ' 128' ' ' VAL . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.582 HG12 ' O ' ' A' ' 22' ' ' VAL . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.592 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.866 HD11 ' CD1' ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.817 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.86 HD21 HD11 ' A' ' 124' ' ' LEU . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.675 ' CG ' HD11 ' A' ' 95' ' ' ILE . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.804 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.464 ' O ' HD11 ' A' ' 15' ' ' ILE . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.665 HD11 ' HB3' ' A' ' 94' ' ' SER . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 38' ' ' ALA . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.817 HG11 ' CB ' ' A' ' 94' ' ' SER . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.953 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.484 0.938 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 . . . . . 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.325 0.583 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.487 HG11 ' HD1' ' A' ' 43' ' ' TRP . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.817 ' CB ' HG11 ' A' ' 41' ' ' VAL . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.675 HD11 ' CG ' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.6 ' HB3' HD23 ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.518 HG22 ' H ' ' A' ' 100' ' ' GLY . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.518 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.222 0.534 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.575 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.658 ' HB2' HD23 ' A' ' 124' ' ' LEU . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.906 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.636 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.461 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.456 ' C ' HG12 ' A' ' 122' ' ' VAL . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.906 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.953 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.831 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.894 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.407 ' N ' HG21 ' A' ' 117' ' ' VAL . 18.6 mt-10 . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.691 ' HD3' ' HE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 1.097 HG23 HD12 ' A' ' 15' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.691 ' HE1' ' HD3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 1.097 HD12 HG23 ' A' ' 7' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 32' ' ' PRO . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.635 HG23 ' CG2' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.928 HG23 HD21 ' A' ' 27' ' ' LEU . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.95 ' CG1' HG22 ' A' ' 128' ' ' VAL . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.584 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.476 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.928 HD21 HG23 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.738 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.719 HD22 HG12 ' A' ' 19' ' ' ILE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 15' ' ' ILE . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.931 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.443 ' HB2' ' HG3' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.61 ' O ' HD12 ' A' ' 42' ' ' ILE . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 40' ' ' THR . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.91 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.405 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt . . . . . 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 N--CA 1.483 0.905 0 N-CA-C 110.281 -0.699 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.419 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 65' ' ' THR . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 . . . . . 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.229 0.538 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.645 HG11 ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.719 HG22 ' O ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.533 ' H ' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.719 ' O ' HG22 ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.884 ' HB3' HG11 ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.68 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.576 HG22 ' H ' ' A' ' 100' ' ' GLY . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.576 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.231 0.538 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.446 ' H ' HG13 ' A' ' 126' ' ' VAL . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.705 ' HB2' HD23 ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 123' ' ' ASN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.912 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.572 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.515 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.507 ' HB ' ' HD3' ' A' ' 5' ' ' PRO . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.912 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.91 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 125' ' ' THR . . . . . 0.635 ' CG2' HG23 ' A' ' 18' ' ' THR . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.727 HG23 HG22 ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.95 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.503 HD12 ' O ' ' A' ' 130' ' ' ASP . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 129' ' ' ILE . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.569 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.954 HG23 HD12 ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' LYS . 7.3 t-80 . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.954 HD12 HG23 ' A' ' 7' ' ' ILE . 25.5 mt . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.711 ' O ' HD12 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.867 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.894 ' O ' HD13 ' A' ' 27' ' ' LEU . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.765 ' HB ' HD22 ' A' ' 27' ' ' LEU . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 22' ' ' VAL . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.511 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.894 HD13 ' O ' ' A' ' 20' ' ' VAL . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.818 ' N ' HD12 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.67 HD23 ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 15' ' ' ILE . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.457 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.662 HG23 HD11 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.419 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HG3' ' O ' ' A' ' 34' ' ' SER . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.825 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.912 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 N--CA 1.483 0.908 0 N-CA-C 110.44 -0.639 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.203 0.525 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.565 HG11 ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.825 ' HB3' HG11 ' A' ' 41' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.535 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.67 ' HB3' HD23 ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.516 HG22 ' H ' ' A' ' 100' ' ' GLY . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.516 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.247 0.546 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.829 ' HB2' HD23 ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.92 ' CG1' HG13 ' A' ' 122' ' ' VAL . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.62 HG11 HG21 ' A' ' 33' ' ' ILE . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.569 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.492 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLN . . . . . 0.409 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.92 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.912 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.789 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.565 HG22 ' CG1' ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 130' ' ' ASP . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.447 ' N ' HG22 ' A' ' 129' ' ' ILE . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 120.667 0.27 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.556 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PRO . . . . . 0.519 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.899 HG23 HD12 ' A' ' 15' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.46 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.7 p-80 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.899 HD12 HG23 ' A' ' 7' ' ' ILE . 2.0 mt . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.653 ' O ' HG22 ' A' ' 18' ' ' THR . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.759 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' PRO . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.922 HG13 HD21 ' A' ' 27' ' ' LEU . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.904 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.419 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.922 HD21 HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.593 ' N ' HD12 ' A' ' 27' ' ' LEU . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.73 HD21 HD11 ' A' ' 124' ' ' LEU . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.74 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.655 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.975 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLN . . . . . 0.456 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.436 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 110.442 -0.638 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.418 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 65' ' ' THR . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.296 0.57 . . . . 0.0 109.919 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.709 HG22 ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.772 ' O ' HG22 ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.74 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.709 ' CD1' HG22 ' A' ' 87' ' ' VAL . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.691 ' CG1' HD23 ' A' ' 27' ' ' LEU . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.454 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 . . . . . 0 N--CA 1.495 1.792 0 CA-C-O 121.297 0.57 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.627 ' HE1' HG11 ' A' ' 126' ' ' VAL . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.526 HG11 ' CD1' ' A' ' 7' ' ' ILE . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.519 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.556 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . 0.417 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.975 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.739 HG23 HG23 ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.427 HG22 ' CG1' ' A' ' 21' ' ' VAL . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 16.4 mtt-85 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.244 0.545 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.535 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 5.7 pt20 -145.11 -132.9 0.08 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.814 . . . . 0.0 109.866 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -116.4 148.14 41.08 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.118 . . . . 0.0 110.305 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.479 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.428 ' O ' HG22 ' A' ' 33' ' ' ILE . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.943 ' CG2' HD12 ' A' ' 15' ' ' ILE . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.569 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 12.9 t60 -125.27 164.5 20.19 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.621 HD23 ' HG2' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -119.38 -92.48 0.54 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.236 -0.915 . . . . 0.0 110.897 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 13.7 t70 -120.1 -12.69 9.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.955 -1.09 . . . . 0.0 111.758 -178.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.488 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER -170.19 -61.77 0.0 OUTLIER Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.714 -1.241 . . . . 0.0 112.422 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.488 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 40.4 Cg_endo -67.32 -11.79 33.48 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.196 1.103 . . . . 0.0 111.434 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 44.74 48.4 9.09 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.8 ttm180 -128.03 99.2 5.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.208 -1.172 . . . . 0.0 110.516 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.943 HD12 ' CG2' ' A' ' 7' ' ' ILE . 6.8 mt -81.6 119.92 76.69 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.382 -0.824 . . . . 0.0 109.634 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.805 ' CD1' HD21 ' A' ' 27' ' ' LEU . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 27' ' ' LEU . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.988 HG11 ' HB3' ' A' ' 101' ' ' ALA . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 22' ' ' VAL . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.417 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.876 HD12 ' N ' ' A' ' 28' ' ' ARG . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.876 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.727 HD23 ' HB3' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.798 ' HB ' HG23 ' A' ' 15' ' ' ILE . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HG2' HD23 ' A' ' 9' ' ' LEU . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.606 HG21 HG11 ' A' ' 113' ' ' VAL . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.854 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.682 HG22 HG22 ' A' ' 112' ' ' THR . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.97 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 109' ' ' TYR . 18.3 tttt -109.15 151.46 26.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.441 ' HB3' HG12 ' A' ' 108' ' ' VAL . . . -135.81 129.97 33.26 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.356 -0.84 . . . . 0.0 110.138 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.447 HG22 ' O ' ' A' ' 47' ' ' ILE . 48.9 mm -104.98 -1.09 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.301 -0.874 . . . . 0.0 110.605 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 66.1 p 44.29 59.25 3.34 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.415 -0.803 . . . . 0.0 110.913 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -97.54 -73.63 0.6 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 110.152 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 174.75 98.97 0.11 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -154.66 -158.39 0.85 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.365 -1.079 . . . . 0.0 110.164 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.1 -159.96 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.35 -0.844 . . . . 0.0 110.437 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.737 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -51.59 173.23 0.13 Allowed Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.61 -0.682 . . . . 0.0 110.526 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.737 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 46.3 Cg_endo -72.56 166.91 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.816 1.429 . . . . 0.0 110.505 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -158.93 149.07 19.4 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.845 . . . . 0.0 110.206 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.6 73.85 16.78 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.388 -0.82 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.0 -170.74 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.992 1.522 . . . . 0.0 110.456 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -89.42 138.93 28.28 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.199 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.09 96.31 0.94 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.684 1.36 . . . . 0.0 110.45 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.424 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.88 30.73 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.25 -37.78 37.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.35 -0.844 . . . . 0.0 110.186 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -86.31 -167.27 1.81 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.35 -0.844 . . . . 0.0 110.142 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.39 -167.03 2.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.399 -0.813 . . . . 0.0 110.224 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.0 t-105 -104.69 74.5 1.15 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.439 -0.788 . . . . 0.0 110.151 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.423 ' O ' ' N ' ' A' ' 74' ' ' ASP . 57.6 t -67.4 -18.03 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.336 -0.852 . . . . 0.0 110.36 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 21.2 t80 52.89 -90.33 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.415 -0.803 . . . . 0.0 110.439 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 72' ' ' VAL . 2.5 p30 -69.35 -163.99 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.091 -1.006 . . . . 0.0 110.147 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -97.97 128.39 44.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.281 -0.887 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.29 99.75 0.15 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.319 -0.863 . . . . 0.0 110.18 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.438 ' HA ' HD13 ' A' ' 77' ' ' LEU . 2.1 mm? -84.18 -35.03 23.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.825 . . . . 0.0 110.148 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.68 84.09 6.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 110.149 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 3.8 m -83.32 -72.74 0.44 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.381 -0.825 . . . . 0.0 110.225 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -69.47 105.73 2.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.378 -0.826 . . . . 0.0 110.289 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.474 HG22 ' H ' ' A' ' 82' ' ' GLU . 0.2 OUTLIER -73.67 -162.42 0.13 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.327 -0.858 . . . . 0.0 110.025 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.474 ' H ' HG22 ' A' ' 81' ' ' THR . 13.5 mt-10 -82.69 -27.91 30.93 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.361 -0.837 . . . . 0.0 110.246 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -159.11 38.6 0.5 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 13.4 ttt-85 -111.89 -62.5 1.55 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.347 -1.09 . . . . 0.0 110.191 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.87 ' HA ' HG23 ' A' ' 98' ' ' VAL . 7.5 p -135.97 138.16 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.355 -0.84 . . . . 0.0 110.176 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.28 106.91 10.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.327 -0.858 . . . . 0.0 110.085 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.484 ' CG2' HG12 ' A' ' 41' ' ' VAL . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.854 ' HB3' HG11 ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.462 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.87 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -173.48 28.07 0.09 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.988 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -70.89 84.31 0.67 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.529 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.415 ' O ' HG21 ' A' ' 128' ' ' VAL . 55.1 mt-10 -87.86 -173.7 4.4 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -0.861 . . . . 0.0 110.581 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -28.96 19.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.466 -0.771 . . . . 0.0 110.324 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -64.33 -28.63 69.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.378 -0.826 . . . . 0.0 109.809 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -32.36 18.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.452 -0.78 . . . . 0.0 110.014 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -50.59 163.23 0.19 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.415 -0.803 . . . . 0.0 110.554 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.441 HG12 ' HB3' ' A' ' 46' ' ' ALA . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.73 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.682 HG22 HG22 ' A' ' 42' ' ' ILE . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.606 HG11 HG21 ' A' ' 33' ' ' ILE . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.498 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.425 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.535 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.429 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.443 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.97 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 101' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.6 mtm-85 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.208 0.527 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.547 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.6 OUTLIER -61.38 -159.89 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.318 -0.864 . . . . 0.0 110.354 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -81.46 150.46 67.1 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.209 -0.932 . . . . 0.0 110.927 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.527 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.563 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.964 HG23 HD12 ' A' ' 15' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.515 ' HA ' ' HA2' ' A' ' 13' ' ' GLY . 12.4 t-80 -125.43 161.32 27.33 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.527 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -124.11 -98.23 0.43 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.413 -0.804 . . . . 0.0 110.357 179.434 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.433 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 12.5 t70 -109.62 -20.8 12.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.761 -1.212 . . . . 0.0 111.21 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.499 ' HB3' ' CD ' ' A' ' 12' ' ' PRO . 1.8 t -153.66 -66.8 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 120.891 -1.131 . . . . 0.0 111.846 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.527 ' HG2' HD11 ' A' ' 9' ' ' LEU . 41.6 Cg_endo -68.51 -87.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 122.833 0.912 . . . . 0.0 110.828 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.515 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 121.73 49.9 0.26 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.422 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.6 OUTLIER -118.3 93.84 4.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.575 -0.956 . . . . 0.0 109.33 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 33' ' ' ILE . 8.5 mt -79.37 113.02 33.15 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.74 ' OD1' HG11 ' A' ' 31' ' ' VAL . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.642 HG23 ' HB ' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.895 HD11 HD11 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.088 HG11 ' HB3' ' A' ' 101' ' ' ALA . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.542 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.895 HD11 HD11 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.714 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.763 HD13 HD13 ' A' ' 19' ' ' ILE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.74 HG11 ' OD1' ' A' ' 17' ' ' ASP . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.489 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.965 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.749 HG11 ' HB2' ' A' ' 94' ' ' SER . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.961 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER -120.88 147.69 45.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.08 119.05 16.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.396 -0.815 . . . . 0.0 110.085 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.0 mt -103.45 -19.97 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.387 -0.821 . . . . 0.0 110.397 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 6.1 t -54.53 -30.75 54.68 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.27 -0.894 . . . . 0.0 110.535 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 51.17 38.76 21.91 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.365 -0.834 . . . . 0.0 110.593 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -138.23 -110.06 0.92 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -129.51 -68.76 0.71 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.331 -1.099 . . . . 0.0 110.241 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.91 -160.38 0.99 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.862 . . . . 0.0 110.221 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.516 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -92.66 166.71 16.16 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.562 -0.711 . . . . 0.0 110.257 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.516 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.8 Cg_endo -75.91 167.09 26.86 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.862 1.454 . . . . 0.0 110.403 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.06 109.36 18.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 110.154 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.1 ttt-85 -118.43 73.8 11.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.457 -0.777 . . . . 0.0 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.88 155.55 53.28 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.005 1.529 . . . . 0.0 110.437 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.71 149.84 71.53 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.305 -0.872 . . . . 0.0 110.198 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.64 116.33 4.64 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.709 1.373 . . . . 0.0 110.435 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.425 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 65' ' ' THR . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -152.02 74.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 70' ' ' GLU . 1.4 t 52.77 70.05 0.62 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.383 -0.823 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.0 t70 55.4 -87.04 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.481 -0.762 . . . . 0.0 110.602 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 68' ' ' SER . 3.0 mm-40 -65.21 -170.24 0.06 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.015 -1.053 . . . . 0.0 110.19 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.3 t-105 -111.42 77.38 1.04 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.3 -0.875 . . . . 0.0 110.232 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' A' ' 73' ' ' PHE . 60.2 t -79.82 -8.37 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.38 -0.825 . . . . 0.0 110.536 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.493 ' CG ' ' O ' ' A' ' 72' ' ' VAL . 39.2 p90 37.52 -164.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 CA-C-O 121.341 0.591 . . . . 0.0 111.871 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -149.08 -161.98 1.46 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.188 -0.945 . . . . 0.0 110.332 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 mttt -53.77 177.96 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.35 -0.844 . . . . 0.0 110.382 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.9 tptm 60.51 156.44 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.445 -0.785 . . . . 0.0 110.279 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.4 pp -170.41 -177.16 2.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.241 -0.912 . . . . 0.0 110.315 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 127.57 36.36 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.414 -0.804 . . . . 0.0 110.183 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.49 -176.73 0.25 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.4 -0.813 . . . . 0.0 110.203 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -119.2 -175.97 3.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.39 -0.819 . . . . 0.0 110.243 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.8 t -172.77 -156.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 0.0 110.027 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.427 ' N ' ' OG1' ' A' ' 81' ' ' THR . 3.3 tt0 66.5 -66.06 0.19 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.445 -0.785 . . . . 0.0 109.401 -179.191 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -102.45 -21.08 10.95 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.082 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 11.1 mtt85 -91.85 -79.7 0.37 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.337 -1.096 . . . . 0.0 110.312 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.888 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.7 p -122.13 121.01 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.145 -0.972 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.19 115.69 29.67 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.404 HG23 ' HA ' ' A' ' 94' ' ' SER . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.749 ' HB2' HG11 ' A' ' 41' ' ' VAL . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.488 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.888 ' HB ' HG23 ' A' ' 85' ' ' VAL . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -172.9 28.33 0.1 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 1.088 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -69.2 85.77 0.38 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.348 -1.089 . . . . 0.0 109.662 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.438 ' O ' HG21 ' A' ' 128' ' ' VAL . 2.9 tp10 -90.11 174.64 7.52 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.405 -0.809 . . . . 0.0 110.449 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.21 -29.72 23.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.339 -0.851 . . . . 0.0 110.362 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -70.94 -21.0 62.4 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.424 -0.797 . . . . 0.0 110.127 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -87.17 -33.05 19.52 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.375 -0.828 . . . . 0.0 110.032 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.401 ' CG ' ' HA ' ' A' ' 127' ' ' LYS . 2.8 tt0 -52.76 165.68 0.26 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.359 -0.838 . . . . 0.0 110.456 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.782 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.925 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.66 HG23 ' HG3' ' A' ' 121' ' ' GLN . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 33' ' ' ILE . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.563 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.547 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.464 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.66 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.925 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.961 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.642 ' HB ' HG23 ' A' ' 18' ' ' THR . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.495 HG11 ' HE1' ' A' ' 109' ' ' TYR . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.401 ' HA ' ' CG ' ' A' ' 106' ' ' GLU . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.232 0.539 . . . . 0.0 110.178 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' HG3' HG21 ' A' ' 117' ' ' VAL . 8.5 pt20 -85.91 -142.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.385 -0.822 . . . . 0.0 110.219 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -117.92 150.35 47.06 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.101 -0.999 . . . . 0.0 110.299 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.463 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.532 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.698 HG22 ' HB ' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' A' ' 9' ' ' LEU . 1.4 t-80 -126.95 157.85 38.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.787 HD21 ' O ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -120.25 -115.98 0.32 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.227 -0.92 . . . . 0.0 110.776 179.695 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.41 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 2.3 t0 -73.74 -43.16 59.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.462 -1.399 . . . . 0.0 108.984 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.617 ' CB ' ' HD3' ' A' ' 12' ' ' PRO . 0.1 OUTLIER 175.44 -57.97 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.799 -0.563 . . . . 0.0 110.536 179.211 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.617 ' HD3' ' CB ' ' A' ' 11' ' ' CYS . 54.9 Cg_endo -88.48 154.0 6.5 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.352 1.185 . . . . 0.0 111.252 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.787 ' O ' HD21 ' A' ' 9' ' ' LEU . . . 55.21 51.69 52.42 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 178.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.479 ' C ' ' O ' ' A' ' 13' ' ' GLY . 1.4 ptp85 -32.15 -93.22 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.571 -0.958 . . . . 0.0 111.531 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.902 ' CD1' HG23 ' A' ' 33' ' ' ILE . 7.6 mt -140.47 86.52 12.4 Favored Pre-proline 0 N--CA 1.488 1.435 0 O-C-N 120.324 -1.485 . . . . 0.0 110.126 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.647 HG23 ' HB ' ' A' ' 125' ' ' THR . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.991 HD13 HD13 ' A' ' 29' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG22 ' HB3' ' A' ' 127' ' ' LYS . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.003 HG11 ' HB3' ' A' ' 101' ' ' ALA . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' H ' HG22 ' A' ' 22' ' ' VAL . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.9 HD11 ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.691 ' H ' HD12 ' A' ' 27' ' ' LEU . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.991 HD13 HD13 ' A' ' 19' ' ' ILE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 94' ' ' SER . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.783 ' HG2' HD23 ' A' ' 9' ' ' LEU . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.902 HG23 ' CD1' ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.417 ' HB3' ' HB2' ' A' ' 2' ' ' GLN . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.665 HG13 ' O ' ' A' ' 41' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.941 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt -127.31 156.45 41.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.5 150.27 49.73 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.625 HG22 ' O ' ' A' ' 47' ' ' ILE . 76.0 mt -101.51 25.5 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.477 -0.764 . . . . 0.0 109.971 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 67.3 p -74.74 -4.77 39.48 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.368 -0.833 . . . . 0.0 110.567 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 54.68 -151.51 0.37 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.201 -0.937 . . . . 0.0 110.219 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -53.75 -85.05 0.03 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 51.91 -167.52 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.307 -1.113 . . . . 0.0 110.329 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.86 -160.94 0.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.245 -0.909 . . . . 0.0 110.412 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.598 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -63.73 168.96 4.76 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.53 -0.731 . . . . 0.0 110.123 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.598 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.1 Cg_endo -73.75 166.85 28.71 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.799 1.421 . . . . 0.0 110.457 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -116.95 143.74 45.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.08 86.14 13.39 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.366 -0.834 . . . . 0.0 110.351 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.03 169.19 22.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.834 1.439 . . . . 0.0 110.334 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -138.13 120.26 10.76 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 110.129 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.62 116.51 4.74 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.707 1.372 . . . . 0.0 110.393 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' N ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -159.11 32.62 0.21 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.41 97.26 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.402 -0.811 . . . . 0.0 110.46 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -86.69 53.35 2.79 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.272 -0.892 . . . . 0.0 110.329 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -123.58 -167.29 1.59 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.322 -0.861 . . . . 0.0 110.168 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.2 t-105 -103.24 127.66 50.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.258 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 73' ' ' PHE . 98.5 t -110.73 162.14 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 110.202 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 31.7 p90 -141.68 -148.63 0.24 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.492 -0.755 . . . . 0.0 109.963 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -51.23 -63.07 1.25 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.106 -0.996 . . . . 0.0 110.724 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.01 96.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.276 -0.89 . . . . 0.0 110.215 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 37.9 tttp -74.15 119.18 18.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.387 -0.821 . . . . 0.0 110.272 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.26 67.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.327 -0.858 . . . . 0.0 110.239 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.8 pp -167.84 159.54 11.68 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.387 -0.821 . . . . 0.0 110.212 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.8 m -146.84 144.31 29.22 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 110.213 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -107.16 72.32 0.87 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 110.192 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.7 t -113.51 -162.56 0.81 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.365 -0.834 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -84.8 73.18 10.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.39 -0.819 . . . . 0.0 109.788 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 126.94 1.2 6.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.5 mmm180 53.28 88.02 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.106 -1.232 . . . . 0.0 110.434 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.798 ' HA ' HG23 ' A' ' 98' ' ' VAL . 8.5 p -157.34 149.98 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 110.088 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -133.03 94.87 3.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 110.286 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.528 HG21 HG12 ' A' ' 41' ' ' VAL . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.895 HG22 ' O ' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.895 ' O ' HG22 ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.648 ' HB2' HG11 ' A' ' 41' ' ' VAL . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.685 ' HB3' HD23 ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.798 HG23 ' HA ' ' A' ' 85' ' ' VAL . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 179.89 32.22 0.06 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 1.003 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -69.53 82.0 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.183 -1.187 . . . . 0.0 109.9 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.518 ' HA ' HG11 ' A' ' 128' ' ' VAL . 3.8 tt0 -92.96 -169.75 2.25 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.46 -0.775 . . . . 0.0 110.295 -179.68 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -54.07 -27.95 35.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.284 -0.885 . . . . 0.0 110.223 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -71.8 -25.72 62.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -0.816 . . . . 0.0 109.998 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -85.3 -37.86 19.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.506 ' HA ' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -52.64 153.42 3.16 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.29 -0.881 . . . . 0.0 110.406 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.799 ' HB2' HD23 ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.412 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.949 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 114' ' ' LYS . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.648 HG21 ' CD1' ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.432 ' HD2' HG22 ' A' ' 112' ' ' THR . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.532 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.583 HG21 ' HG3' ' A' ' 2' ' ' GLN . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.949 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.4 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 71.2 m-20 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.941 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.647 ' HB ' HG23 ' A' ' 18' ' ' THR . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.506 HG13 ' HA ' ' A' ' 106' ' ' GLU . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.622 ' HB3' HG22 ' A' ' 20' ' ' VAL . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.518 HG11 ' HA ' ' A' ' 102' ' ' GLU . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 130' ' ' ASP . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.443 ' N ' HG22 ' A' ' 129' ' ' ILE . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.188 0.518 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.614 ' HG3' HG21 ' A' ' 117' ' ' VAL . 7.3 pt20 -93.29 -142.64 0.22 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.434 -0.791 . . . . 0.0 110.129 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -116.87 150.37 45.72 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.103 -0.998 . . . . 0.0 110.221 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.501 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.514 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 1.058 HG23 HD12 ' A' ' 15' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.56 ' HA ' ' HA2' ' A' ' 13' ' ' GLY . 2.2 p-80 -125.39 174.75 7.95 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.594 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -127.11 -98.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.372 -0.83 . . . . 0.0 110.934 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -120.09 -13.5 8.96 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.571 -1.331 . . . . 0.0 112.002 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.58 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.67 -70.51 0.02 OUTLIER Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 120.611 -1.306 . . . . 0.0 112.328 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.594 ' HG2' HD11 ' A' ' 9' ' ' LEU . 39.3 Cg_endo -66.7 -84.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.008 1.004 . . . . 0.0 110.803 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 121.56 50.33 0.25 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -134.6 107.54 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.532 -0.981 . . . . 0.0 109.942 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.058 HD12 HG23 ' A' ' 7' ' ' ILE . 2.2 mt -79.38 132.73 61.55 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 0.0 109.527 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.491 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.834 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.914 ' O ' HD13 ' A' ' 27' ' ' LEU . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.641 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 22' ' ' VAL . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.452 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 25.6 t-20 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.914 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.754 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.575 HD23 ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.586 ' OD2' HD11 ' A' ' 95' ' ' ILE . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.706 ' HB ' HG23 ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.66 HG23 HD11 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 91' ' ' LYS . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.836 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.875 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER -95.44 153.65 17.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.598 ' HB1' HD12 ' A' ' 47' ' ' ILE . . . -134.88 143.6 47.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.355 -0.84 . . . . 0.0 110.325 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.671 HG22 ' O ' ' A' ' 47' ' ' ILE . 5.3 mp 53.35 26.81 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.439 -0.788 . . . . 0.0 110.317 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.4 p -98.68 -38.81 8.96 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.338 -0.851 . . . . 0.0 110.115 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -107.49 144.51 34.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.8 . . . . 0.0 110.1 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -116.32 -109.54 2.63 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -126.13 150.88 47.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -158.78 0.91 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.384 -0.823 . . . . 0.0 110.223 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.66 162.73 65.44 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.77 166.97 22.97 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.835 1.439 . . . . 0.0 110.595 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.75 -176.31 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.357 -0.84 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -139.47 76.33 31.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.075 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -76.02 -165.55 0.31 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.774 1.407 . . . . 0.0 110.54 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.2 152.68 29.35 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.386 -0.821 . . . . 0.0 110.269 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.06 102.25 1.43 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.745 1.392 . . . . 0.0 110.418 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.69 172.33 10.69 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.0 m -71.36 99.13 1.9 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -0.832 . . . . 0.0 110.149 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -68.16 -165.59 0.05 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.35 -0.844 . . . . 0.0 110.264 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -165.62 1.3 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.403 -0.81 . . . . 0.0 110.355 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.1 t-105 -103.48 131.69 50.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.462 -0.774 . . . . 0.0 110.15 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 73' ' ' PHE . 98.2 t -113.89 -95.26 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.283 -0.886 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.469 ' N ' HG12 ' A' ' 72' ' ' VAL . 39.2 t80 -172.49 -64.37 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.006 -1.059 . . . . 0.0 110.257 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -85.08 122.56 29.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -167.69 31.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.348 -0.845 . . . . 0.0 110.185 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.3 ttpt -156.23 106.85 2.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.405 -0.809 . . . . 0.0 110.187 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -95.91 51.53 1.26 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.444 -0.785 . . . . 0.0 110.128 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.0 mt -59.66 138.83 57.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.359 -0.838 . . . . 0.0 110.288 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.7 p -60.3 133.01 55.69 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.354 -0.841 . . . . 0.0 110.405 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -83.54 -170.82 3.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.872 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HA ' HG12 ' A' ' 85' ' ' VAL . 0.6 OUTLIER 179.99 -27.62 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.269 -0.894 . . . . 0.0 110.648 179.779 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -64.39 76.45 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.285 -0.884 . . . . 0.0 109.295 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 81' ' ' THR . . . 98.36 4.48 57.32 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -178.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -105.14 -78.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.176 -1.191 . . . . 0.0 110.609 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.901 ' HA ' HG23 ' A' ' 98' ' ' VAL . 9.7 p -84.84 134.31 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.965 . . . . 0.0 110.68 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.13 94.91 3.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.454 -0.779 . . . . 0.0 109.97 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.432 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.836 ' HB3' HG11 ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.586 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.901 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 118.63 45.52 0.47 Allowed Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.77 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -53.58 -82.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.287 -1.125 . . . . 0.0 109.369 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.46 ' HB3' ' N ' ' A' ' 106' ' ' GLU . 1.2 tm-20 -135.58 138.75 43.29 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.291 -0.881 . . . . 0.0 109.56 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.598 ' O ' HG11 ' A' ' 128' ' ' VAL . 0.0 OUTLIER -96.97 -63.23 1.15 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.167 -0.958 . . . . 0.0 111.533 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -97.11 -2.18 43.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.216 -0.927 . . . . 0.0 111.971 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.571 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -119.72 -8.88 9.85 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.899 -1.126 . . . . 0.0 111.8 -178.519 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.629 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.9 OUTLIER 24.01 -121.61 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.559 -0.713 . . . . 0.0 111.52 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.594 ' O ' HG11 ' A' ' 126' ' ' VAL . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.558 ' HB2' HD23 ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.891 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.514 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 2' ' ' GLN . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.438 ' C ' HG12 ' A' ' 122' ' ' VAL . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.891 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.875 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.594 HG11 ' O ' ' A' ' 107' ' ' GLY . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.445 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 129' ' ' ILE . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.7 mtt-85 . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.182 0.515 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.508 ' HG3' HG21 ' A' ' 117' ' ' VAL . 5.8 pt20 -146.7 -155.55 0.63 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.361 -0.837 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -90.55 151.38 44.03 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.373 -0.829 . . . . 0.0 110.219 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.42 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.615 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.847 ' CG2' HD12 ' A' ' 15' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.615 ' CD2' ' HB3' ' A' ' 6' ' ' LYS . 5.4 p80 -100.79 175.16 5.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.562 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -116.58 -103.11 0.42 Allowed 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.243 -0.91 . . . . 0.0 110.892 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -102.07 -24.94 13.9 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.6 -1.313 . . . . 0.0 111.045 -179.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.563 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -147.12 -68.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.031 -1.043 . . . . 0.0 111.664 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.563 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 43.6 Cg_endo -70.04 -92.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 122.935 0.966 . . . . 0.0 110.692 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.4 ' CA ' ' HA ' ' A' ' 8' ' ' HIS . . . 114.83 50.34 0.48 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 mtt-85 -106.43 87.4 2.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.374 -1.074 . . . . 0.0 110.435 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.896 HD11 HG23 ' A' ' 33' ' ' ILE . 6.7 mt -80.02 113.33 37.43 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.41 -0.806 . . . . 0.0 109.672 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.672 ' O ' HG22 ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.772 ' CA ' HD12 ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.672 HG22 ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.808 ' CG2' HD21 ' A' ' 124' ' ' LEU . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.759 ' O ' HD22 ' A' ' 27' ' ' LEU . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 22' ' ' VAL . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.443 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.887 HD12 ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.887 ' N ' HD12 ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.651 HD23 ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.844 ' HB ' HG23 ' A' ' 15' ' ' ILE . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.896 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.824 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.948 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.439 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -111.85 145.94 38.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.14 138.12 41.67 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.422 -0.799 . . . . 0.0 110.113 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.412 ' H ' HG22 ' A' ' 47' ' ' ILE . 16.3 tt -82.25 160.05 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.134 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.408 HG23 ' HA3' ' A' ' 107' ' ' GLY . 74.7 p -102.43 38.03 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.484 -0.76 . . . . 0.0 110.021 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -144.13 179.69 7.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 110.185 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.43 141.78 9.39 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 52.3 52.09 14.95 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.347 -1.09 . . . . 0.0 110.446 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.81 -158.65 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.428 -0.795 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.636 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -84.72 170.72 12.76 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.583 -0.698 . . . . 0.0 110.133 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.636 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 46.0 Cg_endo -72.9 166.85 28.87 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.76 1.4 . . . . 0.0 110.478 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.16 -164.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 110.263 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.41 ' CG ' ' O ' ' A' ' 56' ' ' ARG . 2.0 ptp85 -137.32 87.88 17.71 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.432 -0.793 . . . . 0.0 110.281 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.61 177.73 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.778 1.409 . . . . 0.0 110.491 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.772 ' HB1' ' HD2' ' A' ' 59' ' ' PRO . . . -70.56 174.82 3.04 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.383 -0.823 . . . . 0.0 110.148 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.772 ' HD2' ' HB1' ' A' ' 58' ' ' ALA . 46.3 Cg_endo -73.13 171.46 17.53 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.741 1.39 . . . . 0.0 110.471 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.421 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -166.03 135.61 3.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 55.2 p -79.7 74.36 6.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -72.17 133.4 45.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.826 . . . . 0.0 110.232 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.46 -166.53 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.297 -0.877 . . . . 0.0 110.197 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 73.6 t-105 -97.54 101.27 12.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.344 -0.847 . . . . 0.0 110.279 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 73' ' ' PHE . 7.6 p -61.31 168.86 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.143 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.53 ' N ' HG22 ' A' ' 72' ' ' VAL . 2.3 t80 -98.12 -60.01 1.64 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.54 -0.725 . . . . 0.0 110.2 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t70 52.5 -168.97 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.427 -0.796 . . . . 0.0 110.503 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 91.42 0.06 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.362 -0.836 . . . . 0.0 110.164 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.64 144.26 57.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.398 -0.814 . . . . 0.0 110.029 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.6 tp -107.81 170.26 8.1 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -0.821 . . . . 0.0 110.26 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -138.68 45.86 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.424 -0.797 . . . . 0.0 110.288 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.6 m -153.57 125.0 7.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.863 . . . . 0.0 110.291 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.593 ' H ' HG11 ' A' ' 85' ' ' VAL . 13.9 tp10 -62.03 -61.82 2.21 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.32 -0.862 . . . . 0.0 110.246 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.29 -178.78 6.56 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 110.183 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -62.25 -31.92 72.55 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.175 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.88 38.95 0.09 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -100.18 -52.04 3.5 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.304 -1.115 . . . . 0.0 109.913 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.775 ' HA ' HG23 ' A' ' 98' ' ' VAL . 7.3 p -65.06 136.74 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.364 -0.835 . . . . 0.0 109.878 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.54 103.51 7.15 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.266 -0.896 . . . . 0.0 110.358 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 96' ' ' PHE . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' H ' ' A' ' 92' ' ' ASP . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.561 ' H ' HG23 ' A' ' 90' ' ' THR . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.824 ' HB3' HG11 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.456 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.651 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 27' ' ' LEU . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.903 HG11 ' HB2' ' A' ' 101' ' ' ALA . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 24' ' ' GLY . . . 125.98 41.28 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.903 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -56.48 -85.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.379 -1.071 . . . . 0.0 109.79 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -134.37 151.1 51.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.736 179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.632 ' O ' HG21 ' A' ' 128' ' ' VAL . 8.3 mtmt -95.28 -62.96 1.21 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.125 -0.985 . . . . 0.0 109.887 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -97.63 -2.96 40.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.533 -0.729 . . . . 0.0 110.624 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 106' ' ' GLU . 0.5 OUTLIER -85.08 21.35 1.66 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.185 -0.947 . . . . 0.0 112.436 -178.225 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.926 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.7 OUTLIER -59.32 -148.82 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.888 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 179.407 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' HG13 ' A' ' 126' ' ' VAL . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.745 ' HB2' HD23 ' A' ' 124' ' ' LEU . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.956 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 41' ' ' VAL . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.624 HG21 ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.508 HG21 ' HG3' ' A' ' 2' ' ' GLN . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.426 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.4 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.956 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.948 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.568 HG11 ' HE1' ' A' ' 109' ' ' TYR . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.419 ' O ' HG13 ' A' ' 20' ' ' VAL . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.926 HG23 ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.463 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.283 0.564 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.61 ' HG3' HG21 ' A' ' 117' ' ' VAL . 5.4 pt20 -102.23 -134.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.334 -0.854 . . . . 0.0 110.112 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -126.91 149.81 70.02 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 120.975 -1.078 . . . . 0.0 110.544 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.504 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.558 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.546 ' HE2' ' CE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.986 HG23 HD12 ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.898 ' C ' HD13 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -125.44 156.96 38.05 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.898 HD13 ' C ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -149.78 -157.5 0.82 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.212 -0.93 . . . . 0.0 109.989 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.61 -29.73 62.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.043 -1.036 . . . . 0.0 109.289 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.749 ' H ' HD23 ' A' ' 9' ' ' LEU . 12.6 m -111.69 75.57 1.43 Allowed Pre-proline 0 C--N 1.304 -1.404 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.9 -176.97 0.66 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.905 1.476 . . . . 0.0 111.093 -179.01 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 36.65 1.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.841 -1.704 . . . . 0.0 108.841 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 64.03 145.06 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.528 -0.983 . . . . 0.0 110.356 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.986 HD12 HG23 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -79.0 149.08 73.02 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.429 -0.794 . . . . 0.0 109.05 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.703 ' HG2' HG12 ' A' ' 31' ' ' VAL . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.813 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 18' ' ' THR . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.813 ' CG1' HD21 ' A' ' 27' ' ' LEU . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.863 ' O ' HD13 ' A' ' 27' ' ' LEU . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.561 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.431 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.863 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.849 ' N ' HD12 ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.856 HD21 HD11 ' A' ' 124' ' ' LEU . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.703 HG12 ' HG2' ' A' ' 16' ' ' PRO . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.531 ' O ' HD11 ' A' ' 15' ' ' ILE . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.512 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.945 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp -110.35 119.43 39.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.36 113.49 26.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.394 -0.816 . . . . 0.0 110.18 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.525 HG22 ' HB2' ' A' ' 49' ' ' GLN . 3.6 mp -96.42 -23.44 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.403 -0.81 . . . . 0.0 110.167 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 71.9 p 43.82 54.79 5.5 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.629 -0.67 . . . . 0.0 111.004 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.525 ' HB2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.54 -56.11 2.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.895 . . . . 0.0 110.156 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.13 93.75 1.54 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -65.92 -30.64 71.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.296 -1.12 . . . . 0.0 110.309 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.58 -161.09 0.11 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.296 -0.878 . . . . 0.0 110.412 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.741 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -127.64 173.63 5.2 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.604 -0.685 . . . . 0.0 110.173 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.741 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 45.8 Cg_endo -72.53 166.48 29.73 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.855 1.45 . . . . 0.0 110.449 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -121.55 -176.13 3.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.39 -0.819 . . . . 0.0 110.286 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.87 81.22 22.75 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.462 -0.774 . . . . 0.0 110.247 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.7 160.34 31.31 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.907 1.478 . . . . 0.0 110.488 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.13 162.63 52.89 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.328 -0.858 . . . . 0.0 110.141 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.84 161.62 43.25 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.804 1.423 . . . . 0.0 110.467 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -168.8 161.04 10.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.0 t -62.49 102.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.339 -0.85 . . . . 0.0 110.123 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -54.82 -55.81 26.24 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.364 -0.835 . . . . 0.0 110.368 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -154.49 -168.53 2.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.336 -0.852 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 75.3 t-105 -141.28 165.93 26.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.397 -0.814 . . . . 0.0 110.129 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 74' ' ' ASP . 92.3 t -86.95 -83.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.844 . . . . 0.0 110.236 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.403 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 25.7 t80 51.36 -89.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.435 -0.791 . . . . 0.0 110.587 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.456 ' N ' ' O ' ' A' ' 72' ' ' VAL . 72.2 m-20 -53.36 137.67 34.71 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.071 -1.018 . . . . 0.0 110.507 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.85 -70.17 0.73 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.439 -0.788 . . . . 0.0 110.211 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -121.55 56.86 1.04 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 110.197 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 77' ' ' LEU . 5.8 tt -142.57 84.24 1.85 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.317 -0.864 . . . . 0.0 110.397 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.1 mt -111.86 38.29 2.7 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.342 -0.849 . . . . 0.0 109.992 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.6 p -131.77 54.87 1.9 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 110.433 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -97.25 40.73 1.14 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.351 -0.843 . . . . 0.0 109.939 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.457 ' OG1' HG12 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -89.95 48.68 1.61 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.383 -0.823 . . . . 0.0 110.283 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 81' ' ' THR . 9.1 pt-20 32.77 72.71 0.07 Allowed 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.692 -0.63 . . . . 0.0 111.612 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 127.97 4.34 5.6 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 54.42 87.98 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.969 -1.312 . . . . 0.0 110.522 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.806 ' HA ' HG23 ' A' ' 98' ' ' VAL . 10.6 p -74.91 145.51 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 110.142 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -115.31 94.77 4.86 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.747 HG22 ' CD1' ' A' ' 96' ' ' PHE . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.451 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.747 ' CD1' HG22 ' A' ' 87' ' ' VAL . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.806 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 120.96 40.38 0.56 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.711 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -58.09 -84.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.235 -1.156 . . . . 0.0 109.751 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -134.24 146.68 50.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.187 -0.945 . . . . 0.0 109.522 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.745 ' HA ' HG11 ' A' ' 128' ' ' VAL . 0.0 OUTLIER -95.93 -63.31 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.152 -0.967 . . . . 0.0 110.396 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.26 -3.92 36.33 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.389 -0.819 . . . . 0.0 110.817 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.535 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.4 OUTLIER -76.51 -56.24 4.8 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.226 -0.921 . . . . 0.0 111.483 -178.696 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.913 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.8 OUTLIER 22.88 -138.37 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.815 -0.553 . . . . 0.0 111.821 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.629 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.68 ' HB2' HD23 ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.874 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.478 HG11 HG21 ' A' ' 33' ' ' ILE . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.558 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.61 HG21 ' HG3' ' A' ' 2' ' ' GLN . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.444 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.874 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.945 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 107' ' ' GLY . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.913 HG23 ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 37.0 ptt85 . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.24 0.543 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.535 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -148.44 -161.08 1.26 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.391 -0.818 . . . . 0.0 110.359 -179.966 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -82.66 145.81 51.66 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.726 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.636 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 1.037 HG23 HD12 ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.443 ' HA ' ' HA2' ' A' ' 13' ' ' GLY . 5.6 t-80 -118.67 152.43 36.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.67 HD11 ' H ' ' A' ' 13' ' ' GLY . 0.4 OUTLIER -136.43 -121.22 0.15 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.339 -0.851 . . . . 0.0 110.729 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -52.01 -30.9 27.31 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.682 -1.261 . . . . 0.0 111.007 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.465 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.1 OUTLIER 179.98 -57.4 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.04 -1.037 . . . . 0.0 111.94 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 11' ' ' CYS . 38.7 Cg_endo -67.18 -64.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.208 1.109 . . . . 0.0 111.32 -178.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.67 ' H ' HD11 ' A' ' 9' ' ' LEU . . . 120.54 47.8 0.32 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 20.3 mtt180 -106.26 85.31 2.17 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -1.088 . . . . 0.0 110.271 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.037 HD12 HG23 ' A' ' 7' ' ' ILE . 3.9 mt -79.5 121.85 83.17 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.314 -0.866 . . . . 0.0 109.338 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.664 ' O ' HG22 ' A' ' 18' ' ' THR . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.806 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.664 HG22 ' O ' ' A' ' 16' ' ' PRO . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.866 ' CD1' HD11 ' A' ' 27' ' ' LEU . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.501 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.894 ' CG1' HG22 ' A' ' 128' ' ' VAL . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.582 HG12 ' O ' ' A' ' 22' ' ' VAL . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.592 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.866 HD11 ' CD1' ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.817 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.86 HD21 HD11 ' A' ' 124' ' ' LEU . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.675 ' CG ' HD11 ' A' ' 95' ' ' ILE . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.804 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.464 ' O ' HD11 ' A' ' 15' ' ' ILE . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.665 HD11 ' HB3' ' A' ' 94' ' ' SER . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 38' ' ' ALA . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.817 HG11 ' CB ' ' A' ' 94' ' ' SER . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.953 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt -112.96 86.03 2.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -69.84 143.29 52.91 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.41 -0.807 . . . . 0.0 109.94 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 49' ' ' GLN . 50.1 mm -93.77 -52.17 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -0.934 . . . . 0.0 110.085 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 65.5 p 43.05 30.56 0.27 Allowed 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.857 -0.527 . . . . 0.0 110.873 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.444 ' H ' HG22 ' A' ' 47' ' ' ILE . 27.9 mt-30 -117.05 -179.37 3.68 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.419 -0.801 . . . . 0.0 110.302 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 63.07 -89.31 0.06 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -165.78 122.16 1.36 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.363 -1.08 . . . . 0.0 110.165 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.8 -160.36 0.12 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.341 -0.849 . . . . 0.0 110.458 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.534 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -89.83 167.23 17.78 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.64 -0.662 . . . . 0.0 110.266 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.534 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.6 Cg_endo -75.46 167.12 27.28 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.813 1.428 . . . . 0.0 110.395 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.05 91.47 0.8 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.391 -0.818 . . . . 0.0 110.171 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' A' ' 56' ' ' ARG . 5.6 ptp85 -139.6 73.67 34.84 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.31 -0.869 . . . . 0.0 110.238 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.22 139.52 18.91 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.855 1.45 . . . . 0.0 110.436 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.09 128.92 17.78 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.328 -0.858 . . . . 0.0 110.174 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.28 94.93 0.83 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.699 1.368 . . . . 0.0 110.414 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -62.1 -174.9 0.06 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -109.15 43.05 1.32 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.289 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -75.69 147.19 39.59 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.379 -0.825 . . . . 0.0 110.153 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.18 -169.79 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.8 t-105 -93.5 146.16 23.98 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.432 -0.793 . . . . 0.0 110.203 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.95 161.6 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.376 -0.828 . . . . 0.0 110.173 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -97.85 -64.38 1.04 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -0.825 . . . . 0.0 110.219 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.92 -179.69 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.397 -0.814 . . . . 0.0 110.469 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.8 ttpt -124.65 -4.05 7.72 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.345 -0.847 . . . . 0.0 110.733 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 52.38 63.37 2.27 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.13 -0.981 . . . . 0.0 110.394 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -168.67 77.38 0.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.346 -0.847 . . . . 0.0 110.103 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.5 pp -167.8 -179.62 4.33 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.364 -0.835 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.0 p -132.01 137.37 47.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.352 -0.842 . . . . 0.0 110.22 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -109.94 41.48 1.7 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.347 -0.845 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -135.06 52.69 2.02 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.165 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 52.93 26.58 4.78 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.342 -0.849 . . . . 0.0 110.241 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 66.15 54.98 21.1 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.57 -60.44 1.66 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.428 -1.042 . . . . 0.0 110.384 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.937 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.7 p -106.83 144.9 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.332 -0.855 . . . . 0.0 110.505 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -129.06 97.76 4.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.417 -0.802 . . . . 0.0 109.989 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.487 HG11 ' HD1' ' A' ' 43' ' ' TRP . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.817 ' CB ' HG11 ' A' ' 41' ' ' VAL . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.675 HD11 ' CG ' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.6 ' HB3' HD23 ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.937 ' HB ' HG23 ' A' ' 85' ' ' VAL . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.518 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -171.79 26.74 0.1 OUTLIER Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.689 ' O ' HG11 ' A' ' 21' ' ' VAL . . . -74.8 87.37 2.24 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.399 -1.059 . . . . 0.0 109.369 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.731 ' O ' HG21 ' A' ' 128' ' ' VAL . 3.8 tt0 -99.52 -169.7 1.79 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 -179.363 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.9 tttt -54.57 -37.38 65.42 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.447 -0.783 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.406 ' HG3' ' N ' ' A' ' 105' ' ' ASP . 0.7 OUTLIER -59.67 -20.97 59.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.316 -0.865 . . . . 0.0 110.12 179.697 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASP . . . . . 0.406 ' N ' ' HG3' ' A' ' 104' ' ' GLU . 0.7 OUTLIER -93.37 -23.44 18.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.066 179.66 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -51.2 166.28 0.11 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.352 -0.842 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.575 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.658 ' HB2' HD23 ' A' ' 124' ' ' LEU . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.906 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.636 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.461 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.456 ' C ' HG12 ' A' ' 122' ' ' VAL . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.906 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.953 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.831 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.894 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.22 0.534 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.544 ' HG3' HG23 ' A' ' 117' ' ' VAL . 0.5 OUTLIER -161.18 -102.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.407 ' N ' HG21 ' A' ' 117' ' ' VAL . 18.6 mt-10 -126.3 150.35 69.8 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.842 -1.161 . . . . 0.0 110.234 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.691 ' HD3' ' HE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 1.097 HG23 HD12 ' A' ' 15' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.905 ' C ' HD13 ' A' ' 9' ' ' LEU . 0.0 OUTLIER -125.72 167.3 15.34 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.905 HD13 ' C ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -148.14 -153.31 0.48 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.373 -0.83 . . . . 0.0 109.864 -179.775 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -54.24 -31.44 53.41 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.008 -1.058 . . . . 0.0 108.998 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.705 ' H ' HD23 ' A' ' 9' ' ' LEU . 4.6 t -111.73 76.87 1.71 Allowed Pre-proline 0 C--N 1.304 -1.397 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.81 -166.48 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 124.0 1.526 . . . . 0.0 111.141 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 14' ' ' ARG . . . 116.32 33.71 1.43 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' A' ' 13' ' ' GLY . 4.7 mmt85 60.88 145.29 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.645 -0.915 . . . . 0.0 110.482 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 1.097 HD12 HG23 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -79.17 139.88 56.74 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.276 -0.89 . . . . 0.0 109.196 179.839 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 32' ' ' PRO . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.635 HG23 ' CG2' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.928 HG23 HD21 ' A' ' 27' ' ' LEU . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.95 ' CG1' HG22 ' A' ' 128' ' ' VAL . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.584 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.476 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.928 HD21 HG23 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.738 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.719 HD22 HG12 ' A' ' 19' ' ' ILE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 15' ' ' ILE . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.931 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.443 ' HB2' ' HG3' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.61 ' O ' HD12 ' A' ' 42' ' ' ILE . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 40' ' ' THR . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.91 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.405 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt -105.26 128.18 53.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -113.09 92.01 3.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.294 -0.879 . . . . 0.0 110.287 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.3 mt -103.56 -16.96 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.486 -0.759 . . . . 0.0 110.08 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.418 HG23 ' OE1' ' A' ' 49' ' ' GLN . 4.9 t -56.08 -23.15 32.02 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.345 -0.847 . . . . 0.0 110.571 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.418 ' OE1' HG23 ' A' ' 48' ' ' THR . 2.2 pt20 -128.64 -169.97 2.17 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.26 -0.9 . . . . 0.0 110.291 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.65 -34.68 4.89 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -166.44 -60.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.314 -1.109 . . . . 0.0 110.268 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -158.44 0.24 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.308 -0.87 . . . . 0.0 110.454 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.632 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -127.96 170.23 10.81 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.571 -0.706 . . . . 0.0 110.256 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.632 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.6 Cg_endo -73.25 166.31 30.29 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.761 1.401 . . . . 0.0 110.402 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.32 92.48 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.347 -0.846 . . . . 0.0 110.537 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.3 ptm180 -125.16 73.8 66.68 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.402 -0.812 . . . . 0.0 110.247 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.92 140.87 20.76 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.881 1.464 . . . . 0.0 110.292 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.99 155.85 80.96 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.311 -0.868 . . . . 0.0 110.247 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.09 105.19 1.91 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.821 1.432 . . . . 0.0 110.281 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.419 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 65' ' ' THR . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -104.37 -165.18 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.32 35.15 2.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.368 -0.832 . . . . 0.0 110.281 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -85.75 -179.05 6.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 110.166 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -124.29 -174.5 3.02 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.328 -0.857 . . . . 0.0 110.259 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 71.6 t-105 -102.03 141.99 34.0 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.395 -0.816 . . . . 0.0 110.276 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.644 HG11 ' HB2' ' A' ' 75' ' ' LYS . 60.3 t -94.34 166.91 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.415 -0.803 . . . . 0.0 110.13 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.478 ' N ' HG12 ' A' ' 72' ' ' VAL . 0.1 OUTLIER -76.69 -49.99 14.76 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 0.0 110.101 179.962 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.9 p30 -133.4 63.36 1.63 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.345 -0.847 . . . . 0.0 110.258 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.644 ' HB2' HG11 ' A' ' 72' ' ' VAL . 0.1 OUTLIER -159.3 88.38 0.87 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.256 -0.902 . . . . 0.0 110.181 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.23 32.41 3.98 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.358 -0.839 . . . . 0.0 110.252 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.21 85.63 1.81 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.368 -0.832 . . . . 0.0 110.132 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 6.9 mp -83.01 96.51 8.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.398 -0.814 . . . . 0.0 110.184 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 67.3 m -60.8 134.16 56.82 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.346 -0.846 . . . . 0.0 110.16 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -114.5 77.1 1.03 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.401 -0.812 . . . . 0.0 110.173 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.2 p -104.38 67.77 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.388 -0.82 . . . . 0.0 110.109 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 54.79 -87.74 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.502 -0.749 . . . . 0.0 110.597 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -103.76 27.09 21.13 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.7 ttt-85 62.17 127.54 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.363 -1.081 . . . . 0.0 110.423 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.916 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.4 p -60.73 127.16 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.297 -0.877 . . . . 0.0 110.19 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -109.9 102.89 11.62 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.328 -0.857 . . . . 0.0 110.27 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.645 HG11 ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.719 HG22 ' O ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.533 ' H ' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.719 ' O ' HG22 ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.884 ' HB3' HG11 ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.68 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.916 ' HB ' HG23 ' A' ' 85' ' ' VAL . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.576 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -166.28 25.12 0.15 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.687 ' O ' HG11 ' A' ' 21' ' ' VAL . . . -74.66 87.5 2.18 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.351 -1.087 . . . . 0.0 109.477 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.553 ' O ' HG21 ' A' ' 128' ' ' VAL . 0.6 OUTLIER -112.35 -168.88 1.37 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.528 -0.732 . . . . 0.0 110.385 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.09 -29.74 22.91 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.377 -0.827 . . . . 0.0 110.299 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -74.35 -22.22 59.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.444 -0.785 . . . . 0.0 110.149 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -85.98 -28.23 24.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.345 -0.847 . . . . 0.0 110.25 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -49.68 169.31 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.329 -0.857 . . . . 0.0 110.722 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.446 ' H ' HG13 ' A' ' 126' ' ' VAL . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.705 ' HB2' HD23 ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 123' ' ' ASN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.912 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.572 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.515 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.422 ' HG2' ' HG2' ' A' ' 2' ' ' GLN . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.544 HG23 ' HG3' ' A' ' 2' ' ' GLN . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.912 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.91 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 125' ' ' THR . . . . . 0.635 ' CG2' HG23 ' A' ' 18' ' ' THR . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.727 HG23 HG22 ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.95 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.503 HD12 ' O ' ' A' ' 130' ' ' ASP . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 129' ' ' ILE . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.152 0.501 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.665 ' HG3' HG21 ' A' ' 117' ' ' VAL . 5.0 pt20 -65.7 -144.45 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.446 -0.784 . . . . 0.0 110.079 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -114.11 147.84 38.73 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.087 -1.008 . . . . 0.0 110.262 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.569 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.954 HG23 HD12 ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.511 ' HA ' ' HA2' ' A' ' 13' ' ' GLY . 7.3 t-80 -119.11 152.21 36.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.485 HD11 ' H ' ' A' ' 13' ' ' GLY . 0.4 OUTLIER -137.07 -120.78 0.15 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.219 -0.926 . . . . 0.0 110.968 179.947 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -54.62 -31.6 57.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 111.306 -178.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.446 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.1 OUTLIER -175.09 -58.84 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.789 0 C-N-CA 119.084 -1.046 . . . . 0.0 112.023 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 38.1 Cg_endo -66.0 -71.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.21 1.111 . . . . 0.0 111.106 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 120.64 49.95 0.28 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.483 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.1 OUTLIER -113.89 87.83 2.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.503 -0.998 . . . . 0.0 109.743 179.502 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.954 HD12 HG23 ' A' ' 7' ' ' ILE . 25.5 mt -79.31 110.82 16.45 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 14' ' ' ARG . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.711 ' O ' HD12 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.867 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.894 ' O ' HD13 ' A' ' 27' ' ' LEU . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.788 HG11 ' CB ' ' A' ' 101' ' ' ALA . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 22' ' ' VAL . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.511 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.894 HD13 ' O ' ' A' ' 20' ' ' VAL . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.818 ' N ' HD12 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.67 HD23 ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 15' ' ' ILE . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.457 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.662 HG23 HD11 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.419 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HG3' ' O ' ' A' ' 34' ' ' SER . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.825 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.912 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.09 163.45 16.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' A' ' 108' ' ' VAL . . . -136.37 91.83 2.71 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.455 -0.778 . . . . 0.0 110.126 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.623 HG22 ' O ' ' A' ' 47' ' ' ILE . 74.0 mt -138.38 26.95 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.586 -0.696 . . . . 0.0 109.402 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.2 t -125.4 39.41 3.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.46 -0.775 . . . . 0.0 110.188 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -62.16 146.78 49.65 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -150.3 -78.66 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -143.19 78.89 1.62 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.373 -1.074 . . . . 0.0 110.232 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.58 -157.68 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.461 -0.774 . . . . 0.0 110.283 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -56.11 174.06 0.26 Allowed Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.632 -0.667 . . . . 0.0 110.407 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 44.9 Cg_endo -71.7 167.24 27.06 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.788 1.415 . . . . 0.0 110.453 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' PRO . . . 59.93 106.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.439 -0.788 . . . . 0.0 110.249 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.91 88.42 36.02 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.854 . . . . 0.0 110.329 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.88 165.6 28.24 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.821 1.432 . . . . 0.0 110.458 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.29 87.43 56.39 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.387 -0.821 . . . . 0.0 110.202 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.58 143.03 37.35 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.761 1.401 . . . . 0.0 110.44 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -169.39 -162.43 0.35 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 p 49.19 31.23 3.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.431 -0.793 . . . . 0.0 110.702 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -60.42 -68.73 0.27 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.381 -0.824 . . . . 0.0 110.214 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -77.43 -172.08 2.37 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.324 -0.86 . . . . 0.0 110.075 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.5 t-105 -99.58 96.48 7.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.283 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.519 HG22 ' N ' ' A' ' 73' ' ' PHE . 7.3 p -62.37 168.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.356 -0.84 . . . . 0.0 110.311 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.519 ' N ' HG22 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -112.19 -165.73 1.02 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.557 -0.715 . . . . 0.0 110.078 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 53.2 p-10 -156.29 -170.72 3.45 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 110.374 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.7 mttm 52.95 -165.91 0.07 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.301 -0.875 . . . . 0.0 110.423 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.67 28.29 7.84 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.358 -0.839 . . . . 0.0 110.468 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.429 HD13 ' H ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -94.7 142.47 27.42 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 110.109 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 78' ' ' LEU . 3.5 mp -73.13 -53.18 11.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.169 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 4.7 m -80.6 -9.36 59.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.379 -0.826 . . . . 0.0 110.543 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 55.67 47.71 20.02 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.178 -0.951 . . . . 0.0 110.293 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.6 p -130.05 -78.1 0.54 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.367 -0.833 . . . . 0.0 110.184 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -173.23 38.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 110.027 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 118.38 36.87 0.89 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 52.18 85.45 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.356 -1.084 . . . . 0.0 110.42 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.901 HG23 ' HB ' ' A' ' 98' ' ' VAL . 10.1 p -127.26 130.87 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 110.406 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -114.74 110.89 20.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.381 -0.824 . . . . 0.0 110.043 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.565 HG11 ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.825 ' HB3' HG11 ' A' ' 41' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.535 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.67 ' HB3' HD23 ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.901 ' HB ' HG23 ' A' ' 85' ' ' VAL . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.516 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -167.17 24.75 0.13 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.788 ' CB ' HG11 ' A' ' 21' ' ' VAL . . . -69.47 86.86 0.45 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.305 -1.115 . . . . 0.0 109.552 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.469 ' O ' HG21 ' A' ' 128' ' ' VAL . 1.4 tp10 -95.34 -175.99 3.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 0.0 110.456 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -52.81 -32.98 46.93 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -0.856 . . . . 0.0 110.185 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.64 -20.63 66.4 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.431 -0.793 . . . . 0.0 110.08 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.78 -32.19 17.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -0.867 . . . . 0.0 109.908 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -51.71 169.13 0.07 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.38 -0.825 . . . . 0.0 110.412 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.432 ' HB ' ' HB3' ' A' ' 46' ' ' ALA . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.829 ' HB2' HD23 ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.92 ' CG1' HG13 ' A' ' 122' ' ' VAL . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.62 HG11 HG21 ' A' ' 33' ' ' ILE . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.665 HG21 ' HG3' ' A' ' 2' ' ' GLN . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.492 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLN . . . . . 0.409 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.92 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.912 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.789 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.565 HG22 ' CG1' ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 130' ' ' ASP . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.447 ' N ' HG22 ' A' ' 129' ' ' ILE . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 8.0 ptt180 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.279 0.561 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.528 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -145.69 -165.77 2.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.889 . . . . 0.0 110.404 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -79.64 150.95 73.73 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.229 -0.919 . . . . 0.0 110.754 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.556 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.519 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.899 HG23 HD12 ' A' ' 15' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.46 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 2.7 p-80 -118.47 174.84 6.02 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.554 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -122.85 -102.77 0.39 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.319 -0.863 . . . . 0.0 110.756 -179.762 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -101.92 -24.38 14.02 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.627 -1.296 . . . . 0.0 111.159 -179.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.544 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.45 -67.23 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 120.992 -1.068 . . . . 0.0 111.758 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.554 ' HG2' HD11 ' A' ' 9' ' ' LEU . 44.0 Cg_endo -69.66 -93.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.032 1.017 . . . . 0.0 110.568 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.442 ' CA ' ' HA ' ' A' ' 8' ' ' HIS . . . 119.98 50.04 0.29 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 5.2 mtt180 -109.56 91.46 3.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.411 -1.053 . . . . 0.0 110.089 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.899 HD12 HG23 ' A' ' 7' ' ' ILE . 2.0 mt -79.57 114.81 48.68 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.653 ' O ' HG22 ' A' ' 18' ' ' THR . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.759 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' PRO . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.922 HG13 HD21 ' A' ' 27' ' ' LEU . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.904 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.021 HG11 ' HB3' ' A' ' 101' ' ' ALA . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 22' ' ' VAL . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.419 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.922 HD21 HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.593 ' N ' HD12 ' A' ' 27' ' ' LEU . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.73 HD21 HD11 ' A' ' 124' ' ' LEU . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.74 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.655 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.506 ' HG2' HD23 ' A' ' 9' ' ' LEU . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.975 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLN . . . . . 0.456 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.436 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt -124.58 159.12 31.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -131.89 91.43 2.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.526 -0.733 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 104' ' ' GLU . 72.1 mt -133.72 28.02 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.574 -0.704 . . . . 0.0 109.364 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.8 t -117.44 30.54 7.23 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.495 -0.753 . . . . 0.0 110.278 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 61.6 mm-40 -101.11 -34.07 9.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.346 -0.847 . . . . 0.0 110.07 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -162.4 146.4 11.88 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -138.45 -64.11 0.53 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.329 -1.101 . . . . 0.0 110.209 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.33 -160.56 0.74 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.234 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -86.2 171.35 10.51 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.59 -0.694 . . . . 0.0 110.269 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 45.8 Cg_endo -72.34 166.78 28.75 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.695 1.366 . . . . 0.0 110.389 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -163.45 74.61 0.35 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.373 -0.829 . . . . 0.0 110.34 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.6 ttt180 -119.31 73.75 14.79 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.858 . . . . 0.0 109.96 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.26 -166.49 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.012 1.533 . . . . 0.0 110.556 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 59' ' ' PRO . . . -61.6 171.15 1.46 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 110.213 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 58' ' ' ALA . 46.3 Cg_endo -73.06 110.75 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.702 1.37 . . . . 0.0 110.442 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.418 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 65' ' ' THR . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -90.17 157.09 17.89 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.2 t -70.69 78.16 0.6 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.169 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.52 173.25 2.8 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.422 -0.798 . . . . 0.0 110.262 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -121.51 -166.19 1.34 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.418 -0.802 . . . . 0.0 110.168 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 67.2 t-105 -73.7 174.86 7.78 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.335 -0.853 . . . . 0.0 109.914 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.575 ' O ' HG12 ' A' ' 72' ' ' VAL . 49.6 t -86.86 14.32 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.16 -0.962 . . . . 0.0 110.838 -179.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -56.11 -173.08 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.063 -1.023 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -129.69 140.7 51.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.369 -0.832 . . . . 0.0 110.272 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.4 tptp -168.74 -47.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.441 -0.787 . . . . 0.0 110.132 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 154.77 32.34 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.352 -0.842 . . . . 0.0 110.201 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.13 177.59 8.94 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -0.873 . . . . 0.0 110.166 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -114.83 43.02 2.04 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.367 -0.833 . . . . 0.0 110.208 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -141.93 50.39 1.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.324 -0.86 . . . . 0.0 110.357 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.04 67.24 3.84 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 25.82 10.47 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.42 -0.8 . . . . 0.0 110.286 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 51.11 82.36 0.06 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.298 -0.876 . . . . 0.0 110.505 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.81 9.62 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 59.64 107.8 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.266 -1.138 . . . . 0.0 110.224 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.771 ' HA ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -68.61 144.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.274 -0.891 . . . . 0.0 109.954 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -97.42 94.74 7.21 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.211 -0.93 . . . . 0.0 109.919 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.709 HG22 ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.772 ' O ' HG22 ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.74 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.709 ' CD1' HG22 ' A' ' 87' ' ' VAL . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.771 HG23 ' HA ' ' A' ' 85' ' ' VAL . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.454 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -177.82 31.53 0.07 OUTLIER Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 1.021 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -70.23 83.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.333 -1.098 . . . . 0.0 109.699 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.454 ' O ' HG21 ' A' ' 128' ' ' VAL . 2.7 mt-10 -92.51 -169.57 2.25 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.261 -0.899 . . . . 0.0 110.519 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 2.2 mmtt -52.76 -34.35 52.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 110.198 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 47' ' ' ILE . 10.0 mm-40 -60.29 -25.0 65.4 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.361 -0.837 . . . . 0.0 109.799 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -91.27 -32.17 15.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.434 -0.791 . . . . 0.0 109.824 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -52.32 166.34 0.18 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.366 -0.834 . . . . 0.0 110.359 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.627 ' HE1' HG11 ' A' ' 126' ' ' VAL . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.526 HG11 ' CD1' ' A' ' 7' ' ' ILE . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.519 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.556 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.417 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.975 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.739 HG23 HG23 ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 102' ' ' GLU . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 110.305 -0.257 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.479 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.428 ' O ' HG22 ' A' ' 33' ' ' ILE . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.943 ' CG2' HD12 ' A' ' 15' ' ' ILE . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.9 t60 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.943 HD12 ' CG2' ' A' ' 7' ' ' ILE . 6.8 mt . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.805 ' CD1' HD21 ' A' ' 27' ' ' LEU . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 27' ' ' LEU . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.597 ' O ' HG12 ' A' ' 22' ' ' VAL . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.417 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.876 HD12 ' N ' ' A' ' 28' ' ' ARG . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.876 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.727 HD23 ' HB3' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.798 ' HB ' HG23 ' A' ' 15' ' ' ILE . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.422 ' O ' HG12 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.606 HG21 HG11 ' A' ' 113' ' ' VAL . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.854 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.682 HG22 HG22 ' A' ' 112' ' ' THR . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.97 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 109' ' ' TYR . 18.3 tttt . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 110.45 -0.635 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.424 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.16 0.505 . . . . 0.0 110.085 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.484 ' CG2' HG12 ' A' ' 41' ' ' VAL . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.854 ' HB3' HG11 ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.462 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.411 HG22 ' H ' ' A' ' 100' ' ' GLY . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.282 0.563 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.73 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.682 HG22 HG22 ' A' ' 42' ' ' ILE . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.606 HG11 HG21 ' A' ' 33' ' ' ILE . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.498 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.425 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.479 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.429 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.443 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.97 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.417 HG12 ' HB2' ' A' ' 23' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 120.65 0.262 . . . . 0.0 110.927 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.527 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.563 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.964 HG23 HD12 ' A' ' 15' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.418 ' HB3' ' HG3' ' A' ' 6' ' ' LYS . 12.0 t60 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 33' ' ' ILE . 8.5 mt . . . . . 0 N--CA 1.493 1.712 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.74 ' OD1' HG11 ' A' ' 31' ' ' VAL . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.642 HG23 ' HB ' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.895 HD11 HD11 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.777 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.542 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.895 HD11 HD11 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.714 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.763 HD13 HD13 ' A' ' 19' ' ' ILE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.74 HG11 ' OD1' ' A' ' 17' ' ' ASP . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.489 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.965 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.749 HG11 ' HB2' ' A' ' 94' ' ' SER . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.961 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.425 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 65' ' ' THR . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.223 0.535 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.404 HG23 ' HA ' ' A' ' 94' ' ' SER . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.749 ' HB2' HG11 ' A' ' 41' ' ' VAL . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.488 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.445 HG22 ' H ' ' A' ' 100' ' ' GLY . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.401 ' CG ' ' HA ' ' A' ' 127' ' ' LYS . 2.8 tt0 . . . . . 0 N--CA 1.494 1.766 0 CA-C-O 121.239 0.542 . . . . 0.0 110.456 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.782 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.925 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.66 HG23 ' HG3' ' A' ' 121' ' ' GLN . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 33' ' ' ILE . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.563 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.464 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.66 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.925 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.961 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.642 ' HB ' HG23 ' A' ' 18' ' ' THR . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.495 HG11 ' HE1' ' A' ' 109' ' ' TYR . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.401 ' HA ' ' CG ' ' A' ' 106' ' ' GLU . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.463 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.532 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.698 HG22 ' HB ' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.443 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 1.8 t60 . . . . . 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.902 ' CD1' HG23 ' A' ' 33' ' ' ILE . 7.6 mt . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 120.857 0.361 . . . . 0.0 110.126 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.647 HG23 ' HB ' ' A' ' 125' ' ' THR . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.991 HD13 HD13 ' A' ' 29' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG22 ' HB3' ' A' ' 127' ' ' LYS . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.599 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' H ' HG22 ' A' ' 22' ' ' VAL . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.9 HD11 ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.691 ' H ' HD12 ' A' ' 27' ' ' LEU . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.991 HD13 HD13 ' A' ' 19' ' ' ILE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 94' ' ' SER . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.446 ' O ' HD11 ' A' ' 15' ' ' ILE . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.902 HG23 ' CD1' ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.665 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.941 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo . . . . . 0 N--CA 1.484 0.949 0 N-CA-C 110.393 -0.657 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.219 0.533 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.528 HG21 HG12 ' A' ' 41' ' ' VAL . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.895 HG22 ' O ' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.895 ' O ' HG22 ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.648 ' HB2' HG11 ' A' ' 41' ' ' VAL . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.685 ' HB3' HD23 ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.506 ' HA ' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.251 0.548 . . . . 0.0 110.406 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.799 ' HB2' HD23 ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.483 HG23 HD22 ' A' ' 123' ' ' ASN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.949 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 114' ' ' LYS . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.648 HG21 ' CD1' ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.432 ' HD2' HG22 ' A' ' 112' ' ' THR . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.532 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.479 ' HB ' ' HD3' ' A' ' 5' ' ' PRO . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.949 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.483 HD22 HG23 ' A' ' 110' ' ' THR . 18.4 m120 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.941 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.647 ' HB ' HG23 ' A' ' 18' ' ' THR . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.506 HG13 ' HA ' ' A' ' 106' ' ' GLU . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.622 ' HB3' HG22 ' A' ' 20' ' ' VAL . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 130' ' ' ASP . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.443 ' N ' HG22 ' A' ' 129' ' ' ILE . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 110.221 -0.289 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.501 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.514 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 1.058 HG23 HD12 ' A' ' 15' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.475 ' C ' ' CD2' ' A' ' 8' ' ' HIS . 2.2 p-80 . . . . . 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.058 HD12 HG23 ' A' ' 7' ' ' ILE . 2.2 mt . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.491 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.834 HG13 HD21 ' A' ' 27' ' ' LEU . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.914 ' O ' HD13 ' A' ' 27' ' ' LEU . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.641 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.569 ' O ' HG12 ' A' ' 22' ' ' VAL . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.452 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 4.3 t30 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.914 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.754 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.575 HD23 ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.586 ' OD2' HD11 ' A' ' 95' ' ' ILE . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.706 ' HB ' HG23 ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.66 HG23 HD11 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.465 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.836 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.875 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.483 0.891 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.167 0.508 . . . . 0.0 109.97 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.432 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.836 ' HB3' HG11 ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.586 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.468 ' CG1' HD23 ' A' ' 27' ' ' LEU . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.629 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.9 OUTLIER . . . . . 0 N--CA 1.5 2.06 0 CA-C-O 120.76 0.314 . . . . 0.0 111.52 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.594 ' O ' HG11 ' A' ' 126' ' ' VAL . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.558 ' HB2' HD23 ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.891 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.514 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.501 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.438 ' C ' HG12 ' A' ' 122' ' ' VAL . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.891 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.875 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.594 HG11 ' O ' ' A' ' 107' ' ' GLY . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.445 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 129' ' ' ILE . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.42 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.442 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.847 ' CG2' HD12 ' A' ' 15' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.433 ' CE1' ' CB ' ' A' ' 6' ' ' LYS . 3.3 p-80 . . . . . 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.896 HD11 HG23 ' A' ' 33' ' ' ILE . 6.7 mt . . . . . 0 N--CA 1.493 1.713 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.672 ' O ' HG22 ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.772 ' CA ' HD12 ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.672 HG22 ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.808 ' CG2' HD21 ' A' ' 124' ' ' LEU . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.759 ' O ' HD22 ' A' ' 27' ' ' LEU . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.578 ' O ' HG12 ' A' ' 22' ' ' VAL . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.443 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.887 HD12 ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.887 ' N ' HD12 ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.651 HD23 ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.844 ' HB ' HG23 ' A' ' 15' ' ' ILE . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.896 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.824 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.948 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.439 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.982 0 N-CA-C 110.471 -0.626 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.421 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.286 0.565 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 96' ' ' PHE . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' H ' ' A' ' 92' ' ' ASP . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.561 ' H ' HG23 ' A' ' 90' ' ' THR . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.824 ' HB3' HG11 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.456 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.651 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 27' ' ' LEU . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 24' ' ' GLY . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.926 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.497 1.888 0 CA-C-O 121.446 0.641 . . . . 0.0 110.162 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' HG13 ' A' ' 126' ' ' VAL . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.745 ' HB2' HD23 ' A' ' 124' ' ' LEU . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.956 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 41' ' ' VAL . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.624 HG21 ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.42 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.426 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.4 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.956 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.948 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.568 HG11 ' HE1' ' A' ' 109' ' ' TYR . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.419 ' O ' HG13 ' A' ' 20' ' ' VAL . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.926 HG23 ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.463 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.557 0.218 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.504 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.558 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.512 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.986 HG23 HD12 ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.506 ' CD2' ' HB3' ' A' ' 6' ' ' LYS . 0.4 OUTLIER . . . . . 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.986 HD12 HG23 ' A' ' 7' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.703 ' HG2' HG12 ' A' ' 31' ' ' VAL . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.813 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 18' ' ' THR . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.813 ' CG1' HD21 ' A' ' 27' ' ' LEU . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.863 ' O ' HD13 ' A' ' 27' ' ' LEU . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.431 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.863 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.849 ' N ' HD12 ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.856 HD21 HD11 ' A' ' 124' ' ' LEU . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.703 HG12 ' HG2' ' A' ' 16' ' ' PRO . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.531 ' O ' HD11 ' A' ' 15' ' ' ILE . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.512 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.945 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp . . . . . 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.933 0 N-CA-C 110.467 -0.628 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.209 0.528 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.747 HG22 ' CD1' ' A' ' 96' ' ' PHE . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.451 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.747 ' CD1' HG22 ' A' ' 87' ' ' VAL . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.913 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.8 OUTLIER . . . . . 0 N--CA 1.504 2.234 0 CA-C-O 121.027 0.442 . . . . 0.0 111.821 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.629 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.68 ' HB2' HD23 ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.874 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.478 HG11 HG21 ' A' ' 33' ' ' ILE . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.558 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.504 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.444 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.874 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.945 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 107' ' ' GLY . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.913 HG23 ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.677 0.275 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.636 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 1.037 HG23 HD12 ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.41 ' CD2' ' C ' ' A' ' 8' ' ' HIS . 3.8 t60 . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.037 HD12 HG23 ' A' ' 7' ' ' ILE . 3.9 mt . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.664 ' O ' HG22 ' A' ' 18' ' ' THR . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.806 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.664 HG22 ' O ' ' A' ' 16' ' ' PRO . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.866 ' CD1' HD11 ' A' ' 27' ' ' LEU . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.501 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.894 ' CG1' HG22 ' A' ' 128' ' ' VAL . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.582 ' O ' HG12 ' A' ' 22' ' ' VAL . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.592 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.866 HD11 ' CD1' ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.817 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.86 HD21 HD11 ' A' ' 124' ' ' LEU . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.675 ' CG ' HD11 ' A' ' 95' ' ' ILE . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.804 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.464 ' O ' HD11 ' A' ' 15' ' ' ILE . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.665 HD11 ' HB3' ' A' ' 94' ' ' SER . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 38' ' ' ALA . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.817 HG11 ' CB ' ' A' ' 94' ' ' SER . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.953 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.484 0.938 0 N-CA-C 110.414 -0.648 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 . . . . . 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.325 0.583 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.487 HG11 ' HD1' ' A' ' 43' ' ' TRP . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.817 ' CB ' HG11 ' A' ' 41' ' ' VAL . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.675 HD11 ' CG ' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.6 ' HB3' HD23 ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.518 HG22 ' H ' ' A' ' 100' ' ' GLY . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.518 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 . . . . . 0 N--CA 1.495 1.795 0 CA-C-O 121.222 0.534 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.575 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.658 ' HB2' HD23 ' A' ' 124' ' ' LEU . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.906 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.636 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.461 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.456 ' C ' HG12 ' A' ' 122' ' ' VAL . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.906 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.953 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.831 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.894 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.407 ' N ' HG21 ' A' ' 117' ' ' VAL . 18.6 mt-10 . . . . . 0 N--CA 1.492 1.651 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.484 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 1.097 HG23 HD12 ' A' ' 15' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.472 ' CD2' ' HB2' ' A' ' 6' ' ' LYS . 0.7 OUTLIER . . . . . 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 1.097 HD12 HG23 ' A' ' 7' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 32' ' ' PRO . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.635 HG23 ' CG2' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.928 HG23 HD21 ' A' ' 27' ' ' LEU . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.95 ' CG1' HG22 ' A' ' 128' ' ' VAL . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.584 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.476 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.928 HD21 HG23 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.738 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.719 HD22 HG12 ' A' ' 19' ' ' ILE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 15' ' ' ILE . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.931 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.443 ' HB2' ' HG3' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.61 ' O ' HD12 ' A' ' 42' ' ' ILE . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 40' ' ' THR . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.91 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.405 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt . . . . . 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 N--CA 1.483 0.905 0 N-CA-C 110.281 -0.699 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.419 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 65' ' ' THR . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 . . . . . 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 121.229 0.538 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.645 HG11 ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.719 HG22 ' O ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.533 ' H ' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.719 ' O ' HG22 ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.884 ' HB3' HG11 ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.68 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.576 HG22 ' H ' ' A' ' 100' ' ' GLY . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.576 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.231 0.538 . . . . 0.0 110.722 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.446 ' H ' HG13 ' A' ' 126' ' ' VAL . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.705 ' HB2' HD23 ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 123' ' ' ASN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.912 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.572 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.515 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.507 ' HB ' ' HD3' ' A' ' 5' ' ' PRO . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.912 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.91 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . 0.635 ' CG2' HG23 ' A' ' 18' ' ' THR . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.727 HG23 HG22 ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.95 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.503 HD12 ' O ' ' A' ' 130' ' ' ASP . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 129' ' ' ILE . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.569 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.954 HG23 HD12 ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.446 ' N ' ' O ' ' A' ' 6' ' ' LYS . 5.0 t60 . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.954 HD12 HG23 ' A' ' 7' ' ' ILE . 25.5 mt . . . . . 0 N--CA 1.493 1.689 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.711 ' O ' HD12 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.867 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.894 ' O ' HD13 ' A' ' 27' ' ' LEU . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.765 ' HB ' HD22 ' A' ' 27' ' ' LEU . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.592 ' O ' HG12 ' A' ' 22' ' ' VAL . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.511 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.894 HD13 ' O ' ' A' ' 20' ' ' VAL . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.818 ' N ' HD12 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.67 HD23 ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 15' ' ' ILE . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.457 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.662 HG23 HD11 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.419 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HG3' ' O ' ' A' ' 34' ' ' SER . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.825 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.912 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 N--CA 1.483 0.908 0 N-CA-C 110.44 -0.639 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.203 0.525 . . . . 0.0 110.043 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.565 HG11 ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.825 ' HB3' HG11 ' A' ' 41' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.535 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.67 ' HB3' HD23 ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.516 HG22 ' H ' ' A' ' 100' ' ' GLY . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.516 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.247 0.546 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.829 ' HB2' HD23 ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.92 ' CG1' HG13 ' A' ' 122' ' ' VAL . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.62 HG11 HG21 ' A' ' 33' ' ' ILE . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.569 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.492 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . 0.409 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.92 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.912 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.789 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.565 HG22 ' CG1' ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 130' ' ' ASP . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.447 ' N ' HG22 ' A' ' 129' ' ' ILE . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 120.667 0.27 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.556 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PRO . . . . . 0.519 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.899 HG23 HD12 ' A' ' 15' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.46 ' C ' ' CD2' ' A' ' 8' ' ' HIS . 2.7 p-80 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.899 HD12 HG23 ' A' ' 7' ' ' ILE . 2.0 mt . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.653 ' O ' HG22 ' A' ' 18' ' ' THR . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.759 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' PRO . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.922 HG13 HD21 ' A' ' 27' ' ' LEU . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.904 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.786 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.419 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.922 HD21 HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.593 ' N ' HD12 ' A' ' 27' ' ' LEU . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.73 HD21 HD11 ' A' ' 124' ' ' LEU . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.74 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.655 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.975 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.456 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.436 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 110.442 -0.638 . . . . 0.0 110.442 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.418 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 65' ' ' THR . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.296 0.57 . . . . 0.0 109.919 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.709 HG22 ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.772 ' O ' HG22 ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.74 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.709 ' CD1' HG22 ' A' ' 87' ' ' VAL . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.691 ' CG1' HD23 ' A' ' 27' ' ' LEU . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.454 ' H ' HG22 ' A' ' 98' ' ' VAL . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 . . . . . 0 N--CA 1.495 1.792 0 CA-C-O 121.297 0.57 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.627 ' HE1' HG11 ' A' ' 126' ' ' VAL . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.526 HG11 ' CD1' ' A' ' 7' ' ' ILE . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.519 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.556 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . 0.417 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.975 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.739 HG23 HG23 ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.427 HG22 ' CG1' ' A' ' 21' ' ' VAL . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 16.4 mtt-85 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.244 0.545 . . . . 0.0 110.175 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.535 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 5.7 pt20 -145.11 -132.9 0.08 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.814 . . . . 0.0 109.866 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -116.4 148.14 41.08 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.912 -1.118 . . . . 0.0 110.305 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.479 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.4 Cg_endo -65.1 129.26 22.52 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.748 1.394 . . . . 0.0 110.907 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 48.6 Cg_endo -70.04 147.81 61.86 Favored 'Trans proline' 0 C--N 1.311 -1.435 0 O-C-N 123.981 1.516 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.428 ' O ' HG22 ' A' ' 33' ' ' ILE . 10.9 mttt -170.53 153.58 4.29 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.828 . . . . 0.0 110.269 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.943 ' CG2' HD12 ' A' ' 15' ' ' ILE . 22.1 mm -81.09 54.02 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.359 -0.838 . . . . 0.0 109.798 179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.569 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 12.9 t60 -125.27 164.5 20.19 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.326 -0.858 . . . . 0.0 110.014 -179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.621 HD23 ' HG2' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -119.38 -92.48 0.54 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.236 -0.915 . . . . 0.0 110.897 179.591 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.404 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 13.7 t70 -120.1 -12.69 9.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.955 -1.09 . . . . 0.0 111.758 -178.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.488 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 0.5 OUTLIER -170.19 -61.77 0.0 OUTLIER Pre-proline 0 N--CA 1.5 2.034 0 O-C-N 120.714 -1.241 . . . . 0.0 112.422 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.488 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 40.4 Cg_endo -67.32 -11.79 33.48 Favored 'Trans proline' 0 C--N 1.312 -1.374 0 O-C-N 123.196 1.103 . . . . 0.0 111.434 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 44.74 48.4 9.09 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.8 ttm180 -128.03 99.2 5.39 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.208 -1.172 . . . . 0.0 110.516 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.943 HD12 ' CG2' ' A' ' 7' ' ' ILE . 6.8 mt -81.6 119.92 76.69 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.382 -0.824 . . . . 0.0 109.634 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.02 60.29 3.04 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.67 1.352 . . . . 0.0 110.631 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -65.56 80.13 0.06 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.364 -0.835 . . . . 0.0 110.303 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.6 m -139.33 102.9 4.6 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.262 -0.898 . . . . 0.0 109.926 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.805 ' CD1' HD21 ' A' ' 27' ' ' LEU . 10.7 tp -96.77 116.99 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.333 -0.854 . . . . 0.0 110.361 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.776 ' O ' HD22 ' A' ' 27' ' ' LEU . 67.5 t -129.01 146.93 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.644 -179.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.988 HG11 ' HB3' ' A' ' 101' ' ' ALA . 2.8 p -147.85 159.49 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.553 -0.717 . . . . 0.0 110.056 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.597 ' O ' HG12 ' A' ' 22' ' ' VAL . 66.1 t -93.35 54.8 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.382 -0.824 . . . . 0.0 110.032 179.685 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.417 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 45.25 93.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.6 -0.687 . . . . 0.0 111.454 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 49.41 5.96 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.09 -1.204 . . . . 0.0 110.09 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -139.23 163.25 32.94 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.31 -1.112 . . . . 0.0 110.117 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.6 mtpt -76.78 110.0 11.02 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.485 -0.759 . . . . 0.0 109.85 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.876 HD12 ' N ' ' A' ' 28' ' ' ARG . 1.9 tp -111.63 142.56 43.79 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.254 -0.904 . . . . 0.0 110.388 -179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.876 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -129.96 130.91 45.68 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.584 -0.697 . . . . 0.0 109.636 179.484 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.727 HD23 ' HB3' ' A' ' 96' ' ' PHE . 49.7 tp -127.43 127.97 44.99 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.239 -0.913 . . . . 0.0 110.119 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -123.37 127.15 48.06 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.489 -0.757 . . . . 0.0 110.642 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.798 ' HB ' HG23 ' A' ' 15' ' ' ILE . 4.3 m -140.56 121.7 9.2 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.471 -0.768 . . . . 0.0 109.736 179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HG2' HD23 ' A' ' 9' ' ' LEU . 50.3 Cg_endo -77.24 145.74 24.49 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.617 1.325 . . . . 0.0 111.392 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.606 HG21 HG11 ' A' ' 113' ' ' VAL . 1.2 mt -139.3 169.87 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.377 -0.827 . . . . 0.0 109.827 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.14 -147.68 0.06 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.378 -0.826 . . . . 0.0 109.777 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.17 146.88 3.05 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.4 t70 -152.21 133.27 7.84 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.414 -1.051 . . . . 0.0 110.105 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 46.4 Cg_endo -77.1 -59.16 0.13 OUTLIER 'Cis proline' 0 N--CA 1.487 1.092 0 C-N-CA 122.229 -1.988 . . . . 0.0 110.569 -0.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -111.19 126.52 28.49 Favored Pre-proline 0 N--CA 1.493 1.691 0 O-C-N 121.387 -0.821 . . . . 0.0 110.245 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -85.39 -167.5 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.497 0 O-C-N 123.749 1.394 . . . . 0.0 110.494 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -121.16 86.96 2.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.488 -0.758 . . . . 0.0 109.428 179.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.854 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -91.89 98.99 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.649 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.682 HG22 HG22 ' A' ' 112' ' ' THR . 0.0 OUTLIER -89.83 120.47 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.317 -0.864 . . . . 0.0 110.033 179.941 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.97 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 89.1 m95 -80.13 104.51 10.74 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.325 -0.86 . . . . 0.0 109.783 179.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -97.41 160.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.172 -0.955 . . . . 0.0 110.288 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 109' ' ' TYR . 18.3 tttt -109.15 151.46 26.42 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.364 -0.835 . . . . 0.0 110.175 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.441 ' HB3' HG12 ' A' ' 108' ' ' VAL . . . -135.81 129.97 33.26 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.356 -0.84 . . . . 0.0 110.138 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.447 HG22 ' O ' ' A' ' 47' ' ' ILE . 48.9 mm -104.98 -1.09 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.301 -0.874 . . . . 0.0 110.605 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 66.1 p 44.29 59.25 3.34 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.415 -0.803 . . . . 0.0 110.913 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -97.54 -73.63 0.6 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 110.152 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 174.75 98.97 0.11 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -154.66 -158.39 0.85 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.365 -1.079 . . . . 0.0 110.164 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.1 -159.96 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.35 -0.844 . . . . 0.0 110.437 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.737 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -51.59 173.23 0.13 Allowed Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.61 -0.682 . . . . 0.0 110.526 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.737 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 46.3 Cg_endo -72.56 166.91 28.5 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.816 1.429 . . . . 0.0 110.505 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -158.93 149.07 19.4 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.845 . . . . 0.0 110.206 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -119.6 73.85 16.78 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.388 -0.82 . . . . 0.0 110.07 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.0 -170.74 0.66 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.992 1.522 . . . . 0.0 110.456 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -89.42 138.93 28.28 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.199 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.09 96.31 0.94 Allowed 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.684 1.36 . . . . 0.0 110.45 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 5.9 m-20 -128.86 62.81 1.48 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.38 -0.825 . . . . 0.0 110.288 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.61 98.02 0.16 Allowed Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.639 -0.663 . . . . 0.0 110.466 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.424 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.5 Cg_endo -91.55 111.16 0.31 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.864 1.455 . . . . 0.0 110.536 -178.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.08 132.16 50.98 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.327 -0.858 . . . . 0.0 110.159 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -166.35 -171.41 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.411 -0.806 . . . . 0.0 110.164 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.6 p -98.21 -38.67 9.2 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.39 -0.819 . . . . 0.0 110.19 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 66.82 65.14 2.92 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.88 30.73 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.365 -1.079 . . . . 0.0 110.194 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.25 -37.78 37.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.35 -0.844 . . . . 0.0 110.186 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -86.31 -167.27 1.81 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.35 -0.844 . . . . 0.0 110.142 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.39 -167.03 2.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.399 -0.813 . . . . 0.0 110.224 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.0 t-105 -104.69 74.5 1.15 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.439 -0.788 . . . . 0.0 110.151 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.423 ' O ' ' N ' ' A' ' 74' ' ' ASP . 57.6 t -67.4 -18.03 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.336 -0.852 . . . . 0.0 110.36 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.418 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 21.2 t80 52.89 -90.33 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.415 -0.803 . . . . 0.0 110.439 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 72' ' ' VAL . 2.5 p30 -69.35 -163.99 0.06 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.091 -1.006 . . . . 0.0 110.147 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -97.97 128.39 44.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.281 -0.887 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -62.29 99.75 0.15 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.319 -0.863 . . . . 0.0 110.18 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.438 ' HA ' HD13 ' A' ' 77' ' ' LEU . 2.1 mm? -84.18 -35.03 23.85 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.825 . . . . 0.0 110.148 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -80.68 84.09 6.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.33 -0.856 . . . . 0.0 110.149 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 3.8 m -83.32 -72.74 0.44 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.381 -0.825 . . . . 0.0 110.225 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -69.47 105.73 2.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.378 -0.826 . . . . 0.0 110.289 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.474 HG22 ' H ' ' A' ' 82' ' ' GLU . 0.2 OUTLIER -73.67 -162.42 0.13 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.327 -0.858 . . . . 0.0 110.025 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.474 ' H ' HG22 ' A' ' 81' ' ' THR . 13.5 mt-10 -82.69 -27.91 30.93 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.361 -0.837 . . . . 0.0 110.246 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -159.11 38.6 0.5 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 13.4 ttt-85 -111.89 -62.5 1.55 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.347 -1.09 . . . . 0.0 110.191 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.87 ' HA ' HG23 ' A' ' 98' ' ' VAL . 7.5 p -135.97 138.16 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.355 -0.84 . . . . 0.0 110.176 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -125.28 106.91 10.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.327 -0.858 . . . . 0.0 110.085 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 96' ' ' PHE . 58.2 t -122.05 116.11 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.359 -0.838 . . . . 0.0 110.11 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -135.15 152.78 51.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.353 -0.842 . . . . 0.0 110.223 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.484 ' CG2' HG12 ' A' ' 41' ' ' VAL . 25.3 m -96.08 124.33 40.05 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.363 -0.835 . . . . 0.0 110.179 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -67.8 -177.49 0.8 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 110.367 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.27 -40.47 86.17 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.428 -0.795 . . . . 0.0 111.469 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.9 40.24 2.34 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.944 -1.097 . . . . 0.0 111.061 -179.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -178.68 168.13 1.73 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.28 -0.887 . . . . 0.0 109.789 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.854 ' HB3' HG11 ' A' ' 41' ' ' VAL . 73.0 p -107.38 143.12 36.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.35 -0.844 . . . . 0.0 110.359 -179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.462 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.9 OUTLIER -127.83 127.54 68.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.323 -0.861 . . . . 0.0 109.987 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.0 OUTLIER -113.78 95.53 5.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.273 -0.892 . . . . 0.0 109.29 178.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -120.46 106.47 11.85 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.338 -0.851 . . . . 0.0 109.931 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.87 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.4 p -120.41 139.67 46.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.421 -0.799 . . . . 0.0 110.388 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.7 pm0 -106.89 43.93 1.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.423 -0.798 . . . . 0.0 109.982 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -173.48 28.07 0.09 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.988 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -70.89 84.31 0.67 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.25 -1.147 . . . . 0.0 109.529 179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.415 ' O ' HG21 ' A' ' 128' ' ' VAL . 55.1 mt-10 -87.86 -173.7 4.4 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -0.861 . . . . 0.0 110.581 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.07 -28.96 19.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.466 -0.771 . . . . 0.0 110.324 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -64.33 -28.63 69.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.378 -0.826 . . . . 0.0 109.809 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -32.36 18.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.452 -0.78 . . . . 0.0 110.014 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -50.59 163.23 0.19 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.415 -0.803 . . . . 0.0 110.554 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 128.71 -123.76 4.41 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.441 HG12 ' HB3' ' A' ' 46' ' ' ALA . 66.9 t -142.25 154.86 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.347 -1.09 . . . . 0.0 110.067 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.73 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.5 m-85 -138.46 159.55 41.78 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.418 -0.801 . . . . 0.0 110.641 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.9 m -135.29 101.6 4.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.533 -0.729 . . . . 0.0 109.255 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 5.6 p -84.13 137.77 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.351 -0.843 . . . . 0.0 110.249 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.682 HG22 HG22 ' A' ' 42' ' ' ILE . 10.9 t -119.95 127.98 53.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.357 -0.839 . . . . 0.0 110.827 -179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.606 HG11 HG21 ' A' ' 33' ' ' ILE . 14.6 m -102.95 134.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -136.67 159.74 40.91 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.179 -0.951 . . . . 0.0 110.988 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.498 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.4 m-20 -166.61 176.51 1.79 Allowed Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.582 -0.699 . . . . 0.0 109.543 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.425 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.8 Cg_endo -70.33 -6.48 18.98 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.613 1.323 . . . . 0.0 111.667 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.535 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 52.9 t -105.19 -34.05 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.892 -1.13 . . . . 0.0 110.549 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.93 -148.85 6.33 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.053 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -168.97 150.31 4.53 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.459 -1.024 . . . . 0.0 109.87 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.429 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -139.6 174.16 10.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.328 -0.858 . . . . 0.0 110.185 -179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.443 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.1 OUTLIER -146.27 166.12 27.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 -179.749 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -168.3 162.65 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.561 -0.712 . . . . 0.0 109.279 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.403 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 3.8 p-10 -105.61 141.97 36.16 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.325 -0.86 . . . . 0.0 110.62 -179.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.97 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.25 122.83 46.11 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.734 -0.604 . . . . 0.0 109.783 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 36.8 m -89.8 131.84 35.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.397 -0.814 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.8 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -117.46 159.82 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.361 -0.837 . . . . 0.0 110.182 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -164.02 117.44 1.44 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.159 -0.963 . . . . 0.0 110.298 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 101' ' ' ALA . 58.3 t -95.2 119.22 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.415 -0.803 . . . . 0.0 110.036 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 36.7 mm -93.79 160.71 2.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.496 -0.752 . . . . 0.0 109.469 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.9 t0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.216 -179.906 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 25.6 mtm-85 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.208 0.527 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.547 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.6 OUTLIER -61.38 -159.89 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.318 -0.864 . . . . 0.0 110.354 -179.873 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -81.46 150.46 67.1 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.209 -0.932 . . . . 0.0 110.927 -179.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.527 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.8 Cg_endo -66.43 130.61 24.18 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.814 1.428 . . . . 0.0 111.028 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.563 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 54.1 Cg_endo -70.94 141.12 39.72 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.95 1.5 . . . . 0.0 110.215 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 8' ' ' HIS . 36.1 pttt -170.47 149.63 3.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.149 -0.97 . . . . 0.0 110.904 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.964 HG23 HD12 ' A' ' 15' ' ' ILE . 12.1 mm -68.81 63.77 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.676 -0.64 . . . . 0.0 109.915 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 12.0 t60 -125.43 161.32 27.33 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.338 -0.851 . . . . 0.0 110.344 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.537 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -124.11 -98.23 0.43 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.413 -0.804 . . . . 0.0 110.357 179.434 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.433 ' H ' ' CD1' ' A' ' 9' ' ' LEU . 12.5 t70 -109.62 -20.8 12.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.761 -1.212 . . . . 0.0 111.21 -179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.499 ' HB3' ' CD ' ' A' ' 12' ' ' PRO . 1.8 t -153.66 -66.8 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 120.891 -1.131 . . . . 0.0 111.846 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.527 ' HG2' HD11 ' A' ' 9' ' ' LEU . 41.6 Cg_endo -68.51 -87.35 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 122.833 0.912 . . . . 0.0 110.828 -179.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.515 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 121.73 49.9 0.26 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.422 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.6 OUTLIER -118.3 93.84 4.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.575 -0.956 . . . . 0.0 109.33 179.235 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 33' ' ' ILE . 8.5 mt -79.37 113.02 33.15 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.048 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.491 ' O ' ' N ' ' A' ' 18' ' ' THR . 51.4 Cg_endo -80.46 61.68 8.29 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 O-C-N 123.673 1.354 . . . . 0.0 110.0 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.74 ' OD1' HG11 ' A' ' 31' ' ' VAL . 39.3 m-20 -59.22 79.91 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.363 -0.836 . . . . 0.0 110.578 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.642 HG23 ' HB ' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.85 135.73 31.66 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.895 HD11 HD11 ' A' ' 27' ' ' LEU . 10.8 tp -143.14 147.94 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.053 -1.029 . . . . 0.0 111.353 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.6 t -133.51 154.42 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.427 -0.796 . . . . 0.0 109.818 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.088 HG11 ' HB3' ' A' ' 101' ' ' ALA . 7.1 p -151.13 159.48 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.36 -0.838 . . . . 0.0 109.904 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.542 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.1 t -93.88 60.55 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.286 -0.884 . . . . 0.0 110.69 -179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 40.66 95.18 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.606 -0.683 . . . . 0.0 112.109 179.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.58 55.11 4.02 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -139.35 160.56 39.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -1.172 . . . . 0.0 110.224 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.62 106.29 2.55 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.366 -0.834 . . . . 0.0 109.631 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.895 HD11 HD11 ' A' ' 19' ' ' ILE . 8.4 tp -112.64 142.87 44.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.901 . . . . 0.0 110.679 -179.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.714 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.9 OUTLIER -135.25 141.69 45.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.593 -0.692 . . . . 0.0 109.87 179.468 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.763 HD13 HD13 ' A' ' 19' ' ' ILE . 60.4 tp -135.48 139.94 44.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.207 -0.933 . . . . 0.0 110.469 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -132.79 120.5 21.67 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.39 -0.819 . . . . 0.0 110.495 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.74 HG11 ' OD1' ' A' ' 17' ' ' ASP . 32.6 m -126.27 128.15 24.48 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.367 -0.833 . . . . 0.0 109.735 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.489 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.3 Cg_endo -79.66 139.4 14.15 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 123.444 1.233 . . . . 0.0 111.213 -178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.965 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.99 162.11 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.335 -0.853 . . . . 0.0 109.633 179.526 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.79 -145.45 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.29 -0.881 . . . . 0.0 109.732 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.55 143.47 13.27 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.8 t70 -152.36 109.66 2.79 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.395 -1.062 . . . . 0.0 109.992 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -73.56 -59.78 0.1 OUTLIER 'Cis proline' 0 N--CA 1.488 1.154 0 C-N-CA 122.237 -1.985 . . . . 0.0 110.839 0.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.527 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.6 134.48 23.85 Favored Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.287 -0.883 . . . . 0.0 110.567 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 50.9 Cg_endo -82.41 -170.02 0.86 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.675 1.355 . . . . 0.0 110.485 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.0 m -116.02 85.82 2.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.577 -0.702 . . . . 0.0 109.295 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.749 HG11 ' HB2' ' A' ' 94' ' ' SER . 7.9 p -85.86 98.71 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 CA-C-O 121.648 0.737 . . . . 0.0 110.045 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.492 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 21.4 mm -87.03 115.18 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.618 -0.676 . . . . 0.0 110.925 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.961 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 82.7 m95 -77.38 103.02 7.07 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.313 -0.867 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.7 tm0? -94.15 154.16 17.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.533 -179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 0.9 OUTLIER -120.88 147.69 45.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.458 -0.776 . . . . 0.0 110.336 -179.806 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.08 119.05 16.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.396 -0.815 . . . . 0.0 110.085 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.0 mt -103.45 -19.97 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.387 -0.821 . . . . 0.0 110.397 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 6.1 t -54.53 -30.75 54.68 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.27 -0.894 . . . . 0.0 110.535 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 51.17 38.76 21.91 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.365 -0.834 . . . . 0.0 110.593 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -138.23 -110.06 0.92 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -129.51 -68.76 0.71 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.331 -1.099 . . . . 0.0 110.241 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.91 -160.38 0.99 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.862 . . . . 0.0 110.221 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.516 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -92.66 166.71 16.16 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.562 -0.711 . . . . 0.0 110.257 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.516 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.8 Cg_endo -75.91 167.09 26.86 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.862 1.454 . . . . 0.0 110.403 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -86.06 109.36 18.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.334 -0.854 . . . . 0.0 110.154 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 13.1 ttt-85 -118.43 73.8 11.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.457 -0.777 . . . . 0.0 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.88 155.55 53.28 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.005 1.529 . . . . 0.0 110.437 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.71 149.84 71.53 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.305 -0.872 . . . . 0.0 110.198 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.64 116.33 4.64 Favored 'Trans proline' 0 C--N 1.311 -1.419 0 O-C-N 123.709 1.373 . . . . 0.0 110.435 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.425 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 7.0 m-20 52.83 65.95 1.37 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.278 -0.889 . . . . 0.0 110.445 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.94 98.23 0.17 Allowed Pre-proline 0 N--CA 1.499 2.02 0 O-C-N 121.65 -0.656 . . . . 0.0 110.321 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.9 Cg_endo -91.48 156.99 3.63 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 O-C-N 123.75 1.395 . . . . 0.0 110.573 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -67.74 78.73 0.2 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -63.78 111.62 2.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.308 -0.87 . . . . 0.0 110.199 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.404 HG22 ' O ' ' A' ' 65' ' ' THR . 22.7 m -121.01 48.49 1.63 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.377 -0.827 . . . . 0.0 110.191 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 165.12 -162.17 35.46 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -152.02 74.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.26 -1.141 . . . . 0.0 110.187 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 70' ' ' GLU . 1.4 t 52.77 70.05 0.62 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.383 -0.823 . . . . 0.0 110.504 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.0 t70 55.4 -87.04 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.481 -0.762 . . . . 0.0 110.602 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 68' ' ' SER . 3.0 mm-40 -65.21 -170.24 0.06 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.015 -1.053 . . . . 0.0 110.19 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.3 t-105 -111.42 77.38 1.04 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.3 -0.875 . . . . 0.0 110.232 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' A' ' 73' ' ' PHE . 60.2 t -79.82 -8.37 11.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.38 -0.825 . . . . 0.0 110.536 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.493 ' CG ' ' O ' ' A' ' 72' ' ' VAL . 39.2 p90 37.52 -164.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 CA-C-O 121.341 0.591 . . . . 0.0 111.871 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 61.9 m-20 -149.08 -161.98 1.46 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.188 -0.945 . . . . 0.0 110.332 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.1 mttt -53.77 177.96 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.35 -0.844 . . . . 0.0 110.382 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 1.9 tptm 60.51 156.44 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.445 -0.785 . . . . 0.0 110.279 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.4 pp -170.41 -177.16 2.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.241 -0.912 . . . . 0.0 110.315 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.71 127.57 36.36 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.414 -0.804 . . . . 0.0 110.183 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.49 -176.73 0.25 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.4 -0.813 . . . . 0.0 110.203 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -119.2 -175.97 3.03 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.39 -0.819 . . . . 0.0 110.243 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.47 ' O ' ' N ' ' A' ' 83' ' ' GLY . 3.8 t -172.77 -156.1 0.09 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.414 -0.804 . . . . 0.0 110.027 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.427 ' N ' ' OG1' ' A' ' 81' ' ' THR . 3.3 tt0 66.5 -66.06 0.19 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.445 -0.785 . . . . 0.0 109.401 -179.191 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -102.45 -21.08 10.95 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 179.082 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 11.1 mtt85 -91.85 -79.7 0.37 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.337 -1.096 . . . . 0.0 110.312 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.888 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.7 p -122.13 121.01 62.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.145 -0.972 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.19 115.69 29.67 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.372 -0.83 . . . . 0.0 110.292 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 71.6 t -126.72 111.64 26.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 110.112 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -135.68 154.17 51.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.362 -0.836 . . . . 0.0 110.397 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.404 HG23 ' HA ' ' A' ' 94' ' ' SER . 99.6 m -112.78 150.26 31.86 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.45 -0.781 . . . . 0.0 110.038 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 40.6 p -98.47 -172.32 2.3 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.354 -0.841 . . . . 0.0 110.19 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 1.0 OUTLIER -55.45 -31.33 61.86 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.518 -0.739 . . . . 0.0 110.775 -179.716 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -154.68 48.42 0.58 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.164 -0.96 . . . . 0.0 110.593 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -176.14 110.32 0.1 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.183 -0.948 . . . . 0.0 110.533 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.749 ' HB2' HG11 ' A' ' 41' ' ' VAL . 23.4 t -73.89 142.83 45.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.781 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -127.48 132.34 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.484 -179.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.727 ' HB3' HD23 ' A' ' 29' ' ' LEU . 78.3 t80 -117.82 95.66 5.02 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.362 -0.837 . . . . 0.0 109.037 178.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.488 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.1 OUTLIER -119.47 110.42 16.88 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.445 -0.785 . . . . 0.0 109.77 -179.763 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.888 ' HB ' HG23 ' A' ' 85' ' ' VAL . 4.8 p -118.68 132.12 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -0.817 . . . . 0.0 110.528 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -100.57 44.01 1.03 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.406 -0.809 . . . . 0.0 109.924 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.445 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -172.9 28.33 0.1 OUTLIER Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 1.088 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -69.2 85.77 0.38 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.348 -1.089 . . . . 0.0 109.662 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.438 ' O ' HG21 ' A' ' 128' ' ' VAL . 2.9 tp10 -90.11 174.64 7.52 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.405 -0.809 . . . . 0.0 110.449 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.21 -29.72 23.94 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.339 -0.851 . . . . 0.0 110.362 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -70.94 -21.0 62.4 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.424 -0.797 . . . . 0.0 110.127 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -87.17 -33.05 19.52 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.375 -0.828 . . . . 0.0 110.032 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.401 ' CG ' ' HA ' ' A' ' 127' ' ' LYS . 2.8 tt0 -52.76 165.68 0.26 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.359 -0.838 . . . . 0.0 110.456 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 142.31 -129.96 4.08 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 55.2 t -133.06 148.99 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.389 -1.065 . . . . 0.0 109.998 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.782 ' HB2' HD23 ' A' ' 124' ' ' LEU . 56.3 m-85 -136.9 158.7 43.86 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.504 -0.747 . . . . 0.0 110.417 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 8.5 m -138.32 101.4 4.37 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.925 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.8 p -86.39 134.21 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.354 -0.841 . . . . 0.0 110.369 -179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.66 HG23 ' HG3' ' A' ' 121' ' ' GLN . 89.8 m -120.18 129.09 53.96 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.351 -0.843 . . . . 0.0 111.055 -178.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 33' ' ' ILE . 9.2 m -101.57 131.03 50.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.32 -0.863 . . . . 0.0 109.334 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.72 164.59 26.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.146 -0.971 . . . . 0.0 111.206 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.563 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.2 m-20 -170.42 176.37 1.23 Allowed Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.667 -0.645 . . . . 0.0 109.321 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.6 Cg_endo -71.29 -3.8 13.67 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.527 1.278 . . . . 0.0 111.867 -178.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.547 ' CG2' ' HG3' ' A' ' 2' ' ' GLN . 47.4 t -107.84 -33.36 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.888 -1.133 . . . . 0.0 110.638 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.464 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.25 -148.95 6.42 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 119.43 -1.367 . . . . 0.0 109.995 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -169.39 149.0 3.95 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.357 -1.084 . . . . 0.0 110.501 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.447 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -136.38 168.83 18.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.328 -0.858 . . . . 0.0 109.621 179.566 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.66 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.0 OUTLIER -145.72 160.55 41.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.178 -0.951 . . . . 0.0 110.952 -179.48 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.925 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -161.68 159.18 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.616 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -100.8 143.29 31.14 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.188 -0.945 . . . . 0.0 110.521 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.961 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.52 124.36 49.7 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.477 -0.765 . . . . 0.0 109.649 179.603 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.642 ' HB ' HG23 ' A' ' 18' ' ' THR . 6.9 m -102.68 134.53 45.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.401 -0.812 . . . . 0.0 110.061 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.495 HG11 ' HE1' ' A' ' 109' ' ' TYR . 7.5 p -122.18 159.33 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.334 -0.854 . . . . 0.0 110.336 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.401 ' HA ' ' CG ' ' A' ' 106' ' ' GLU . 0.1 OUTLIER -151.69 123.95 8.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.412 -0.805 . . . . 0.0 109.984 179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 23' ' ' ALA . 65.3 t -104.72 119.82 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.332 -0.855 . . . . 0.0 110.411 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 34.0 mm -89.12 151.42 3.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.528 -0.733 . . . . 0.0 109.443 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 10.7 t0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.27 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.232 0.539 . . . . 0.0 110.178 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' HG3' HG21 ' A' ' 117' ' ' VAL . 8.5 pt20 -85.91 -142.39 0.1 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.385 -0.822 . . . . 0.0 110.219 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 6.5 mp0 -117.92 150.35 47.06 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.101 -0.999 . . . . 0.0 110.299 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.463 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.24 131.17 31.18 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 123.776 1.408 . . . . 0.0 110.848 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.532 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.56 148.86 60.81 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 124.01 1.531 . . . . 0.0 110.892 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.434 ' CG ' ' CB ' ' A' ' 34' ' ' SER . 5.8 ptpp? -170.62 146.49 2.71 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.473 -0.767 . . . . 0.0 110.189 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.698 HG22 ' HB ' ' A' ' 15' ' ' ILE . 25.6 mm -77.45 47.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.483 -0.761 . . . . 0.0 110.26 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.56 ' CD2' ' O ' ' A' ' 9' ' ' LEU . 1.8 t60 -126.95 157.85 38.38 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.361 -0.837 . . . . 0.0 110.116 -179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.787 HD21 ' O ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -120.25 -115.98 0.32 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 121.227 -0.92 . . . . 0.0 110.776 179.695 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.41 ' N ' ' CD1' ' A' ' 9' ' ' LEU . 2.3 t0 -73.74 -43.16 59.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.462 -1.399 . . . . 0.0 108.984 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.617 ' CB ' ' HD3' ' A' ' 12' ' ' PRO . 0.1 OUTLIER 175.44 -57.97 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.799 -0.563 . . . . 0.0 110.536 179.211 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.617 ' HD3' ' CB ' ' A' ' 11' ' ' CYS . 54.9 Cg_endo -88.48 154.0 6.5 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.352 1.185 . . . . 0.0 111.252 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.787 ' O ' HD21 ' A' ' 9' ' ' LEU . . . 55.21 51.69 52.42 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 178.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.479 ' C ' ' O ' ' A' ' 13' ' ' GLY . 1.4 ptp85 -32.15 -93.22 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.571 -0.958 . . . . 0.0 111.531 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.902 ' CD1' HG23 ' A' ' 33' ' ' ILE . 7.6 mt -140.47 86.52 12.4 Favored Pre-proline 0 N--CA 1.488 1.435 0 O-C-N 120.324 -1.485 . . . . 0.0 110.126 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.462 ' O ' ' N ' ' A' ' 18' ' ' THR . 49.2 Cg_endo -77.08 62.58 7.52 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.628 1.33 . . . . 0.0 109.094 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 124' ' ' LEU . 22.7 p-10 -60.26 80.56 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 CA-C-O 121.682 0.753 . . . . 0.0 110.671 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.647 HG23 ' HB ' ' A' ' 125' ' ' THR . 23.2 m -139.28 138.59 36.88 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.37 -0.831 . . . . 0.0 108.916 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.991 HD13 HD13 ' A' ' 29' ' ' LEU . 9.3 tp -144.53 149.37 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.124 -0.985 . . . . 0.0 111.565 -178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG22 ' HB3' ' A' ' 127' ' ' LYS . 85.1 t -133.02 158.76 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.519 -0.738 . . . . 0.0 109.453 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.003 HG11 ' HB3' ' A' ' 101' ' ' ALA . 7.3 p -151.08 159.29 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.239 -0.913 . . . . 0.0 110.22 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' H ' HG22 ' A' ' 22' ' ' VAL . 34.8 m -91.31 53.72 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.264 -0.898 . . . . 0.0 110.538 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 45.61 100.0 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.755 -0.591 . . . . 0.0 112.488 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.23 52.88 4.08 Favored Glycine 0 N--CA 1.494 2.565 0 C-N-CA 120.361 -0.923 . . . . 0.0 111.155 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -140.17 163.99 31.26 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.948 -1.325 . . . . 0.0 110.272 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -75.43 106.91 7.21 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 109.456 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.9 HD11 ' CG1' ' A' ' 19' ' ' ILE . 10.4 tp -112.54 143.67 43.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.242 -0.911 . . . . 0.0 111.128 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.691 ' H ' HD12 ' A' ' 27' ' ' LEU . 12.0 ptm180 -135.31 148.1 49.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.73 -0.606 . . . . 0.0 109.513 179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.991 HD13 HD13 ' A' ' 19' ' ' ILE . 61.3 tp -141.6 145.44 35.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.055 -1.028 . . . . 0.0 110.525 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -132.2 135.16 46.13 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.443 -0.786 . . . . 0.0 110.475 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 94' ' ' SER . 4.5 m -139.25 114.66 8.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.33 -0.856 . . . . 0.0 109.901 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.783 ' HG2' HD23 ' A' ' 9' ' ' LEU . 51.1 Cg_endo -79.32 124.32 5.87 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.463 1.244 . . . . 0.0 110.866 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.902 HG23 ' CD1' ' A' ' 15' ' ' ILE . 0.4 OUTLIER -123.77 169.5 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 179.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.434 ' CB ' ' CG ' ' A' ' 6' ' ' LYS . 48.3 t -86.19 -150.8 0.15 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.282 -0.886 . . . . 0.0 110.023 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.18 148.79 23.22 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.417 ' HB3' ' HB2' ' A' ' 2' ' ' GLN . 2.1 t70 -152.05 128.82 5.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.402 -1.058 . . . . 0.0 110.25 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -75.62 -56.8 0.14 OUTLIER 'Cis proline' 0 N--CA 1.487 1.106 0 C-N-CA 122.209 -1.996 . . . . 0.0 110.369 -0.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -114.29 132.04 22.97 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.491 -0.756 . . . . 0.0 110.399 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -82.53 -164.71 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.734 1.386 . . . . 0.0 110.092 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.44 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -125.34 86.47 2.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.319 -0.863 . . . . 0.0 109.176 178.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.665 ' O ' HG13 ' A' ' 41' ' ' VAL . 11.6 p -92.64 99.44 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.523 -0.736 . . . . 0.0 110.513 -179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 32.1 mm -92.75 115.03 30.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.324 -0.86 . . . . 0.0 110.483 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.941 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 86.1 m95 -74.11 112.68 10.49 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.302 -0.873 . . . . 0.0 110.109 179.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' THR . 21.2 tt0 -102.22 160.22 14.72 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.231 -0.918 . . . . 0.0 109.908 179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.3 pttt -127.31 156.45 41.94 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.264 -0.897 . . . . 0.0 110.363 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.5 150.27 49.73 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.625 HG22 ' O ' ' A' ' 47' ' ' ILE . 76.0 mt -101.51 25.5 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.477 -0.764 . . . . 0.0 109.971 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 67.3 p -74.74 -4.77 39.48 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.368 -0.833 . . . . 0.0 110.567 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 54.68 -151.51 0.37 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.201 -0.937 . . . . 0.0 110.219 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -53.75 -85.05 0.03 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.7 m-20 51.91 -167.52 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.307 -1.113 . . . . 0.0 110.329 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.86 -160.94 0.13 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.245 -0.909 . . . . 0.0 110.412 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.598 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -63.73 168.96 4.76 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.53 -0.731 . . . . 0.0 110.123 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.598 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.1 Cg_endo -73.75 166.85 28.71 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.799 1.421 . . . . 0.0 110.457 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -116.95 143.74 45.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.08 86.14 13.39 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.366 -0.834 . . . . 0.0 110.351 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.03 169.19 22.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.834 1.439 . . . . 0.0 110.334 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -138.13 120.26 10.76 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.294 -0.879 . . . . 0.0 110.129 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.62 116.51 4.74 Favored 'Trans proline' 0 C--N 1.311 -1.4 0 O-C-N 123.707 1.372 . . . . 0.0 110.393 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 22.6 m-20 -131.43 65.9 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.373 -0.829 . . . . 0.0 110.064 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.66 97.58 0.14 Allowed Pre-proline 0 N--CA 1.5 2.058 0 O-C-N 121.64 -0.663 . . . . 0.0 110.597 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.67 111.1 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.813 1.428 . . . . 0.0 110.506 -178.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -66.93 162.89 20.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.403 -0.811 . . . . 0.0 110.097 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -109.52 147.85 32.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.372 -0.83 . . . . 0.0 110.294 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 10.4 m -117.21 32.2 6.3 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.349 -0.844 . . . . 0.0 110.085 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -175.56 171.41 44.5 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -159.11 32.62 0.21 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.318 -1.107 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.41 97.26 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.402 -0.811 . . . . 0.0 110.46 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -86.69 53.35 2.79 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.272 -0.892 . . . . 0.0 110.329 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -123.58 -167.29 1.59 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.322 -0.861 . . . . 0.0 110.168 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.2 t-105 -103.24 127.66 50.48 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.329 -0.857 . . . . 0.0 110.258 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.412 HG12 ' N ' ' A' ' 73' ' ' PHE . 98.5 t -110.73 162.14 8.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 110.202 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.469 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 31.7 p90 -141.68 -148.63 0.24 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.492 -0.755 . . . . 0.0 109.963 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -51.23 -63.07 1.25 Allowed 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.106 -0.996 . . . . 0.0 110.724 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.01 96.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.276 -0.89 . . . . 0.0 110.215 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 37.9 tttp -74.15 119.18 18.01 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.387 -0.821 . . . . 0.0 110.272 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.26 67.64 1.46 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.327 -0.858 . . . . 0.0 110.239 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.8 pp -167.84 159.54 11.68 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.387 -0.821 . . . . 0.0 110.212 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.8 m -146.84 144.31 29.22 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 110.213 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -107.16 72.32 0.87 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 110.192 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.7 t -113.51 -162.56 0.81 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.365 -0.834 . . . . 0.0 110.282 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -84.8 73.18 10.66 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.39 -0.819 . . . . 0.0 109.788 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 126.94 1.2 6.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.036 -1.226 . . . . 0.0 110.036 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.5 mmm180 53.28 88.02 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.106 -1.232 . . . . 0.0 110.434 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.798 ' HA ' HG23 ' A' ' 98' ' ' VAL . 8.5 p -157.34 149.98 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 110.088 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -133.03 94.87 3.44 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 110.286 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.463 ' CG1' ' CD1' ' A' ' 43' ' ' TRP . 59.6 t -108.18 148.52 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.323 -0.861 . . . . 0.0 110.06 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -167.79 146.51 4.71 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.244 -0.91 . . . . 0.0 110.288 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.528 HG21 HG12 ' A' ' 41' ' ' VAL . 93.5 m -108.04 155.33 20.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.965 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.895 HG22 ' O ' ' A' ' 93' ' ' ARG . 11.0 t -111.05 -169.3 1.43 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.28 -0.887 . . . . 0.0 110.551 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.4 mtmp? -46.96 -41.46 16.22 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.581 -0.699 . . . . 0.0 112.078 -179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -154.09 48.93 0.63 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.827 -1.17 . . . . 0.0 111.143 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.895 ' O ' HG22 ' A' ' 90' ' ' THR . 9.7 ttt180 -175.46 111.02 0.12 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.283 -0.886 . . . . 0.0 110.078 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.648 ' HB2' HG11 ' A' ' 41' ' ' VAL . 7.7 t -73.8 145.85 44.67 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.326 -0.859 . . . . 0.0 109.959 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.418 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -130.59 133.48 63.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 110.485 -179.648 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.685 ' HB3' HD23 ' A' ' 29' ' ' LEU . 59.0 t80 -116.74 95.95 5.26 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 28' ' ' ARG . 0.4 OUTLIER -121.51 116.0 23.87 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.356 -0.84 . . . . 0.0 110.038 -179.563 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.798 HG23 ' HA ' ' A' ' 85' ' ' VAL . 3.7 p -126.82 126.58 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.413 -0.804 . . . . 0.0 110.323 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -94.72 46.42 1.14 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.354 -0.841 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 179.89 32.22 0.06 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 1.003 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -69.53 82.0 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.183 -1.187 . . . . 0.0 109.9 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.518 ' HA ' HG11 ' A' ' 128' ' ' VAL . 3.8 tt0 -92.96 -169.75 2.25 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.46 -0.775 . . . . 0.0 110.295 -179.68 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -54.07 -27.95 35.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.284 -0.885 . . . . 0.0 110.223 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -71.8 -25.72 62.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -0.816 . . . . 0.0 109.998 179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -85.3 -37.86 19.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.335 -0.853 . . . . 0.0 110.149 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.506 ' HA ' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -52.64 153.42 3.16 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.29 -0.881 . . . . 0.0 110.406 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 149.95 -136.55 5.76 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.58 145.87 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.394 -1.063 . . . . 0.0 110.089 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.799 ' HB2' HD23 ' A' ' 124' ' ' LEU . 86.9 m-85 -138.52 158.99 43.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.504 -0.747 . . . . 0.0 110.716 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.483 HG23 HD22 ' A' ' 123' ' ' ASN . 20.9 m -140.03 101.68 4.22 Favored 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.949 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.5 p -83.0 120.96 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.334 -0.854 . . . . 0.0 110.385 -179.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.432 HG22 ' HD2' ' A' ' 114' ' ' LYS . 24.2 m -94.99 128.41 41.8 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.986 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.648 HG21 ' CD1' ' A' ' 7' ' ' ILE . 83.8 t -109.37 123.43 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.527 -0.733 . . . . 0.0 109.437 179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.432 ' HD2' HG22 ' A' ' 112' ' ' THR . 10.5 mtpt -130.08 166.24 20.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.058 -1.026 . . . . 0.0 111.21 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.532 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -169.77 173.98 2.03 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.578 -0.701 . . . . 0.0 109.528 179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -70.13 -22.57 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.57 1.3 . . . . 0.0 111.962 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.583 HG21 ' HG3' ' A' ' 2' ' ' GLN . 60.5 t -90.71 -30.94 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.883 -1.135 . . . . 0.0 110.775 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -171.16 -156.48 11.71 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.836 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 43.8 mt-10 -150.86 175.15 12.29 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.483 -1.01 . . . . 0.0 109.939 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -168.21 162.94 13.1 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.373 -0.83 . . . . 0.0 110.142 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 14.2 tt0 -145.64 148.81 33.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.387 -0.821 . . . . 0.0 110.353 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.949 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -147.71 157.95 8.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.573 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.483 HD22 HG23 ' A' ' 110' ' ' THR . 18.4 m120 -102.1 141.55 34.76 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.264 -0.898 . . . . 0.0 110.574 -179.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.941 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -113.8 124.31 51.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.575 -0.703 . . . . 0.0 109.827 179.834 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.647 ' HB ' HG23 ' A' ' 18' ' ' THR . 19.1 m -105.04 138.39 41.32 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.854 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.506 HG13 ' HA ' ' A' ' 106' ' ' GLU . 6.7 p -126.43 159.52 35.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.262 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.622 ' HB3' HG22 ' A' ' 20' ' ' VAL . 6.9 tttp -151.04 142.58 23.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.361 -0.837 . . . . 0.0 110.107 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.518 HG11 ' HA ' ' A' ' 102' ' ' GLU . 61.4 t -124.0 118.94 55.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.316 -0.865 . . . . 0.0 110.491 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 130' ' ' ASP . 35.7 mm -100.89 166.04 2.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.55 -0.719 . . . . 0.0 109.368 179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.443 ' N ' HG22 ' A' ' 129' ' ' ILE . 26.2 t0 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.189 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.188 0.518 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.614 ' HG3' HG21 ' A' ' 117' ' ' VAL . 7.3 pt20 -93.29 -142.64 0.22 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.434 -0.791 . . . . 0.0 110.129 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -116.87 150.37 45.72 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.103 -0.998 . . . . 0.0 110.221 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.501 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 38.2 Cg_endo -64.36 132.36 33.36 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 O-C-N 123.726 1.382 . . . . 0.0 110.913 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.514 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.0 Cg_endo -70.53 136.64 31.42 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 O-C-N 123.953 1.502 . . . . 0.0 110.58 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.407 ' CG ' ' O ' ' A' ' 5' ' ' PRO . 9.1 mttm -162.36 148.87 13.2 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.448 -0.783 . . . . 0.0 110.282 179.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 1.058 HG23 HD12 ' A' ' 15' ' ' ILE . 17.0 mm -77.49 52.31 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.56 ' HA ' ' HA2' ' A' ' 13' ' ' GLY . 2.2 p-80 -125.39 174.75 7.95 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.909 -1.119 . . . . 0.0 110.494 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.594 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -127.11 -98.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.372 -0.83 . . . . 0.0 110.934 -179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -120.09 -13.5 8.96 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.571 -1.331 . . . . 0.0 112.002 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.58 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.67 -70.51 0.02 OUTLIER Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 120.611 -1.306 . . . . 0.0 112.328 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.594 ' HG2' HD11 ' A' ' 9' ' ' LEU . 39.3 Cg_endo -66.7 -84.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.008 1.004 . . . . 0.0 110.803 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 121.56 50.33 0.25 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -134.6 107.54 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.532 -0.981 . . . . 0.0 109.942 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.058 HD12 HG23 ' A' ' 7' ' ' ILE . 2.2 mt -79.38 132.73 61.55 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.359 -0.838 . . . . 0.0 109.527 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.36 55.5 3.06 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.532 1.28 . . . . 0.0 110.206 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.491 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -66.5 79.14 0.1 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.495 -0.753 . . . . 0.0 110.344 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.6 m -140.37 91.98 2.49 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.394 -0.816 . . . . 0.0 109.666 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.834 HG13 HD21 ' A' ' 27' ' ' LEU . 10.3 tp -82.45 121.4 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.33 -0.856 . . . . 0.0 110.441 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.914 ' O ' HD13 ' A' ' 27' ' ' LEU . 61.7 t -125.72 138.17 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.08 -1.013 . . . . 0.0 110.245 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.641 ' HB ' HD22 ' A' ' 27' ' ' LEU . 4.5 p -132.76 152.61 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.356 -0.84 . . . . 0.0 110.081 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.569 ' O ' HG12 ' A' ' 22' ' ' VAL . 67.7 t -89.45 57.15 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.471 -0.768 . . . . 0.0 109.829 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 47.84 85.9 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.644 -0.66 . . . . 0.0 111.262 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.88 52.67 13.61 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.452 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 4.3 t30 -139.8 165.91 26.03 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.281 -1.129 . . . . 0.0 110.26 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -61.17 116.1 4.31 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.272 -0.893 . . . . 0.0 109.91 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.914 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -118.54 138.05 52.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.849 . . . . 0.0 110.152 -179.541 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.754 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -131.17 147.97 52.66 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.478 -0.763 . . . . 0.0 109.964 179.934 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.575 HD23 ' HB3' ' A' ' 96' ' ' PHE . 64.0 tp -147.98 132.49 17.7 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.344 -0.848 . . . . 0.0 110.24 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.586 ' OD2' HD11 ' A' ' 95' ' ' ILE . 1.4 m-20 -131.7 127.96 37.97 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.433 -0.792 . . . . 0.0 110.344 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.706 ' HB ' HG23 ' A' ' 15' ' ' ILE . 15.5 m -136.07 128.99 17.84 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.299 -0.876 . . . . 0.0 110.04 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -79.9 149.11 20.16 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.508 1.267 . . . . 0.0 111.062 -179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.66 HG23 HD11 ' A' ' 15' ' ' ILE . 0.5 OUTLIER -145.91 179.53 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.471 -0.768 . . . . 0.0 109.685 179.618 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.408 ' OG ' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -96.06 -145.06 0.28 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 179.614 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.2 149.91 16.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 2.0 t70 -152.21 122.61 3.54 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.526 -0.985 . . . . 0.0 109.867 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.0 Cg_endo -73.95 -60.32 0.08 OUTLIER 'Cis proline' 0 N--CA 1.488 1.192 0 C-N-CA 122.229 -1.988 . . . . 0.0 111.029 0.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.465 ' HB2' ' HA ' ' A' ' 91' ' ' LYS . . . -119.69 133.49 23.85 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.217 -0.927 . . . . 0.0 110.668 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -82.43 -169.78 0.81 Allowed 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.723 1.381 . . . . 0.0 110.61 179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -115.52 86.18 2.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.433 -0.792 . . . . 0.0 109.093 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.836 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.6 p -86.61 107.17 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.472 -0.768 . . . . 0.0 109.977 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.443 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 96.5 mt -99.3 103.93 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.304 -0.873 . . . . 0.0 111.342 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.875 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 96.4 m95 -67.12 102.99 1.1 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.116 -0.99 . . . . 0.0 108.778 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -99.18 167.97 10.34 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.082 -1.012 . . . . 0.0 110.639 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HA ' ' CD1' ' A' ' 109' ' ' TYR . 0.8 OUTLIER -95.44 153.65 17.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.506 -0.747 . . . . 0.0 110.274 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.598 ' HB1' HD12 ' A' ' 47' ' ' ILE . . . -134.88 143.6 47.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.355 -0.84 . . . . 0.0 110.325 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.671 HG22 ' O ' ' A' ' 47' ' ' ILE . 5.3 mp 53.35 26.81 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.439 -0.788 . . . . 0.0 110.317 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.4 p -98.68 -38.81 8.96 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.338 -0.851 . . . . 0.0 110.115 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -107.49 144.51 34.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.8 . . . . 0.0 110.1 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -116.32 -109.54 2.63 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -126.13 150.88 47.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.06 -158.78 0.91 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.384 -0.823 . . . . 0.0 110.223 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.66 162.73 65.44 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.513 -0.742 . . . . 0.0 110.142 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.77 166.97 22.97 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.835 1.439 . . . . 0.0 110.595 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.75 -176.31 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.357 -0.84 . . . . 0.0 110.77 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -139.47 76.33 31.01 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.075 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -76.02 -165.55 0.31 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.774 1.407 . . . . 0.0 110.54 -179.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.2 152.68 29.35 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.386 -0.821 . . . . 0.0 110.269 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.06 102.25 1.43 Allowed 'Trans proline' 0 C--N 1.31 -1.49 0 O-C-N 123.745 1.392 . . . . 0.0 110.418 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.7 m-20 -132.38 66.16 1.56 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.336 -0.852 . . . . 0.0 110.11 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -41.76 97.56 0.14 Allowed Pre-proline 0 N--CA 1.501 2.088 0 O-C-N 121.703 -0.623 . . . . 0.0 110.591 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.57 169.08 3.22 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.855 1.45 . . . . 0.0 110.536 -179.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -126.44 148.91 49.58 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.354 -0.841 . . . . 0.0 110.199 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -117.54 91.71 3.65 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.376 -0.828 . . . . 0.0 110.325 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.9 p -137.51 42.66 2.33 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.392 -0.818 . . . . 0.0 110.262 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.72 -50.17 1.57 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.69 172.33 10.69 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.415 -1.05 . . . . 0.0 110.157 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 20.0 m -71.36 99.13 1.9 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.369 -0.832 . . . . 0.0 110.149 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -68.16 -165.59 0.05 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.35 -0.844 . . . . 0.0 110.264 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -165.62 1.3 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.403 -0.81 . . . . 0.0 110.355 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.1 t-105 -103.48 131.69 50.36 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.462 -0.774 . . . . 0.0 110.15 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 73' ' ' PHE . 98.2 t -113.89 -95.26 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.283 -0.886 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.469 ' N ' HG12 ' A' ' 72' ' ' VAL . 39.2 t80 -172.49 -64.37 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.006 -1.059 . . . . 0.0 110.257 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -85.08 122.56 29.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -167.69 31.65 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.348 -0.845 . . . . 0.0 110.185 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 2.3 ttpt -156.23 106.85 2.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.405 -0.809 . . . . 0.0 110.187 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -95.91 51.53 1.26 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.444 -0.785 . . . . 0.0 110.128 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 21.0 mt -59.66 138.83 57.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.359 -0.838 . . . . 0.0 110.288 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.7 p -60.3 133.01 55.69 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.354 -0.841 . . . . 0.0 110.405 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -83.54 -170.82 3.25 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.872 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.887 ' HA ' HG12 ' A' ' 85' ' ' VAL . 0.6 OUTLIER 179.99 -27.62 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.269 -0.894 . . . . 0.0 110.648 179.779 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -64.39 76.45 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.285 -0.884 . . . . 0.0 109.295 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.476 ' N ' ' O ' ' A' ' 81' ' ' THR . . . 98.36 4.48 57.32 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 -178.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -105.14 -78.36 0.57 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.176 -1.191 . . . . 0.0 110.609 -179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.901 ' HA ' HG23 ' A' ' 98' ' ' VAL . 9.7 p -84.84 134.31 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.965 . . . . 0.0 110.68 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.13 94.91 3.31 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.454 -0.779 . . . . 0.0 109.97 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 58.2 t -115.11 116.54 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.337 -0.852 . . . . 0.0 110.304 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -145.52 140.61 27.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.371 -0.831 . . . . 0.0 110.166 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -100.09 156.1 17.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.321 -0.862 . . . . 0.0 110.254 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 93' ' ' ARG . 40.1 p -102.68 -170.9 1.87 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.416 -0.802 . . . . 0.0 110.391 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.465 ' HA ' ' HB2' ' A' ' 38' ' ' ALA . 0.1 OUTLIER -56.15 -30.79 62.66 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.526 -0.734 . . . . 0.0 111.1 -179.504 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -154.46 45.85 0.56 Allowed 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.01 -1.056 . . . . 0.0 110.908 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.432 ' HB3' ' OG1' ' A' ' 90' ' ' THR . 11.8 ttp85 -175.06 110.66 0.12 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 110.381 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.836 ' HB3' HG11 ' A' ' 41' ' ' VAL . 83.6 p -76.82 124.25 27.43 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.384 -0.822 . . . . 0.0 109.862 179.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.586 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -113.43 127.55 70.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 110.523 -179.609 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.4 t80 -109.72 96.81 6.5 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -121.98 102.77 8.37 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.096 -1.003 . . . . 0.0 110.782 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.901 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.2 p -118.12 147.17 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.693 -0.629 . . . . 0.0 109.345 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -104.92 67.29 0.79 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.224 -0.922 . . . . 0.0 110.743 -179.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 118.63 45.52 0.47 Allowed Glycine 0 N--CA 1.487 2.062 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.77 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -53.58 -82.09 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.287 -1.125 . . . . 0.0 109.369 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.46 ' HB3' ' N ' ' A' ' 106' ' ' GLU . 1.2 tm-20 -135.58 138.75 43.29 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.291 -0.881 . . . . 0.0 109.56 178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.598 ' O ' HG11 ' A' ' 128' ' ' VAL . 0.0 OUTLIER -96.97 -63.23 1.15 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.167 -0.958 . . . . 0.0 111.533 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -97.11 -2.18 43.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.216 -0.927 . . . . 0.0 111.971 -178.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.571 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -119.72 -8.88 9.85 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.899 -1.126 . . . . 0.0 111.8 -178.519 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.629 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.9 OUTLIER 24.01 -121.61 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.559 -0.713 . . . . 0.0 111.52 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.594 ' O ' HG11 ' A' ' 126' ' ' VAL . . . 123.71 139.6 5.43 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 94.5 t -84.61 159.91 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.232 -1.158 . . . . 0.0 110.19 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.558 ' HB2' HD23 ' A' ' 124' ' ' LEU . 97.4 m-85 -136.77 143.78 43.41 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.455 -0.778 . . . . 0.0 110.384 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 20.9 m -112.27 108.13 17.23 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.174 -0.953 . . . . 0.0 109.193 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.891 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.7 p -85.47 131.1 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.327 -0.858 . . . . 0.0 110.476 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 5.0 m -116.0 123.79 48.88 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.416 -0.803 . . . . 0.0 110.772 -179.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.4 m -99.22 136.39 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.386 -0.822 . . . . 0.0 109.568 179.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 25.1 mtpt -137.3 162.88 32.35 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.167 -0.958 . . . . 0.0 111.016 -179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.514 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.79 176.06 1.57 Allowed Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.493 -0.754 . . . . 0.0 109.643 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.3 Cg_endo -71.41 -4.82 15.73 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.586 1.308 . . . . 0.0 111.687 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 2' ' ' GLN . 50.9 t -107.27 -32.83 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.844 -1.16 . . . . 0.0 110.607 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -172.41 -147.76 5.93 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.333 -1.413 . . . . 0.0 109.973 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -169.19 150.52 4.41 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.437 -1.037 . . . . 0.0 110.172 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.446 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.2 OUTLIER -139.24 170.22 16.34 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.3 -0.875 . . . . 0.0 110.007 179.829 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.438 ' C ' HG12 ' A' ' 122' ' ' VAL . 13.4 tt0 -145.3 165.8 27.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.328 -0.857 . . . . 0.0 110.392 -179.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.891 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -167.31 162.76 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.883 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.404 ' N ' ' CG2' ' A' ' 122' ' ' VAL . 21.8 t30 -106.01 144.7 32.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.89 . . . . 0.0 110.699 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.875 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 1.0 OUTLIER -117.14 110.79 18.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.87 -0.519 . . . . 0.0 109.71 179.753 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 20.2 m -83.7 158.29 21.87 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.257 -0.902 . . . . 0.0 110.018 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.594 HG11 ' O ' ' A' ' 107' ' ' GLY . 12.0 p -134.01 160.0 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.304 -0.873 . . . . 0.0 110.805 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.534 ' O ' HG13 ' A' ' 20' ' ' VAL . 0.8 OUTLIER -156.4 110.35 2.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.519 -0.738 . . . . 0.0 109.539 179.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 106' ' ' GLU . 34.6 t -79.85 118.14 26.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.221 -0.924 . . . . 0.0 110.599 -179.447 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.445 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.3 mm -95.33 165.47 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.479 -0.763 . . . . 0.0 109.222 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 129' ' ' ILE . 20.1 t0 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.261 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.7 mtt-85 . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.182 0.515 . . . . 0.0 110.129 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.508 ' HG3' HG21 ' A' ' 117' ' ' VAL . 15.8 pt20 -146.7 -155.55 0.63 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.361 -0.837 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -90.55 151.38 44.03 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.373 -0.829 . . . . 0.0 110.219 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.42 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 37.9 Cg_endo -63.68 134.71 45.3 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.658 1.346 . . . . 0.0 110.455 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 51.6 Cg_endo -70.95 154.6 62.94 Favored 'Trans proline' 0 C--N 1.311 -1.428 0 O-C-N 123.937 1.493 . . . . 0.0 110.813 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.442 ' O ' HG22 ' A' ' 33' ' ' ILE . 1.2 mmtt -170.17 156.26 5.79 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.561 -0.712 . . . . 0.0 110.294 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.847 ' CG2' HD12 ' A' ' 15' ' ' ILE . 36.6 mm -83.24 7.2 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.503 -0.748 . . . . 0.0 110.736 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.433 ' CE1' ' CB ' ' A' ' 6' ' ' LYS . 3.3 p-80 -100.79 175.16 5.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.979 -1.075 . . . . 0.0 109.96 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.562 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -116.58 -103.11 0.42 Allowed 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.243 -0.91 . . . . 0.0 110.892 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -102.07 -24.94 13.9 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.6 -1.313 . . . . 0.0 111.045 -179.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.563 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -147.12 -68.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.031 -1.043 . . . . 0.0 111.664 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.563 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 43.6 Cg_endo -70.04 -92.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 122.935 0.966 . . . . 0.0 110.692 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.4 ' CA ' ' HA ' ' A' ' 8' ' ' HIS . . . 114.83 50.34 0.48 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 mtt-85 -106.43 87.4 2.54 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.374 -1.074 . . . . 0.0 110.435 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.896 HD11 HG23 ' A' ' 33' ' ' ILE . 6.7 mt -80.02 113.33 37.43 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.41 -0.806 . . . . 0.0 109.672 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.672 ' O ' HG22 ' A' ' 18' ' ' THR . 45.7 Cg_endo -71.53 60.46 2.71 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.586 1.308 . . . . 0.0 110.326 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.772 ' CA ' HD12 ' A' ' 124' ' ' LEU . 10.9 p30 -62.81 79.78 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.375 -0.828 . . . . 0.0 110.706 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.672 HG22 ' O ' ' A' ' 16' ' ' PRO . 3.6 t -141.2 88.76 2.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.205 -0.934 . . . . 0.0 110.073 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.808 ' CG2' HD21 ' A' ' 124' ' ' LEU . 10.2 tp -83.13 120.2 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.119 -0.988 . . . . 0.0 110.26 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.759 ' O ' HD22 ' A' ' 27' ' ' LEU . 47.4 t -124.93 136.2 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 110.266 -179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.5 p -129.49 151.33 35.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.455 -0.778 . . . . 0.0 109.953 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.578 ' O ' HG12 ' A' ' 22' ' ' VAL . 68.0 t -91.33 55.37 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.417 -0.802 . . . . 0.0 109.52 179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 46.59 80.47 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.748 -0.595 . . . . 0.0 111.395 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 100' ' ' GLY . . . 80.78 51.92 4.61 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.158 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.443 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 0.7 OUTLIER -139.98 169.81 17.02 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.15 -1.206 . . . . 0.0 110.645 179.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 99' ' ' GLU . 4.3 mttm -72.91 124.28 25.11 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.462 -0.774 . . . . 0.0 109.85 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.887 HD12 ' N ' ' A' ' 28' ' ' ARG . 2.1 tp -129.69 142.69 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.208 -0.933 . . . . 0.0 110.542 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.887 ' N ' HD12 ' A' ' 27' ' ' LEU . 10.3 mtp-105 -128.31 141.58 51.39 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.613 -0.679 . . . . 0.0 109.581 179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.651 HD23 ' HB3' ' A' ' 96' ' ' PHE . 35.8 tp -135.52 136.3 41.08 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.19 -0.944 . . . . 0.0 110.153 -179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -132.23 128.35 37.71 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.361 -0.837 . . . . 0.0 110.815 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.844 ' HB ' HG23 ' A' ' 15' ' ' ILE . 10.6 m -147.77 116.51 4.2 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.392 -0.817 . . . . 0.0 109.751 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.01 147.08 38.02 Favored 'Trans proline' 0 C--N 1.312 -1.378 0 O-C-N 123.446 1.234 . . . . 0.0 111.51 -179.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.896 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -146.93 -175.54 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.51 -0.744 . . . . 0.0 109.747 179.695 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -89.65 -139.19 0.13 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.373 -0.83 . . . . 0.0 109.399 179.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.62 140.92 10.02 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.754 -1.339 . . . . 0.0 109.754 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.431 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 0.5 OUTLIER -152.09 111.48 2.87 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.531 -0.982 . . . . 0.0 110.133 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.2 Cg_endo -72.98 -61.48 0.05 OUTLIER 'Cis proline' 0 N--CA 1.488 1.191 0 C-N-CA 122.155 -2.019 . . . . 0.0 110.85 0.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -113.03 133.41 22.02 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.192 -0.943 . . . . 0.0 110.491 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HA ' ' ND2' ' A' ' 115' ' ' ASN . 52.5 Cg_endo -81.52 -165.14 0.32 Allowed 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.733 1.386 . . . . 0.0 110.475 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.77 86.44 2.56 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.46 -0.775 . . . . 0.0 109.251 179.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.824 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.5 p -93.87 99.37 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 CA-C-O 121.606 0.717 . . . . 0.0 109.972 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 31.7 mm -94.11 111.01 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 111.217 -178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.948 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 93.5 m95 -72.41 114.51 10.61 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.366 -0.834 . . . . 0.0 109.705 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.439 ' HB2' ' O ' ' A' ' 110' ' ' THR . 9.9 mm-40 -105.27 149.55 25.91 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.138 -0.977 . . . . 0.0 110.061 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.441 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 0.1 OUTLIER -111.85 145.94 38.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.304 -0.872 . . . . 0.0 110.278 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.14 138.12 41.67 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.422 -0.799 . . . . 0.0 110.113 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.412 ' H ' HG22 ' A' ' 47' ' ' ILE . 16.3 tt -82.25 160.05 3.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.322 -0.861 . . . . 0.0 110.134 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.408 HG23 ' HA3' ' A' ' 107' ' ' GLY . 74.7 p -102.43 38.03 1.78 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.484 -0.76 . . . . 0.0 110.021 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.7 mm-40 -144.13 179.69 7.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 110.185 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.43 141.78 9.39 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 52.3 52.09 14.95 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.347 -1.09 . . . . 0.0 110.446 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.81 -158.65 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.428 -0.795 . . . . 0.0 110.266 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.636 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -84.72 170.72 12.76 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.583 -0.698 . . . . 0.0 110.133 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.636 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 46.0 Cg_endo -72.9 166.85 28.87 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.76 1.4 . . . . 0.0 110.478 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -64.16 -164.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 110.263 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.41 ' CG ' ' O ' ' A' ' 56' ' ' ARG . 2.0 ptp85 -137.32 87.88 17.71 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.432 -0.793 . . . . 0.0 110.281 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.61 177.73 8.46 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.778 1.409 . . . . 0.0 110.491 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.772 ' HB1' ' HD2' ' A' ' 59' ' ' PRO . . . -70.56 174.82 3.04 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.383 -0.823 . . . . 0.0 110.148 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.772 ' HD2' ' HB1' ' A' ' 58' ' ' ALA . 46.3 Cg_endo -73.13 171.46 17.53 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.741 1.39 . . . . 0.0 110.471 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.421 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 68.1 m-20 53.52 67.29 1.02 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.389 -0.819 . . . . 0.0 110.517 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.42 98.44 0.18 Allowed Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.627 -0.67 . . . . 0.0 110.303 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.421 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.26 108.76 0.3 Allowed 'Trans proline' 0 C--N 1.311 -1.438 0 O-C-N 123.819 1.431 . . . . 0.0 110.589 -178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -63.44 140.76 58.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.439 -0.788 . . . . 0.0 110.378 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -112.84 149.83 32.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.368 -0.832 . . . . 0.0 110.2 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 32.5 m -143.38 71.69 1.34 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.385 -0.822 . . . . 0.0 110.281 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.68 -76.44 0.45 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -166.03 135.61 3.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.398 -1.06 . . . . 0.0 110.292 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 55.2 p -79.7 74.36 6.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.236 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -72.17 133.4 45.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.379 -0.826 . . . . 0.0 110.232 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.46 -166.53 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.297 -0.877 . . . . 0.0 110.197 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 73.6 t-105 -97.54 101.27 12.76 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.344 -0.847 . . . . 0.0 110.279 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 73' ' ' PHE . 7.6 p -61.31 168.86 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 110.143 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.53 ' N ' HG22 ' A' ' 72' ' ' VAL . 2.3 t80 -98.12 -60.01 1.64 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.54 -0.725 . . . . 0.0 110.2 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t70 52.5 -168.97 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.427 -0.796 . . . . 0.0 110.503 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.52 91.42 0.06 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.362 -0.836 . . . . 0.0 110.164 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.64 144.26 57.16 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.398 -0.814 . . . . 0.0 110.029 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.6 tp -107.81 170.26 8.1 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -0.821 . . . . 0.0 110.26 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -138.68 45.86 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.424 -0.797 . . . . 0.0 110.288 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 1.6 m -153.57 125.0 7.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.863 . . . . 0.0 110.291 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.593 ' H ' HG11 ' A' ' 85' ' ' VAL . 13.9 tp10 -62.03 -61.82 2.21 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.32 -0.862 . . . . 0.0 110.246 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.29 -178.78 6.56 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 110.183 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -62.25 -31.92 72.55 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.284 -0.885 . . . . 0.0 110.175 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.88 38.95 0.09 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.1 ttt180 -100.18 -52.04 3.5 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.304 -1.115 . . . . 0.0 109.913 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.775 ' HA ' HG23 ' A' ' 98' ' ' VAL . 7.3 p -65.06 136.74 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.364 -0.835 . . . . 0.0 109.878 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -128.54 103.51 7.15 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.266 -0.896 . . . . 0.0 110.358 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 96' ' ' PHE . 99.9 t -130.36 104.64 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.335 -0.853 . . . . 0.0 109.941 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -136.73 122.25 19.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.406 -0.809 . . . . 0.0 110.467 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 94' ' ' SER . 61.0 m -90.79 130.53 36.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.367 -0.833 . . . . 0.0 109.782 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' H ' ' A' ' 92' ' ' ASP . 10.0 t -75.82 -168.03 0.81 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.294 -0.879 . . . . 0.0 110.36 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -55.21 -30.18 59.45 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.469 -0.77 . . . . 0.0 111.438 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.561 ' H ' HG23 ' A' ' 90' ' ' THR . 6.7 t70 -154.4 48.66 0.6 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.884 -1.135 . . . . 0.0 111.048 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.29 106.16 0.39 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.13 -0.981 . . . . 0.0 110.457 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.824 ' HB3' HG11 ' A' ' 41' ' ' VAL . 94.0 p -73.73 118.21 16.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.426 -0.796 . . . . 0.0 109.834 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.456 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.0 OUTLIER -110.95 127.9 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.302 -0.874 . . . . 0.0 110.48 -179.4 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.651 ' HB3' HD23 ' A' ' 29' ' ' LEU . 1.1 t80 -114.69 95.09 5.07 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.448 -0.782 . . . . 0.0 108.928 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 27' ' ' LEU . 0.6 OUTLIER -121.64 103.49 8.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.436 -0.79 . . . . 0.0 109.859 -179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.903 HG11 ' HB2' ' A' ' 101' ' ' ALA . 11.4 p -120.26 144.38 29.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.422 -0.799 . . . . 0.0 110.441 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.432 ' HA ' ' HA ' ' A' ' 26' ' ' LYS . 0.6 OUTLIER -107.55 65.63 0.65 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.401 -0.812 . . . . 0.0 110.146 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.445 ' HA2' ' HA2' ' A' ' 24' ' ' GLY . . . 125.98 41.28 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.903 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -56.48 -85.7 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.379 -1.071 . . . . 0.0 109.79 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -134.37 151.1 51.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.736 179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.632 ' O ' HG21 ' A' ' 128' ' ' VAL . 8.3 mtmt -95.28 -62.96 1.21 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.125 -0.985 . . . . 0.0 109.887 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -97.63 -2.96 40.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.533 -0.729 . . . . 0.0 110.624 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 106' ' ' GLU . 0.5 OUTLIER -85.08 21.35 1.66 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.185 -0.947 . . . . 0.0 112.436 -178.225 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.926 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.7 OUTLIER -59.32 -148.82 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.888 0 O-C-N 120.788 -1.195 . . . . 0.0 110.162 179.407 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.535 ' N ' HG13 ' A' ' 126' ' ' VAL . . . 119.47 -113.29 2.47 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 95.4 t -142.49 159.56 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.256 -1.144 . . . . 0.0 110.85 -179.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.745 ' HB2' HD23 ' A' ' 124' ' ' LEU . 24.3 m-85 -132.14 159.84 37.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.575 -0.703 . . . . 0.0 109.921 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 13.2 m -134.63 101.89 5.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.365 -0.834 . . . . 0.0 109.084 178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.956 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.6 p -87.0 124.52 40.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.34 -0.85 . . . . 0.0 110.002 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 41' ' ' VAL . 98.3 m -101.38 120.92 41.0 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.372 -0.83 . . . . 0.0 111.347 -178.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.624 HG21 ' CD1' ' A' ' 7' ' ' ILE . 64.4 t -98.97 126.18 52.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 178.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -138.13 168.15 20.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.977 -178.472 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 0.2 OUTLIER -169.31 172.93 2.55 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -71.19 -5.45 17.02 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.62 1.326 . . . . 0.0 111.41 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.508 HG21 ' HG3' ' A' ' 2' ' ' GLN . 47.1 t -106.75 -33.23 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.941 -1.1 . . . . 0.0 110.842 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -160.35 -156.55 8.23 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.04 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 114' ' ' LYS . 13.4 tt0 -164.98 128.78 2.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.553 -0.969 . . . . 0.0 109.749 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.426 ' HB3' HG12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -125.82 162.82 24.26 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -0.822 . . . . 0.0 110.112 -179.991 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.4 ' HG3' HG23 ' A' ' 112' ' ' THR . 0.5 OUTLIER -142.59 149.3 38.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.324 -0.86 . . . . 0.0 110.388 179.74 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.956 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -148.73 155.7 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 179.672 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 55.2 m-20 -103.01 140.27 37.49 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.362 -0.836 . . . . 0.0 110.507 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.948 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.16 124.27 49.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.544 -0.722 . . . . 0.0 109.778 179.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 31.8 m -83.64 141.96 31.13 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.252 -0.905 . . . . 0.0 110.383 -179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.568 HG11 ' HE1' ' A' ' 109' ' ' TYR . 10.6 p -126.9 159.54 36.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.383 -0.823 . . . . 0.0 110.277 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.419 ' O ' HG13 ' A' ' 20' ' ' VAL . 11.4 ttpp -165.88 112.86 0.91 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.351 -0.843 . . . . 0.0 109.697 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.926 HG23 ' HB3' ' A' ' 106' ' ' GLU . 42.4 t -79.83 118.6 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.357 -0.84 . . . . 0.0 110.398 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.7 mm -96.29 166.3 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 121.543 -0.723 . . . . 0.0 109.417 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.463 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.2 t70 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.241 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.283 0.564 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.61 ' HG3' HG21 ' A' ' 117' ' ' VAL . 5.4 pt20 -102.23 -134.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.334 -0.854 . . . . 0.0 110.112 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -126.91 149.81 70.02 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 120.975 -1.078 . . . . 0.0 110.544 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.504 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.2 Cg_endo -64.8 128.61 21.33 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.794 1.418 . . . . 0.0 110.725 179.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.558 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.21 124.19 11.05 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.922 1.485 . . . . 0.0 110.669 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.512 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -150.72 161.0 43.47 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.748 . . . . 0.0 109.685 179.381 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.986 HG23 HD12 ' A' ' 15' ' ' ILE . 19.7 mm -82.59 17.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.44 -0.788 . . . . 0.0 110.855 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.898 ' C ' HD13 ' A' ' 9' ' ' LEU . 0.4 OUTLIER -125.44 156.96 38.05 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.849 -1.157 . . . . 0.0 110.818 179.743 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.898 HD13 ' C ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -149.78 -157.5 0.82 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.212 -0.93 . . . . 0.0 109.989 179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.61 -29.73 62.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.043 -1.036 . . . . 0.0 109.289 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.749 ' H ' HD23 ' A' ' 9' ' ' LEU . 12.6 m -111.69 75.57 1.43 Allowed Pre-proline 0 C--N 1.304 -1.404 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.9 -176.97 0.66 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 O-C-N 123.905 1.476 . . . . 0.0 111.093 -179.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 115.91 36.65 1.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.841 -1.704 . . . . 0.0 108.841 -179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 64.03 145.06 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.528 -0.983 . . . . 0.0 110.356 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.986 HD12 HG23 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -79.0 149.08 73.02 Favored Pre-proline 0 N--CA 1.493 1.681 0 O-C-N 121.429 -0.794 . . . . 0.0 109.05 179.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.703 ' HG2' HG12 ' A' ' 31' ' ' VAL . 45.7 Cg_endo -74.97 54.6 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 O-C-N 123.598 1.315 . . . . 0.0 110.056 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.813 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.4 p30 -74.79 79.84 2.09 Favored 'General case' 0 N--CA 1.492 1.668 0 CA-C-O 121.664 0.745 . . . . 0.0 110.641 -179.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 18' ' ' THR . 1.7 t -141.1 88.7 2.19 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.151 -0.968 . . . . 0.0 109.508 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.813 ' CG1' HD21 ' A' ' 27' ' ' LEU . 9.6 tp -83.3 121.58 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.236 -0.915 . . . . 0.0 110.808 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.863 ' O ' HD13 ' A' ' 27' ' ' LEU . 99.0 t -125.11 145.9 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 110.034 179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HD22 ' A' ' 27' ' ' LEU . 7.7 p -140.07 156.91 25.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.396 -0.815 . . . . 0.0 110.236 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.561 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.6 t -96.09 55.99 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.456 -0.778 . . . . 0.0 109.709 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.431 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 42.35 70.02 0.32 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.91 -0.493 . . . . 0.0 111.773 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.07 46.73 2.36 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.085 -1.055 . . . . 0.0 110.561 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 22' ' ' VAL . 14.3 t-20 -139.83 160.57 39.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.096 -1.238 . . . . 0.0 110.449 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.84 118.41 7.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.323 -0.861 . . . . 0.0 109.807 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.863 HD13 ' O ' ' A' ' 20' ' ' VAL . 0.3 OUTLIER -118.51 144.57 45.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.272 -0.893 . . . . 0.0 110.434 -179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.849 ' N ' HD12 ' A' ' 27' ' ' LEU . 12.2 mtm180 -132.28 149.75 52.3 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.464 -0.773 . . . . 0.0 109.832 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.856 HD21 HD11 ' A' ' 124' ' ' LEU . 52.3 tp -143.16 132.34 23.17 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.281 -0.887 . . . . 0.0 110.111 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -128.14 124.52 37.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.36 -0.838 . . . . 0.0 110.728 -179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.703 HG12 ' HG2' ' A' ' 16' ' ' PRO . 7.2 m -139.72 130.4 14.35 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.364 -0.835 . . . . 0.0 109.716 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.531 ' O ' HD11 ' A' ' 15' ' ' ILE . 49.7 Cg_endo -83.85 149.45 12.48 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 O-C-N 123.456 1.24 . . . . 0.0 110.884 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.512 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -145.78 -174.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.298 -0.877 . . . . 0.0 109.905 179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.1 OUTLIER -103.29 -148.04 0.39 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.463 -0.773 . . . . 0.0 109.732 179.652 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.76 147.53 8.83 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -152.32 131.48 6.71 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.417 -1.049 . . . . 0.0 110.269 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -77.62 -60.85 0.05 OUTLIER 'Cis proline' 0 C--N 1.317 -1.084 0 C-N-CA 122.192 -2.003 . . . . 0.0 110.273 -0.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -110.28 126.13 29.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.304 -0.872 . . . . 0.0 110.086 179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HG3' ' O ' ' A' ' 34' ' ' SER . 53.1 Cg_endo -85.5 -166.7 0.35 Allowed 'Trans proline' 0 C--N 1.309 -1.524 0 O-C-N 123.7 1.369 . . . . 0.0 110.546 -179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -122.19 86.73 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.485 -0.76 . . . . 0.0 109.501 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 7.3 p -90.96 99.99 10.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.505 -0.747 . . . . 0.0 110.104 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 28.1 mm -92.63 112.78 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.407 -0.808 . . . . 0.0 111.04 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.945 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 97.1 m95 -74.14 131.92 41.75 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.268 -0.895 . . . . 0.0 109.547 178.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -127.17 159.36 34.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.126 -0.984 . . . . 0.0 110.294 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.9 tttp -110.35 119.43 39.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.402 -0.811 . . . . 0.0 110.113 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.36 113.49 26.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.394 -0.816 . . . . 0.0 110.18 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.525 HG22 ' HB2' ' A' ' 49' ' ' GLN . 3.6 mp -96.42 -23.44 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.403 -0.81 . . . . 0.0 110.167 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 71.9 p 43.82 54.79 5.5 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.629 -0.67 . . . . 0.0 111.004 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.525 ' HB2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -106.54 -56.11 2.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.895 . . . . 0.0 110.156 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.13 93.75 1.54 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 15.6 p-10 -65.92 -30.64 71.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.296 -1.12 . . . . 0.0 110.309 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.58 -161.09 0.11 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.296 -0.878 . . . . 0.0 110.412 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.741 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -127.64 173.63 5.2 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.604 -0.685 . . . . 0.0 110.173 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.741 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 45.8 Cg_endo -72.53 166.48 29.73 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.855 1.45 . . . . 0.0 110.449 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -121.55 -176.13 3.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.39 -0.819 . . . . 0.0 110.286 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.87 81.22 22.75 Favored Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.462 -0.774 . . . . 0.0 110.247 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.7 160.34 31.31 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.907 1.478 . . . . 0.0 110.488 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.13 162.63 52.89 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.328 -0.858 . . . . 0.0 110.141 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.84 161.62 43.25 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.804 1.423 . . . . 0.0 110.467 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.424 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 4.9 m-20 53.33 66.67 1.16 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.393 -0.817 . . . . 0.0 110.41 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.71 98.18 0.17 Allowed Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.659 -0.65 . . . . 0.0 110.453 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.432 ' O ' ' C ' ' A' ' 63' ' ' GLU . 51.0 Cg_endo -91.62 138.68 2.15 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.812 1.427 . . . . 0.0 110.494 -178.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.432 ' C ' ' O ' ' A' ' 62' ' ' PRO . 7.4 pt-20 35.06 48.61 0.36 Allowed 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.77 -0.581 . . . . 0.0 111.548 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -68.0 108.01 2.9 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 110.132 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 17.6 p -63.34 -32.36 73.76 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.415 -0.803 . . . . 0.0 110.263 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 62.36 -147.95 49.09 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -168.8 161.04 10.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.344 -1.092 . . . . 0.0 110.201 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.0 t -62.49 102.33 0.31 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.339 -0.85 . . . . 0.0 110.123 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -54.82 -55.81 26.24 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.364 -0.835 . . . . 0.0 110.368 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -154.49 -168.53 2.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.336 -0.852 . . . . 0.0 110.228 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 75.3 t-105 -141.28 165.93 26.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.397 -0.814 . . . . 0.0 110.129 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.456 ' O ' ' N ' ' A' ' 74' ' ' ASP . 92.3 t -86.95 -83.65 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.35 -0.844 . . . . 0.0 110.236 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.403 ' CG ' ' N ' ' A' ' 74' ' ' ASP . 25.7 t80 51.36 -89.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.435 -0.791 . . . . 0.0 110.587 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.456 ' N ' ' O ' ' A' ' 72' ' ' VAL . 72.2 m-20 -53.36 137.67 34.71 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.071 -1.018 . . . . 0.0 110.507 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.85 -70.17 0.73 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.439 -0.788 . . . . 0.0 110.211 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 12.0 mttt -121.55 56.86 1.04 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.33 -0.856 . . . . 0.0 110.197 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 77' ' ' LEU . 5.8 tt -142.57 84.24 1.85 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.317 -0.864 . . . . 0.0 110.397 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.1 mt -111.86 38.29 2.7 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.342 -0.849 . . . . 0.0 109.992 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 25.6 p -131.77 54.87 1.9 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.35 -0.844 . . . . 0.0 110.433 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -97.25 40.73 1.14 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.351 -0.843 . . . . 0.0 109.939 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.457 ' OG1' HG12 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -89.95 48.68 1.61 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.383 -0.823 . . . . 0.0 110.283 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 81' ' ' THR . 9.1 pt-20 32.77 72.71 0.07 Allowed 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.692 -0.63 . . . . 0.0 111.612 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 127.97 4.34 5.6 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 54.42 87.98 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.969 -1.312 . . . . 0.0 110.522 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.806 ' HA ' HG23 ' A' ' 98' ' ' VAL . 10.6 p -74.91 145.51 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 110.142 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -115.31 94.77 4.86 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.075 179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.747 HG22 ' CD1' ' A' ' 96' ' ' PHE . 48.2 t -116.99 127.28 74.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.38 -0.825 . . . . 0.0 110.162 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -145.04 143.74 30.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.348 -0.845 . . . . 0.0 110.301 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 93.3 m -108.16 147.39 31.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.822 . . . . 0.0 110.026 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -102.63 -169.0 1.6 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.323 -0.861 . . . . 0.0 110.098 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -49.54 -40.4 37.98 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.511 -0.743 . . . . 0.0 111.231 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -153.01 48.55 0.71 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.095 -1.003 . . . . 0.0 110.732 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 24.3 ttm180 -167.9 104.96 0.49 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.134 -0.978 . . . . 0.0 110.424 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 95.1 p -73.76 123.32 23.91 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.318 -0.864 . . . . 0.0 110.261 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.451 HG22 ' O ' ' A' ' 95' ' ' ILE . 0.2 OUTLIER -110.96 127.98 67.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.265 -0.897 . . . . 0.0 110.222 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.747 ' CD1' HG22 ' A' ' 87' ' ' VAL . 2.0 t80 -117.29 95.75 5.11 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.453 -0.78 . . . . 0.0 108.954 178.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -122.29 113.68 19.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.298 -0.877 . . . . 0.0 110.512 -179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.806 HG23 ' HA ' ' A' ' 85' ' ' VAL . 7.4 p -129.8 147.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.505 -0.747 . . . . 0.0 109.676 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -109.03 74.81 0.92 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.237 -0.914 . . . . 0.0 110.556 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 120.96 40.38 0.56 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.711 ' HB2' HG11 ' A' ' 98' ' ' VAL . . . -58.09 -84.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.235 -1.156 . . . . 0.0 109.751 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -134.24 146.68 50.3 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.187 -0.945 . . . . 0.0 109.522 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.745 ' HA ' HG11 ' A' ' 128' ' ' VAL . 0.0 OUTLIER -95.93 -63.31 1.16 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.152 -0.967 . . . . 0.0 110.396 -179.988 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.26 -3.92 36.33 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.389 -0.819 . . . . 0.0 110.817 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.535 ' O ' ' C ' ' A' ' 106' ' ' GLU . 0.4 OUTLIER -76.51 -56.24 4.8 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.226 -0.921 . . . . 0.0 111.483 -178.696 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.913 ' HB3' HG23 ' A' ' 128' ' ' VAL . 0.8 OUTLIER 22.88 -138.37 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.234 0 O-C-N 121.815 -0.553 . . . . 0.0 111.821 -179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.629 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 108.87 -115.91 4.49 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -142.82 159.17 18.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.463 -1.022 . . . . 0.0 110.448 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.68 ' HB2' HD23 ' A' ' 124' ' ' LEU . 44.0 m-85 -131.54 159.77 37.21 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.492 -0.755 . . . . 0.0 109.801 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -134.69 104.32 6.0 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.199 -0.938 . . . . 0.0 109.598 179.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.874 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.9 p -89.59 132.47 34.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.399 -0.813 . . . . 0.0 110.384 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 98.4 m -113.13 124.16 51.93 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.237 -0.915 . . . . 0.0 111.067 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.478 HG11 HG21 ' A' ' 33' ' ' ILE . 13.5 m -99.57 135.44 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.417 -0.802 . . . . 0.0 109.251 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 10.9 mtmt -139.14 164.99 28.33 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.974 -1.079 . . . . 0.0 111.39 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.558 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -173.34 178.19 0.65 Allowed Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.661 -0.65 . . . . 0.0 109.353 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -71.87 -6.09 18.42 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.52 1.274 . . . . 0.0 111.767 -179.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.61 HG21 ' HG3' ' A' ' 2' ' ' GLN . 46.2 t -101.73 -34.1 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 120.823 -1.173 . . . . 0.0 110.526 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.444 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -175.59 -144.4 5.02 Favored Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.015 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -169.06 150.18 4.43 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.6 -0.941 . . . . 0.0 109.954 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.4 OUTLIER -138.67 167.52 21.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.33 -0.856 . . . . 0.0 110.175 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -139.08 162.98 33.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.347 -0.846 . . . . 0.0 110.606 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.874 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -165.62 158.71 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.889 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 27.1 m-80 -106.66 139.45 41.08 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.29 -0.881 . . . . 0.0 110.282 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.945 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -114.93 115.29 26.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.567 -0.708 . . . . 0.0 109.446 179.791 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 12.2 t -76.55 157.49 32.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.373 -0.829 . . . . 0.0 110.743 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 107' ' ' GLY . 7.3 p -141.14 159.22 22.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.452 -0.78 . . . . 0.0 110.341 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.53 114.56 1.62 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.528 -0.733 . . . . 0.0 109.692 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.913 HG23 ' HB3' ' A' ' 106' ' ' GLU . 23.6 t -85.83 119.99 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.28 -0.887 . . . . 0.0 110.417 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 22' ' ' VAL . 1.2 tp -106.47 166.52 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.399 -0.813 . . . . 0.0 109.437 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.132 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 37.0 ptt85 . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 121.24 0.543 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.535 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -148.44 -161.08 1.26 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.391 -0.818 . . . . 0.0 110.359 -179.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.0 mm-40 -82.66 145.81 51.66 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.29 -0.881 . . . . 0.0 110.726 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.636 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.6 Cg_endo -65.99 131.47 27.23 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.715 1.376 . . . . 0.0 110.986 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HB2' ' A' ' 115' ' ' ASN . 48.3 Cg_endo -69.15 141.24 47.16 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 O-C-N 123.995 1.524 . . . . 0.0 110.253 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.36 150.06 3.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.441 -0.787 . . . . 0.0 109.976 179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 1.037 HG23 HD12 ' A' ' 15' ' ' ILE . 12.7 mm -72.22 63.83 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.443 -0.786 . . . . 0.0 109.182 179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.533 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 3.8 t60 -118.67 152.43 36.12 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.626 -0.671 . . . . 0.0 109.745 -179.363 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.67 HD11 ' H ' ' A' ' 13' ' ' GLY . 0.4 OUTLIER -136.43 -121.22 0.15 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.339 -0.851 . . . . 0.0 110.729 179.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -52.01 -30.9 27.31 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.682 -1.261 . . . . 0.0 111.007 -179.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.465 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.1 OUTLIER 179.98 -57.4 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.04 -1.037 . . . . 0.0 111.94 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.449 ' HD2' ' N ' ' A' ' 11' ' ' CYS . 38.7 Cg_endo -67.18 -64.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.208 1.109 . . . . 0.0 111.32 -178.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.67 ' H ' HD11 ' A' ' 9' ' ' LEU . . . 120.54 47.8 0.32 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 20.3 mtt180 -106.26 85.31 2.17 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.351 -1.088 . . . . 0.0 110.271 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.037 HD12 HG23 ' A' ' 7' ' ' ILE . 3.9 mt -79.5 121.85 83.17 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.314 -0.866 . . . . 0.0 109.338 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.664 ' O ' HG22 ' A' ' 18' ' ' THR . 45.0 Cg_endo -72.28 59.9 3.17 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.535 1.281 . . . . 0.0 110.469 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.806 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.2 p30 -64.5 80.01 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.359 -0.838 . . . . 0.0 110.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.664 HG22 ' O ' ' A' ' 16' ' ' PRO . 2.7 t -140.96 114.02 8.49 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.291 -0.881 . . . . 0.0 109.596 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.866 ' CD1' HD11 ' A' ' 27' ' ' LEU . 10.2 tp -109.26 121.46 62.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.114 -0.991 . . . . 0.0 110.878 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.501 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.7 t -122.1 152.33 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.106 -0.996 . . . . 0.0 109.923 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.894 ' CG1' HG22 ' A' ' 128' ' ' VAL . 6.6 p -149.56 159.47 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.564 -0.71 . . . . 0.0 109.891 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.582 ' O ' HG12 ' A' ' 22' ' ' VAL . 59.7 t -100.41 53.58 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.262 -0.899 . . . . 0.0 110.037 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.592 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 45.0 92.67 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.675 -0.64 . . . . 0.0 111.475 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.08 47.9 8.84 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -139.33 165.4 27.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -1.117 . . . . 0.0 110.35 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.75 129.33 34.53 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.355 -0.841 . . . . 0.0 109.51 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.866 HD11 ' CD1' ' A' ' 19' ' ' ILE . 0.1 OUTLIER -132.62 146.78 52.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.246 -0.909 . . . . 0.0 110.489 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.817 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -128.52 143.95 51.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.392 -0.817 . . . . 0.0 110.081 179.78 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.86 HD21 HD11 ' A' ' 124' ' ' LEU . 51.4 tp -138.09 130.94 29.8 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.282 -0.886 . . . . 0.0 109.743 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.675 ' CG ' HD11 ' A' ' 95' ' ' ILE . 0.2 OUTLIER -125.29 130.86 52.87 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.949 -179.318 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.804 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -146.57 119.43 5.0 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.427 -0.796 . . . . 0.0 109.663 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.464 ' O ' HD11 ' A' ' 15' ' ' ILE . 48.2 Cg_endo -75.2 151.3 38.47 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 O-C-N 123.424 1.223 . . . . 0.0 111.683 -178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.665 HD11 ' HB3' ' A' ' 94' ' ' SER . 0.4 OUTLIER -146.7 178.45 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.51 -0.744 . . . . 0.0 109.649 179.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.9 t -94.01 -144.98 0.24 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.163 -0.961 . . . . 0.0 109.905 179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 83.36 145.8 6.4 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.7 t70 -152.27 129.21 5.55 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.323 -1.104 . . . . 0.0 110.159 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 43.6 Cg_endo -76.3 -69.89 0.03 OUTLIER 'Cis proline' 0 C--N 1.318 -1.049 0 C-N-CA 122.247 -1.981 . . . . 0.0 110.674 -0.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -103.32 127.09 30.44 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.179 -0.951 . . . . 0.0 110.362 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 38' ' ' ALA . 50.8 Cg_endo -84.88 -166.66 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.715 1.376 . . . . 0.0 110.484 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -122.61 86.26 2.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.411 -0.806 . . . . 0.0 109.642 179.351 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.817 HG11 ' CB ' ' A' ' 94' ' ' SER . 7.5 p -89.82 100.36 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.487 -0.758 . . . . 0.0 109.669 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 87.4 mt -94.22 111.25 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.457 -0.777 . . . . 0.0 111.542 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.953 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 99.0 m95 -75.08 110.98 9.84 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.273 -0.892 . . . . 0.0 109.327 178.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 110' ' ' THR . 2.2 mm100 -92.02 168.44 11.39 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.08 -1.012 . . . . 0.0 110.442 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HG3' ' CE2' ' A' ' 109' ' ' TYR . 2.5 mptt -112.96 86.03 2.29 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.385 -0.822 . . . . 0.0 110.41 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -69.84 143.29 52.91 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.41 -0.807 . . . . 0.0 109.94 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.444 HG22 ' H ' ' A' ' 49' ' ' GLN . 50.1 mm -93.77 -52.17 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -0.934 . . . . 0.0 110.085 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 65.5 p 43.05 30.56 0.27 Allowed 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.857 -0.527 . . . . 0.0 110.873 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.444 ' H ' HG22 ' A' ' 47' ' ' ILE . 27.9 mt-30 -117.05 -179.37 3.68 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.419 -0.801 . . . . 0.0 110.302 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 63.07 -89.31 0.06 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 -165.78 122.16 1.36 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.363 -1.08 . . . . 0.0 110.165 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.8 -160.36 0.12 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.341 -0.849 . . . . 0.0 110.458 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.534 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -89.83 167.23 17.78 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.64 -0.662 . . . . 0.0 110.266 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.534 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.6 Cg_endo -75.46 167.12 27.28 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.813 1.428 . . . . 0.0 110.395 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -162.05 91.47 0.8 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.391 -0.818 . . . . 0.0 110.171 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' A' ' 56' ' ' ARG . 5.6 ptp85 -139.6 73.67 34.84 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.31 -0.869 . . . . 0.0 110.238 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.22 139.52 18.91 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.855 1.45 . . . . 0.0 110.436 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -136.09 128.92 17.78 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.328 -0.858 . . . . 0.0 110.174 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.28 94.93 0.83 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.699 1.368 . . . . 0.0 110.414 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.423 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 6.2 m-20 -149.41 74.04 1.22 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.335 -0.853 . . . . 0.0 110.231 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -44.53 99.09 0.2 Allowed Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.534 -0.729 . . . . 0.0 110.233 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.6 Cg_endo -91.29 135.72 1.83 Allowed 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.774 1.407 . . . . 0.0 110.55 -178.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.03 159.84 27.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.358 -0.839 . . . . 0.0 110.256 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -167.94 102.01 0.46 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -0.875 . . . . 0.0 110.226 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 5.5 m 52.98 30.73 9.82 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.353 -0.842 . . . . 0.0 110.515 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -64.52 -31.43 80.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 74.7 m-20 -62.1 -174.9 0.06 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.448 -1.031 . . . . 0.0 110.234 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -109.15 43.05 1.32 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.345 -0.847 . . . . 0.0 110.289 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -75.69 147.19 39.59 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.379 -0.825 . . . . 0.0 110.153 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.18 -169.79 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.398 -0.814 . . . . 0.0 110.362 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.8 t-105 -93.5 146.16 23.98 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.432 -0.793 . . . . 0.0 110.203 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 61.0 t -78.95 161.6 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.376 -0.828 . . . . 0.0 110.173 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -97.85 -64.38 1.04 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -0.825 . . . . 0.0 110.219 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.92 -179.69 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.397 -0.814 . . . . 0.0 110.469 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.8 ttpt -124.65 -4.05 7.72 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.345 -0.847 . . . . 0.0 110.733 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 52.38 63.37 2.27 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.13 -0.981 . . . . 0.0 110.394 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -168.67 77.38 0.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.346 -0.847 . . . . 0.0 110.103 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.5 pp -167.8 -179.62 4.33 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.364 -0.835 . . . . 0.0 110.314 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.0 p -132.01 137.37 47.82 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.352 -0.842 . . . . 0.0 110.22 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -109.94 41.48 1.7 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.347 -0.845 . . . . 0.0 110.347 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -135.06 52.69 2.02 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.165 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 52.93 26.58 4.78 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.342 -0.849 . . . . 0.0 110.241 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 66.15 54.98 21.1 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.57 -60.44 1.66 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.428 -1.042 . . . . 0.0 110.384 -179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.937 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.7 p -106.83 144.9 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.332 -0.855 . . . . 0.0 110.505 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.1 ttt180 -129.06 97.76 4.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.417 -0.802 . . . . 0.0 109.989 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.487 HG11 ' HD1' ' A' ' 43' ' ' TRP . 94.9 t -103.5 138.42 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.302 -0.874 . . . . 0.0 110.168 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -155.67 130.97 9.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.395 -0.816 . . . . 0.0 110.188 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.5 t -102.13 155.8 17.97 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.151 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 10.4 p -102.13 -169.5 1.68 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.46 -0.775 . . . . 0.0 110.203 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.6 ptpt -54.41 -33.32 59.16 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.44 -0.788 . . . . 0.0 110.596 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -154.28 48.23 0.61 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.178 -0.951 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 7.8 mtp180 -170.33 104.8 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.334 -0.854 . . . . 0.0 110.399 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.817 ' CB ' HG11 ' A' ' 41' ' ' VAL . 90.4 p -73.66 132.52 42.82 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.331 -0.856 . . . . 0.0 109.792 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.675 HD11 ' CG ' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -120.67 128.13 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.222 -0.923 . . . . 0.0 110.325 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.6 ' HB3' HD23 ' A' ' 29' ' ' LEU . 21.9 t80 -109.88 96.72 6.43 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.27 107.1 11.3 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.291 -0.881 . . . . 0.0 109.801 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.937 ' HB ' HG23 ' A' ' 85' ' ' VAL . 2.8 p -116.96 136.44 54.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.581 -0.699 . . . . 0.0 110.402 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -100.98 43.52 1.06 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.429 -0.794 . . . . 0.0 109.842 179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.518 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -171.79 26.74 0.1 OUTLIER Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.689 ' O ' HG11 ' A' ' 21' ' ' VAL . . . -74.8 87.37 2.24 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.399 -1.059 . . . . 0.0 109.369 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.731 ' O ' HG21 ' A' ' 128' ' ' VAL . 3.8 tt0 -99.52 -169.7 1.79 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.473 -0.767 . . . . 0.0 110.421 -179.363 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 5.9 tttt -54.57 -37.38 65.42 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.447 -0.783 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.406 ' HG3' ' N ' ' A' ' 105' ' ' ASP . 0.7 OUTLIER -59.67 -20.97 59.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.316 -0.865 . . . . 0.0 110.12 179.697 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . 0.406 ' N ' ' HG3' ' A' ' 104' ' ' GLU . 0.7 OUTLIER -93.37 -23.44 18.44 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.066 179.66 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -51.2 166.28 0.11 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.352 -0.842 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.575 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 126.96 -120.53 3.64 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 86.3 t -142.4 156.26 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -1.083 . . . . 0.0 110.282 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.658 ' HB2' HD23 ' A' ' 124' ' ' LEU . 45.3 m-85 -138.05 120.1 15.55 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.537 -0.727 . . . . 0.0 110.085 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.431 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 3.5 m -99.91 110.24 22.59 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.005 -1.059 . . . . 0.0 109.622 179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.906 ' CG1' HG13 ' A' ' 122' ' ' VAL . 9.3 p -89.84 129.06 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.263 -0.898 . . . . 0.0 110.596 -179.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 10.3 m -111.88 120.66 42.68 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.379 -0.825 . . . . 0.0 110.827 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.465 ' CG2' ' CB ' ' A' ' 120' ' ' ASP . 11.1 m -97.36 129.04 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.413 -0.804 . . . . 0.0 109.016 178.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.5 tmtt? -137.78 156.43 47.98 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.06 -1.025 . . . . 0.0 111.279 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.508 ' HB2' ' HB3' ' A' ' 5' ' ' PRO . 1.3 m-20 -160.43 178.79 1.53 Allowed Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 43.7 Cg_endo -70.95 -5.56 17.22 Favored 'Trans proline' 0 C--N 1.311 -1.413 0 O-C-N 123.422 1.222 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.636 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 24.7 t -102.84 -36.14 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 120.911 -1.118 . . . . 0.0 110.396 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.461 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -173.86 -145.46 5.18 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -169.38 155.63 6.38 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.338 -1.095 . . . . 0.0 110.513 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.465 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.3 OUTLIER -140.28 169.82 16.97 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.38 -0.825 . . . . 0.0 109.629 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.456 ' C ' HG12 ' A' ' 122' ' ' VAL . 1.2 mt-30 -142.51 166.02 25.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.171 -0.956 . . . . 0.0 110.748 -179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.906 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -171.17 161.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -109.38 140.17 43.42 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.252 -0.905 . . . . 0.0 110.639 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.953 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -115.91 117.76 31.08 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.709 -0.619 . . . . 0.0 109.486 179.77 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 4.2 m -80.02 146.25 32.08 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.33 -0.856 . . . . 0.0 110.292 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.831 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -132.58 158.29 43.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.323 -0.861 . . . . 0.0 110.366 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 4.9 mttm -163.33 108.49 1.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.357 -0.84 . . . . 0.0 110.403 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.894 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.1 t -82.39 120.3 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -0.929 . . . . 0.0 109.988 179.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 37.8 mm -91.33 161.13 2.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.432 -0.792 . . . . 0.0 109.428 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.6 t0 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.198 -179.891 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.22 0.534 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.544 ' HG3' HG23 ' A' ' 117' ' ' VAL . 0.5 OUTLIER -161.18 -102.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.407 ' N ' HG21 ' A' ' 117' ' ' VAL . 18.6 mt-10 -126.3 150.35 69.8 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.842 -1.161 . . . . 0.0 110.234 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.37 121.5 8.46 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.78 1.41 . . . . 0.0 110.789 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.515 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.7 Cg_endo -70.54 152.88 65.58 Favored 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 123.828 1.436 . . . . 0.0 110.382 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.484 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -170.29 152.28 4.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.247 -0.908 . . . . 0.0 110.582 179.647 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 1.097 HG23 HD12 ' A' ' 15' ' ' ILE . 20.7 mm -77.88 0.14 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.562 -0.711 . . . . 0.0 111.396 -179.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.905 ' C ' HD13 ' A' ' 9' ' ' LEU . 0.7 OUTLIER -125.72 167.3 15.34 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.991 -1.068 . . . . 0.0 110.871 179.785 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.905 HD13 ' C ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -148.14 -153.31 0.48 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.373 -0.83 . . . . 0.0 109.864 -179.775 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -54.24 -31.44 53.41 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.008 -1.058 . . . . 0.0 108.998 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.705 ' H ' HD23 ' A' ' 9' ' ' LEU . 4.6 t -111.73 76.87 1.71 Allowed Pre-proline 0 C--N 1.304 -1.397 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.81 -166.48 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 124.0 1.526 . . . . 0.0 111.141 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 14' ' ' ARG . . . 116.32 33.71 1.43 Allowed Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.123 -1.591 . . . . 0.0 109.123 -179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' A' ' 13' ' ' GLY . 4.7 mmt85 60.88 145.29 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.645 -0.915 . . . . 0.0 110.482 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 1.097 HD12 HG23 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -79.17 139.88 56.74 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.276 -0.89 . . . . 0.0 109.196 179.839 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 32' ' ' PRO . 47.3 Cg_endo -73.75 57.09 3.65 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.61 1.321 . . . . 0.0 110.54 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' A' ' 17' ' ' ASP . 1.4 p30 -73.74 78.29 1.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.377 -0.827 . . . . 0.0 110.484 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.635 HG23 ' CG2' ' A' ' 125' ' ' THR . 0.6 OUTLIER -140.91 115.87 9.78 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.153 -0.967 . . . . 0.0 109.455 179.09 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.928 HG23 HD21 ' A' ' 27' ' ' LEU . 1.4 mm -105.85 122.98 60.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.253 -0.904 . . . . 0.0 110.693 -179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 58.8 t -127.74 149.81 33.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.466 -0.772 . . . . 0.0 109.598 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.95 ' CG1' HG22 ' A' ' 128' ' ' VAL . 7.2 p -151.45 159.34 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.584 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.3 t -96.09 53.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.811 -0.756 . . . . 0.0 109.762 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.476 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 44.45 78.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.735 -0.603 . . . . 0.0 111.453 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.1 50.02 2.14 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -139.59 161.2 38.07 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.175 -1.191 . . . . 0.0 110.233 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mttp -65.74 122.93 18.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.438 -0.788 . . . . 0.0 109.806 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.928 HD21 HG23 ' A' ' 19' ' ' ILE . 1.9 tp -121.9 138.11 54.53 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.304 -0.873 . . . . 0.0 110.488 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.738 ' N ' HD12 ' A' ' 27' ' ' LEU . 0.0 OUTLIER -134.01 148.1 51.07 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.535 -0.728 . . . . 0.0 109.44 179.5 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.719 HD22 HG12 ' A' ' 19' ' ' ILE . 48.7 tp -143.65 132.22 22.34 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.128 -0.982 . . . . 0.0 110.368 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -128.61 105.8 8.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.492 -0.755 . . . . 0.0 110.613 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 15' ' ' ILE . 19.6 m -112.43 128.62 25.29 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.31 -0.869 . . . . 0.0 109.477 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.433 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 49.4 Cg_endo -81.01 145.77 15.73 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 O-C-N 123.506 1.266 . . . . 0.0 111.488 -178.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.931 HG23 HD11 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -150.35 -175.26 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.655 -0.653 . . . . 0.0 109.768 179.274 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.443 ' HB2' ' HG3' ' A' ' 6' ' ' LYS . 39.6 t -98.99 -136.94 0.29 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.306 -0.872 . . . . 0.0 109.824 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.3 131.25 5.81 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.1 t70 -144.42 114.89 5.28 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.393 -1.063 . . . . 0.0 109.983 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 41.9 Cg_endo -70.81 -60.14 0.09 OUTLIER 'Cis proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.312 -1.953 . . . . 0.0 110.927 0.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.68 134.76 24.3 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.311 -0.868 . . . . 0.0 110.575 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HG3' ' O ' ' A' ' 34' ' ' SER . 51.1 Cg_endo -81.79 -165.94 0.37 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 O-C-N 123.818 1.431 . . . . 0.0 110.185 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.61 ' O ' HD12 ' A' ' 42' ' ' ILE . 0.2 OUTLIER -122.06 86.53 2.59 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.416 -0.803 . . . . 0.0 109.327 179.139 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.7 p -88.88 102.97 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.466 -0.771 . . . . 0.0 109.916 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 40' ' ' THR . 3.6 mp -94.66 107.99 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.499 -0.75 . . . . 0.0 111.023 -179.052 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.91 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 95.2 m95 -70.8 102.55 2.37 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.235 -0.916 . . . . 0.0 109.182 178.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.411 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.5 tp60 -86.1 142.95 28.32 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.073 -1.017 . . . . 0.0 110.511 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.405 ' HA ' ' CD2' ' A' ' 109' ' ' TYR . 22.3 mtmt -105.26 128.18 53.31 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.476 -0.765 . . . . 0.0 109.966 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -113.09 92.01 3.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.294 -0.879 . . . . 0.0 110.287 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.3 mt -103.56 -16.96 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.486 -0.759 . . . . 0.0 110.08 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.418 HG23 ' OE1' ' A' ' 49' ' ' GLN . 4.9 t -56.08 -23.15 32.02 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.345 -0.847 . . . . 0.0 110.571 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.418 ' OE1' HG23 ' A' ' 48' ' ' THR . 2.2 pt20 -128.64 -169.97 2.17 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.26 -0.9 . . . . 0.0 110.291 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 113.65 -34.68 4.89 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -166.44 -60.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.314 -1.109 . . . . 0.0 110.268 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -158.44 0.24 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.308 -0.87 . . . . 0.0 110.454 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.632 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -127.96 170.23 10.81 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.571 -0.706 . . . . 0.0 110.256 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.632 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 47.6 Cg_endo -73.25 166.31 30.29 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.761 1.401 . . . . 0.0 110.402 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 51.32 92.48 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.347 -0.846 . . . . 0.0 110.537 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 5.3 ptm180 -125.16 73.8 66.68 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.402 -0.812 . . . . 0.0 110.247 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.92 140.87 20.76 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.881 1.464 . . . . 0.0 110.292 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -130.99 155.85 80.96 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.311 -0.868 . . . . 0.0 110.247 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.09 105.19 1.91 Allowed 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.821 1.432 . . . . 0.0 110.281 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.419 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 34.6 m-20 -150.7 75.13 1.2 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.368 -0.833 . . . . 0.0 110.277 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -43.54 98.72 0.19 Allowed Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.604 -0.685 . . . . 0.0 110.228 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.419 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.8 Cg_endo -91.06 124.35 0.9 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 O-C-N 123.773 1.407 . . . . 0.0 110.613 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.34 153.97 42.42 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.302 -0.874 . . . . 0.0 110.205 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 65' ' ' THR . 5.4 t0 -94.57 90.17 6.06 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.343 -0.848 . . . . 0.0 110.357 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.561 HG23 ' O ' ' A' ' 64' ' ' ASP . 4.6 p -155.08 -77.76 0.1 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.444 -0.785 . . . . 0.0 110.065 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 58.51 -143.98 43.87 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -104.37 -165.18 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.426 -1.043 . . . . 0.0 110.125 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.32 35.15 2.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.368 -0.832 . . . . 0.0 110.281 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -85.75 -179.05 6.77 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.323 -0.861 . . . . 0.0 110.166 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -124.29 -174.5 3.02 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.328 -0.857 . . . . 0.0 110.259 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 71.6 t-105 -102.03 141.99 34.0 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.395 -0.816 . . . . 0.0 110.276 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.644 HG11 ' HB2' ' A' ' 75' ' ' LYS . 60.3 t -94.34 166.91 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.415 -0.803 . . . . 0.0 110.13 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.478 ' N ' HG12 ' A' ' 72' ' ' VAL . 0.1 OUTLIER -76.69 -49.99 14.76 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 0.0 110.101 179.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.9 p30 -133.4 63.36 1.63 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.345 -0.847 . . . . 0.0 110.258 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.644 ' HB2' HG11 ' A' ' 72' ' ' VAL . 0.1 OUTLIER -159.3 88.38 0.87 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.256 -0.902 . . . . 0.0 110.181 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.23 32.41 3.98 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.358 -0.839 . . . . 0.0 110.252 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.21 85.63 1.81 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.368 -0.832 . . . . 0.0 110.132 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 6.9 mp -83.01 96.51 8.36 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.398 -0.814 . . . . 0.0 110.184 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 67.3 m -60.8 134.16 56.82 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.346 -0.846 . . . . 0.0 110.16 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -114.5 77.1 1.03 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.401 -0.812 . . . . 0.0 110.173 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' N ' ' A' ' 83' ' ' GLY . 2.2 p -104.38 67.77 0.85 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.388 -0.82 . . . . 0.0 110.109 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 54.79 -87.74 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.502 -0.749 . . . . 0.0 110.597 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 81' ' ' THR . . . -103.76 27.09 21.13 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.7 ttt-85 62.17 127.54 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.363 -1.081 . . . . 0.0 110.423 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.916 HG23 ' HB ' ' A' ' 98' ' ' VAL . 7.4 p -60.73 127.16 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.297 -0.877 . . . . 0.0 110.19 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -109.9 102.89 11.62 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.328 -0.857 . . . . 0.0 110.27 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.645 HG11 ' CD1' ' A' ' 43' ' ' TRP . 60.0 t -114.29 121.81 67.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.264 -0.898 . . . . 0.0 110.094 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -132.79 145.84 51.33 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.348 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 99.6 m -109.02 140.59 42.34 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.464 -0.772 . . . . 0.0 109.975 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.719 HG22 ' O ' ' A' ' 93' ' ' ARG . 8.9 t -92.55 -168.28 1.93 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.362 -0.836 . . . . 0.0 110.358 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -53.0 -33.73 53.0 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.364 -0.835 . . . . 0.0 111.451 -179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.533 ' H ' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -154.2 48.96 0.62 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.054 -1.029 . . . . 0.0 110.801 -179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.719 ' O ' HG22 ' A' ' 90' ' ' THR . 4.5 ttp180 -171.85 111.24 0.29 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.209 -0.932 . . . . 0.0 110.467 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.884 ' HB3' HG11 ' A' ' 41' ' ' VAL . 70.2 p -82.48 113.92 20.56 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.399 -0.813 . . . . 0.0 109.589 179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' LEU . 0.1 OUTLIER -103.09 139.37 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.898 . . . . 0.0 110.56 -179.435 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.68 ' HB3' HD23 ' A' ' 29' ' ' LEU . 18.9 t80 -118.75 98.67 6.33 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.12 113.95 19.03 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.36 -0.837 . . . . 0.0 109.72 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.916 ' HB ' HG23 ' A' ' 85' ' ' VAL . 2.4 p -123.31 133.42 69.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.574 -0.704 . . . . 0.0 110.462 -179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -97.58 42.89 1.08 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.47 -0.769 . . . . 0.0 109.652 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.576 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -166.28 25.12 0.15 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.687 ' O ' HG11 ' A' ' 21' ' ' VAL . . . -74.66 87.5 2.18 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.351 -1.087 . . . . 0.0 109.477 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.553 ' O ' HG21 ' A' ' 128' ' ' VAL . 0.6 OUTLIER -112.35 -168.88 1.37 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.528 -0.732 . . . . 0.0 110.385 -179.567 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -52.09 -29.74 22.91 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.377 -0.827 . . . . 0.0 110.299 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -74.35 -22.22 59.32 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.444 -0.785 . . . . 0.0 110.149 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -85.98 -28.23 24.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.345 -0.847 . . . . 0.0 110.25 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -49.68 169.31 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.329 -0.857 . . . . 0.0 110.722 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.446 ' H ' HG13 ' A' ' 126' ' ' VAL . . . 137.51 -133.77 6.61 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.124 -1.59 . . . . 0.0 109.124 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 53.9 t -142.47 150.72 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.304 -1.115 . . . . 0.0 110.106 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.705 ' HB2' HD23 ' A' ' 124' ' ' LEU . 87.9 m-85 -138.29 158.79 43.59 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.452 -0.78 . . . . 0.0 110.691 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 123' ' ' ASN . 58.2 m -139.46 101.57 4.26 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.912 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.6 p -81.84 134.78 26.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.185 -0.947 . . . . 0.0 110.527 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 1.2 m -119.65 124.09 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.4 -0.813 . . . . 0.0 110.845 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.572 HG11 ' CD1' ' A' ' 7' ' ' ILE . 9.3 m -97.09 133.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.424 -0.798 . . . . 0.0 108.926 178.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 16.9 tttt -134.36 158.56 43.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.036 -1.04 . . . . 0.0 111.217 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.515 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -168.73 168.2 5.53 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.706 -0.621 . . . . 0.0 109.39 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.422 ' HG2' ' HG2' ' A' ' 2' ' ' GLN . 44.8 Cg_endo -70.07 -8.19 23.01 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.634 1.334 . . . . 0.0 111.655 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.544 HG23 ' HG3' ' A' ' 2' ' ' GLN . 44.1 t -103.17 -34.08 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.86 -1.15 . . . . 0.0 110.456 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -165.36 -155.98 8.91 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -169.14 147.68 3.86 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.55 -0.97 . . . . 0.0 110.045 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.413 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.5 OUTLIER -142.81 170.26 16.03 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.289 -0.882 . . . . 0.0 110.147 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -147.18 163.45 36.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -0.845 . . . . 0.0 110.428 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.912 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.1 OUTLIER -162.43 162.82 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.044 179.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' THR . 24.1 m120 -106.42 139.75 40.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.249 -0.907 . . . . 0.0 110.501 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.91 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.3 OUTLIER -116.55 110.65 18.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.649 -0.657 . . . . 0.0 109.372 179.454 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . 0.635 ' CG2' HG23 ' A' ' 18' ' ' THR . 9.6 t -86.03 150.71 24.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.343 -0.848 . . . . 0.0 110.153 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.727 HG23 HG22 ' A' ' 19' ' ' ILE . 4.6 p -129.55 159.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.848 . . . . 0.0 110.432 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -156.66 122.8 4.93 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.164 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.95 HG22 ' CG1' ' A' ' 21' ' ' VAL . 91.7 t -106.21 120.68 57.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 109.828 179.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.503 HD12 ' O ' ' A' ' 130' ' ' ASP . 1.1 pp -113.18 166.67 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.437 -0.79 . . . . 0.0 109.666 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 129' ' ' ILE . 10.3 p-10 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.152 0.501 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.665 ' HG3' HG21 ' A' ' 117' ' ' VAL . 5.0 pt20 -65.7 -144.45 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.446 -0.784 . . . . 0.0 110.079 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -114.11 147.84 38.73 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.087 -1.008 . . . . 0.0 110.262 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.569 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 39.1 Cg_endo -64.45 131.76 31.04 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 O-C-N 123.737 1.388 . . . . 0.0 111.065 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.503 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 50.2 Cg_endo -69.51 131.6 21.94 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 O-C-N 123.927 1.488 . . . . 0.0 110.133 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' HIS . 5.3 mttp -161.91 145.93 12.47 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.443 -0.786 . . . . 0.0 110.336 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.954 HG23 HD12 ' A' ' 15' ' ' ILE . 12.3 mm -68.7 65.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.509 -0.744 . . . . 0.0 109.34 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.525 ' CD2' ' N ' ' A' ' 9' ' ' LEU . 5.0 t60 -119.11 152.21 36.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.457 -0.777 . . . . 0.0 109.866 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.525 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -137.07 -120.78 0.15 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.219 -0.926 . . . . 0.0 110.968 179.947 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -54.62 -31.6 57.48 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.825 -1.172 . . . . 0.0 111.306 -178.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.446 ' H ' HD12 ' A' ' 9' ' ' LEU . 0.1 OUTLIER -175.09 -58.84 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.789 0 C-N-CA 119.084 -1.046 . . . . 0.0 112.023 -179.9 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 11' ' ' CYS . 38.1 Cg_endo -66.0 -71.28 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.21 1.111 . . . . 0.0 111.106 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 8' ' ' HIS . . . 120.64 49.95 0.28 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.784 -1.327 . . . . 0.0 109.784 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.483 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 0.1 OUTLIER -113.89 87.83 2.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.503 -0.998 . . . . 0.0 109.743 179.502 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.954 HD12 HG23 ' A' ' 7' ' ' ILE . 25.5 mt -79.31 110.82 16.45 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.493 -0.754 . . . . 0.0 109.781 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 14' ' ' ARG . 50.8 Cg_endo -77.45 59.83 6.84 Favored 'Trans proline' 0 C--N 1.312 -1.394 0 O-C-N 123.599 1.315 . . . . 0.0 109.884 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.711 ' O ' HD12 ' A' ' 124' ' ' LEU . 22.3 p-10 -67.52 79.64 0.17 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.288 -0.882 . . . . 0.0 110.09 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 27.4 m -120.98 105.4 10.62 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.383 -0.823 . . . . 0.0 109.143 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.867 ' CG1' HD21 ' A' ' 27' ' ' LEU . 10.2 tp -90.28 119.95 38.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.537 -0.727 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.894 ' O ' HD13 ' A' ' 27' ' ' LEU . 51.5 t -126.39 148.78 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.167 -0.958 . . . . 0.0 109.828 179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.788 HG11 ' CB ' ' A' ' 101' ' ' ALA . 6.3 p -151.19 159.43 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.399 -0.813 . . . . 0.0 110.159 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.592 ' O ' HG12 ' A' ' 22' ' ' VAL . 57.8 t -96.58 53.56 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.383 -0.823 . . . . 0.0 110.316 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.511 ' H ' HG13 ' A' ' 128' ' ' VAL . . . 46.16 96.38 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.602 -0.686 . . . . 0.0 111.654 179.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.93 50.55 10.66 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 179.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -139.38 159.24 42.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.294 -1.121 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 34.9 mtmt -64.31 107.1 1.24 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 109.603 179.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.894 HD13 ' O ' ' A' ' 20' ' ' VAL . 2.0 tp -108.82 141.16 41.26 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.165 -0.959 . . . . 0.0 110.58 -179.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.818 ' N ' HD12 ' A' ' 27' ' ' LEU . 15.5 mtt-85 -134.8 149.83 50.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.603 -0.686 . . . . 0.0 109.659 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.67 HD23 ' HB3' ' A' ' 96' ' ' PHE . 50.4 tp -147.18 135.8 21.96 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.204 -0.935 . . . . 0.0 110.202 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.535 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.6 OUTLIER -132.4 136.79 47.02 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.395 -0.816 . . . . 0.0 110.71 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.675 ' HB ' HG23 ' A' ' 15' ' ' ILE . 2.7 m -147.98 129.95 7.51 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 121.444 -0.785 . . . . 0.0 109.729 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.457 ' O ' HD11 ' A' ' 15' ' ' ILE . 50.9 Cg_endo -82.2 142.49 12.15 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.618 1.325 . . . . 0.0 111.347 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.662 HG23 HD11 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -143.93 164.3 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.49 -0.756 . . . . 0.0 109.514 179.301 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.419 ' O ' ' HG3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -79.53 -145.37 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.173 -0.954 . . . . 0.0 109.819 179.725 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.07 143.97 10.1 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' PRO . 1.0 OUTLIER -152.05 125.64 4.29 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.402 -1.058 . . . . 0.0 109.93 179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 36' ' ' ASP . 44.7 Cg_endo -74.85 -59.26 0.13 OUTLIER 'Cis proline' 0 N--CA 1.489 1.214 0 C-N-CA 122.25 -1.979 . . . . 0.0 110.732 -0.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . . . -115.97 130.6 24.28 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.404 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HG3' ' O ' ' A' ' 34' ' ' SER . 52.4 Cg_endo -83.91 -169.54 0.7 Allowed 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.794 1.418 . . . . 0.0 110.438 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 113' ' ' VAL . 1.9 m -120.74 86.15 2.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.457 -0.777 . . . . 0.0 109.434 179.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.825 HG11 ' HB3' ' A' ' 94' ' ' SER . 8.3 p -86.36 99.27 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.005 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.515 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 70.2 mt -87.07 107.93 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.554 -0.716 . . . . 0.0 111.254 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.912 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 80.1 m95 -72.18 102.87 3.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.219 -0.925 . . . . 0.0 109.45 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.404 ' CB ' ' O ' ' A' ' 110' ' ' THR . 1.0 OUTLIER -94.68 157.38 15.99 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.114 -0.991 . . . . 0.0 110.308 -179.862 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -117.09 163.45 16.23 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.377 -0.827 . . . . 0.0 110.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.432 ' HB3' ' HB ' ' A' ' 108' ' ' VAL . . . -136.37 91.83 2.71 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.455 -0.778 . . . . 0.0 110.126 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.623 HG22 ' O ' ' A' ' 47' ' ' ILE . 74.0 mt -138.38 26.95 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.586 -0.696 . . . . 0.0 109.402 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.2 t -125.4 39.41 3.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.46 -0.775 . . . . 0.0 110.188 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -62.16 146.78 49.65 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.338 -0.851 . . . . 0.0 110.139 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -150.3 -78.66 0.02 OUTLIER Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 -143.19 78.89 1.62 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.373 -1.074 . . . . 0.0 110.232 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.58 -157.68 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.461 -0.774 . . . . 0.0 110.283 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -56.11 174.06 0.26 Allowed Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.632 -0.667 . . . . 0.0 110.407 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 44.9 Cg_endo -71.7 167.24 27.06 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 O-C-N 123.788 1.415 . . . . 0.0 110.453 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 54' ' ' PRO . . . 59.93 106.96 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.439 -0.788 . . . . 0.0 110.249 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.91 88.42 36.02 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.854 . . . . 0.0 110.329 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.88 165.6 28.24 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.821 1.432 . . . . 0.0 110.458 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -127.29 87.43 56.39 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.387 -0.821 . . . . 0.0 110.202 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.58 143.03 37.35 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 O-C-N 123.761 1.401 . . . . 0.0 110.44 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.426 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 3.4 m-20 52.88 65.32 1.55 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.315 -0.866 . . . . 0.0 110.52 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.67 98.15 0.17 Allowed Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.621 -0.674 . . . . 0.0 110.377 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.426 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 51.2 Cg_endo -91.04 118.28 0.56 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.768 1.404 . . . . 0.0 110.458 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.09 100.74 6.67 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.441 -0.787 . . . . 0.0 110.252 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -100.41 162.88 12.65 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.331 -0.856 . . . . 0.0 110.186 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 21.4 p -93.56 16.43 13.72 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 110.468 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 61.02 -177.26 4.18 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -169.39 -162.43 0.35 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.427 -1.043 . . . . 0.0 110.039 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 12.4 p 49.19 31.23 3.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.431 -0.793 . . . . 0.0 110.702 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -60.42 -68.73 0.27 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.381 -0.824 . . . . 0.0 110.214 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -77.43 -172.08 2.37 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.324 -0.86 . . . . 0.0 110.075 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 72.5 t-105 -99.58 96.48 7.68 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.283 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.519 HG22 ' N ' ' A' ' 73' ' ' PHE . 7.3 p -62.37 168.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.356 -0.84 . . . . 0.0 110.311 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.519 ' N ' HG22 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -112.19 -165.73 1.02 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.557 -0.715 . . . . 0.0 110.078 179.875 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 53.2 p-10 -156.29 -170.72 3.45 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 110.374 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 1.7 mttm 52.95 -165.91 0.07 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.301 -0.875 . . . . 0.0 110.423 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.67 28.29 7.84 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.358 -0.839 . . . . 0.0 110.468 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.429 HD13 ' H ' ' A' ' 78' ' ' LEU . 0.1 OUTLIER -94.7 142.47 27.42 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 110.109 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.508 ' H ' HD12 ' A' ' 78' ' ' LEU . 3.5 mp -73.13 -53.18 11.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.898 . . . . 0.0 110.169 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 4.7 m -80.6 -9.36 59.79 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.379 -0.826 . . . . 0.0 110.543 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 55.67 47.71 20.02 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.178 -0.951 . . . . 0.0 110.293 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.6 p -130.05 -78.1 0.54 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.367 -0.833 . . . . 0.0 110.184 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -173.23 38.31 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.309 -0.869 . . . . 0.0 110.027 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 118.38 36.87 0.89 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 52.18 85.45 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.356 -1.084 . . . . 0.0 110.42 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.901 HG23 ' HB ' ' A' ' 98' ' ' VAL . 10.1 p -127.26 130.87 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.332 -0.855 . . . . 0.0 110.406 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -114.74 110.89 20.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.381 -0.824 . . . . 0.0 110.043 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.565 HG11 ' CD1' ' A' ' 43' ' ' TRP . 59.1 t -122.47 126.0 73.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 110.166 -179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -138.47 151.26 47.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.382 -0.824 . . . . 0.0 110.125 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 14.8 t -112.23 156.01 23.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.344 -0.847 . . . . 0.0 110.176 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.0 p -108.62 -168.21 1.32 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.459 -0.776 . . . . 0.0 110.233 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -50.95 -38.41 50.36 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.515 -0.741 . . . . 0.0 110.777 -179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -154.26 47.78 0.6 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.139 -0.976 . . . . 0.0 110.467 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 26.5 ttp180 -166.96 104.64 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.167 -0.958 . . . . 0.0 110.642 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.825 ' HB3' HG11 ' A' ' 41' ' ' VAL . 82.7 p -75.02 123.89 25.98 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.357 -0.84 . . . . 0.0 109.739 179.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.535 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.1 OUTLIER -110.01 136.88 44.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -0.916 . . . . 0.0 110.677 -179.499 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.67 ' HB3' HD23 ' A' ' 29' ' ' LEU . 12.4 t80 -119.1 98.98 6.44 Favored 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -124.92 108.85 12.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.342 -0.849 . . . . 0.0 110.046 -179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.901 ' HB ' HG23 ' A' ' 85' ' ' VAL . 4.3 p -121.84 140.48 45.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.668 -0.645 . . . . 0.0 110.162 -179.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -105.6 42.74 1.2 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.395 -0.815 . . . . 0.0 109.946 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.516 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -167.17 24.75 0.13 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.788 ' CB ' HG11 ' A' ' 21' ' ' VAL . . . -69.47 86.86 0.45 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.305 -1.115 . . . . 0.0 109.552 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.469 ' O ' HG21 ' A' ' 128' ' ' VAL . 1.4 tp10 -95.34 -175.99 3.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.421 -0.799 . . . . 0.0 110.456 -179.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -52.81 -32.98 46.93 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.331 -0.856 . . . . 0.0 110.185 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -64.64 -20.63 66.4 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.431 -0.793 . . . . 0.0 110.08 179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.78 -32.19 17.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.313 -0.867 . . . . 0.0 109.908 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -51.71 169.13 0.07 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.38 -0.825 . . . . 0.0 110.412 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 130.24 -124.98 4.5 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.228 -1.549 . . . . 0.0 109.228 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.432 ' HB ' ' HB3' ' A' ' 46' ' ' ALA . 65.9 t -140.71 152.35 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -1.094 . . . . 0.0 110.182 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.829 ' HB2' HD23 ' A' ' 124' ' ' LEU . 55.0 m-85 -138.29 157.03 47.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.393 -0.817 . . . . 0.0 110.248 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 44' ' ' GLN . 3.2 m -134.31 102.05 5.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.429 -0.794 . . . . 0.0 109.191 178.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.92 ' CG1' HG13 ' A' ' 122' ' ' VAL . 6.5 p -84.94 129.34 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.313 -0.867 . . . . 0.0 110.514 -179.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 17.2 m -115.72 124.85 51.87 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.83 . . . . 0.0 111.008 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.62 HG11 HG21 ' A' ' 33' ' ' ILE . 10.9 m -98.08 135.67 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.0 109.27 179.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -139.02 166.29 24.88 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.062 -1.024 . . . . 0.0 111.276 -179.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.503 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 m-20 -171.24 178.34 0.8 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.659 -0.651 . . . . 0.0 109.271 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.433 ' HD2' ' CB ' ' A' ' 115' ' ' ASN . 44.8 Cg_endo -72.37 0.25 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.504 1.265 . . . . 0.0 111.718 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.665 HG21 ' HG3' ' A' ' 2' ' ' GLN . 45.6 t -111.01 -32.97 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 120.855 -1.153 . . . . 0.0 110.69 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.492 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -174.61 -147.71 6.27 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.569 -1.301 . . . . 0.0 109.983 179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -169.47 149.26 3.94 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.318 -1.107 . . . . 0.0 110.554 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.428 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 0.6 OUTLIER -134.67 171.89 13.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.42 -0.8 . . . . 0.0 109.748 179.386 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . 0.409 ' C ' HG12 ' A' ' 122' ' ' VAL . 0.0 OUTLIER -147.14 165.47 29.88 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.199 -0.938 . . . . 0.0 110.957 -179.57 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.92 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -167.45 161.55 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 21.2 t30 -103.26 144.88 30.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.307 -0.87 . . . . 0.0 110.528 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.912 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.37 113.29 22.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.717 -0.615 . . . . 0.0 109.588 179.659 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 65.3 m -86.72 123.26 31.69 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.789 HG23 HG23 ' A' ' 19' ' ' ILE . 7.2 p -110.17 159.77 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.394 -0.817 . . . . 0.0 110.294 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 7.1 tptt -163.51 104.67 0.95 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.286 -0.884 . . . . 0.0 110.334 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.565 HG22 ' CG1' ' A' ' 21' ' ' VAL . 65.6 t -82.37 120.01 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.334 -0.854 . . . . 0.0 110.167 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.447 HG22 ' N ' ' A' ' 130' ' ' ASP . 39.1 mm -95.39 165.67 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.493 -0.754 . . . . 0.0 109.603 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.447 ' N ' HG22 ' A' ' 129' ' ' ILE . 9.3 t70 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.247 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 8.0 ptt180 . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.279 0.561 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.528 ' HG3' ' CG2' ' A' ' 117' ' ' VAL . 0.0 OUTLIER -145.69 -165.77 2.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.278 -0.889 . . . . 0.0 110.404 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -79.64 150.95 73.73 Favored Pre-proline 0 N--CA 1.493 1.714 0 O-C-N 121.229 -0.919 . . . . 0.0 110.754 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.556 ' HA ' ' HB ' ' A' ' 117' ' ' VAL . 40.5 Cg_endo -66.15 134.11 35.49 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 O-C-N 123.904 1.476 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.519 ' HG3' ' HB2' ' A' ' 115' ' ' ASN . 49.1 Cg_endo -70.19 151.87 66.83 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 O-C-N 123.934 1.492 . . . . 0.0 110.3 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 33' ' ' ILE . 0.5 OUTLIER -170.28 162.22 8.51 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.406 -0.809 . . . . 0.0 110.348 179.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.899 HG23 HD12 ' A' ' 15' ' ' ILE . 26.7 mm -86.7 35.36 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.486 -0.758 . . . . 0.0 110.626 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.46 ' C ' ' CD2' ' A' ' 8' ' ' HIS . 2.7 p-80 -118.47 174.84 6.02 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.943 -1.098 . . . . 0.0 110.244 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.554 HD11 ' HG2' ' A' ' 12' ' ' PRO . 0.2 OUTLIER -122.85 -102.77 0.39 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.319 -0.863 . . . . 0.0 110.756 -179.762 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -101.92 -24.38 14.02 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.627 -1.296 . . . . 0.0 111.159 -179.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.544 ' CB ' ' CD ' ' A' ' 12' ' ' PRO . 1.3 m -149.45 -67.23 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 120.992 -1.068 . . . . 0.0 111.758 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.554 ' HG2' HD11 ' A' ' 9' ' ' LEU . 44.0 Cg_endo -69.66 -93.08 0.01 OUTLIER 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.032 1.017 . . . . 0.0 110.568 -179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.442 ' CA ' ' HA ' ' A' ' 8' ' ' HIS . . . 119.98 50.04 0.29 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 5.2 mtt180 -109.56 91.46 3.66 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.411 -1.053 . . . . 0.0 110.089 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.899 HD12 HG23 ' A' ' 7' ' ' ILE . 2.0 mt -79.57 114.81 48.68 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.653 ' O ' HG22 ' A' ' 18' ' ' THR . 44.1 Cg_endo -71.94 60.71 3.03 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 O-C-N 123.629 1.331 . . . . 0.0 110.262 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.759 ' CA ' HD12 ' A' ' 124' ' ' LEU . 1.3 p30 -65.48 78.96 0.06 Allowed 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.504 -0.747 . . . . 0.0 110.608 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' PRO . 1.4 t -142.29 93.41 2.53 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.235 -0.916 . . . . 0.0 109.608 179.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.922 HG13 HD21 ' A' ' 27' ' ' LEU . 9.8 tp -88.26 116.63 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.114 -0.991 . . . . 0.0 110.739 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.904 ' O ' HD13 ' A' ' 27' ' ' LEU . 64.8 t -128.28 149.11 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.129 -0.982 . . . . 0.0 109.944 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.021 HG11 ' HB3' ' A' ' 101' ' ' ALA . 4.2 p -151.53 159.6 4.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 22' ' ' VAL . 58.7 t -94.14 52.86 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.364 -0.835 . . . . 0.0 110.337 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.419 ' HB2' HG12 ' A' ' 128' ' ' VAL . . . 44.8 96.26 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.657 -0.652 . . . . 0.0 111.642 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.14 48.53 7.52 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -139.36 157.16 46.35 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.337 -1.096 . . . . 0.0 110.257 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -62.29 107.34 0.89 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.414 -0.804 . . . . 0.0 109.859 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.922 HD21 HG13 ' A' ' 19' ' ' ILE . 4.8 tp -110.72 134.3 52.58 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.212 -0.93 . . . . 0.0 110.495 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.593 ' N ' HD12 ' A' ' 27' ' ' LEU . 3.7 ptt180 -133.88 141.93 47.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.587 -0.696 . . . . 0.0 109.594 179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.73 HD21 HD11 ' A' ' 124' ' ' LEU . 59.3 tp -141.95 128.63 20.37 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.19 -0.944 . . . . 0.0 110.099 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.74 ' OD2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -124.32 137.75 54.45 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.515 -0.741 . . . . 0.0 110.841 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.655 ' HB ' HG23 ' A' ' 15' ' ' ILE . 11.2 m -147.33 116.09 4.3 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.444 -0.785 . . . . 0.0 109.753 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.506 ' HG2' HD23 ' A' ' 9' ' ' LEU . 44.3 Cg_endo -71.15 148.12 55.48 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.364 1.192 . . . . 0.0 111.171 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.578 HG22 ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -144.67 -174.91 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.528 -0.732 . . . . 0.0 109.721 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.95 -144.93 0.31 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.306 -0.871 . . . . 0.0 109.744 179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 96.86 151.08 27.62 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.8 t0 -152.3 108.5 2.79 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.369 -1.077 . . . . 0.0 109.904 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -70.11 -81.03 0.0 OUTLIER 'Cis proline' 0 N--CA 1.49 1.282 0 C-N-CA 122.275 -1.969 . . . . 0.0 110.934 0.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -104.84 138.68 19.58 Favored Pre-proline 0 N--CA 1.491 1.624 0 O-C-N 121.063 -1.023 . . . . 0.0 110.297 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -78.79 -168.61 0.65 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.737 1.388 . . . . 0.0 110.637 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.97 86.16 2.36 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.861 HG11 ' HB3' ' A' ' 94' ' ' SER . 9.5 p -85.87 102.55 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 CA-C-O 121.649 0.737 . . . . 0.0 110.123 -179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.559 ' O ' ' HA ' ' A' ' 111' ' ' VAL . 93.9 mt -93.18 106.76 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.805 . . . . 0.0 111.394 -178.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.975 ' CZ3' HD13 ' A' ' 124' ' ' LEU . 88.8 m95 -70.77 102.69 2.39 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.262 -0.899 . . . . 0.0 109.811 178.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.456 ' HB2' ' O ' ' A' ' 110' ' ' THR . 36.5 mt-30 -89.99 156.11 18.64 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.963 -1.086 . . . . 0.0 109.684 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.436 ' HB3' ' CE2' ' A' ' 109' ' ' TYR . 24.6 pttt -124.58 159.12 31.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.234 -0.916 . . . . 0.0 110.666 -179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -131.89 91.43 2.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.526 -0.733 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 104' ' ' GLU . 72.1 mt -133.72 28.02 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.574 -0.704 . . . . 0.0 109.364 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.8 t -117.44 30.54 7.23 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.495 -0.753 . . . . 0.0 110.278 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 61.6 mm-40 -101.11 -34.07 9.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.346 -0.847 . . . . 0.0 110.07 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -162.4 146.4 11.88 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -138.45 -64.11 0.53 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.329 -1.101 . . . . 0.0 110.209 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.33 -160.56 0.74 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.324 -0.86 . . . . 0.0 110.234 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 54' ' ' PRO . . . -86.2 171.35 10.51 Favored Pre-proline 0 N--CA 1.492 1.634 0 O-C-N 121.59 -0.694 . . . . 0.0 110.269 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 53' ' ' ALA . 45.8 Cg_endo -72.34 166.78 28.75 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.695 1.366 . . . . 0.0 110.389 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -163.45 74.61 0.35 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.373 -0.829 . . . . 0.0 110.34 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.6 ttt180 -119.31 73.75 14.79 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.326 -0.858 . . . . 0.0 109.96 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -73.26 -166.49 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.012 1.533 . . . . 0.0 110.556 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 59' ' ' PRO . . . -61.6 171.15 1.46 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 110.213 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 58' ' ' ALA . 46.3 Cg_endo -73.06 110.75 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.702 1.37 . . . . 0.0 110.442 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.418 ' O ' ' CD ' ' A' ' 62' ' ' PRO . 51.2 m-20 -133.04 66.17 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.371 -0.831 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -42.58 98.26 0.17 Allowed Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.619 -0.676 . . . . 0.0 110.305 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.418 ' CD ' ' O ' ' A' ' 60' ' ' ASP . 52.5 Cg_endo -91.01 152.16 3.88 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.799 1.42 . . . . 0.0 110.489 -178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -81.59 170.86 15.33 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.396 -0.815 . . . . 0.0 110.191 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 -95.52 85.11 4.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.454 HG22 ' O ' ' A' ' 65' ' ' THR . 21.1 m -148.03 40.03 0.95 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.394 -0.816 . . . . 0.0 110.207 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.68 -97.0 0.52 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -90.17 157.09 17.89 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.332 -1.099 . . . . 0.0 110.197 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.2 t -70.69 78.16 0.6 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.169 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.52 173.25 2.8 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.422 -0.798 . . . . 0.0 110.262 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -121.51 -166.19 1.34 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.418 -0.802 . . . . 0.0 110.168 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 67.2 t-105 -73.7 174.86 7.78 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.335 -0.853 . . . . 0.0 109.914 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.575 HG12 ' O ' ' A' ' 72' ' ' VAL . 49.6 t -86.86 14.32 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.16 -0.962 . . . . 0.0 110.838 -179.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -56.11 -173.08 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.063 -1.023 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -129.69 140.7 51.06 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.369 -0.832 . . . . 0.0 110.272 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 4.4 tptp -168.74 -47.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.441 -0.787 . . . . 0.0 110.132 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 154.77 32.34 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.352 -0.842 . . . . 0.0 110.201 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.13 177.59 8.94 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -0.873 . . . . 0.0 110.166 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -114.83 43.02 2.04 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.367 -0.833 . . . . 0.0 110.208 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -141.93 50.39 1.54 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.324 -0.86 . . . . 0.0 110.357 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.04 67.24 3.84 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.02 25.82 10.47 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.42 -0.8 . . . . 0.0 110.286 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 51.11 82.36 0.06 Allowed 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.298 -0.876 . . . . 0.0 110.505 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.81 9.62 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 59.64 107.8 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.266 -1.138 . . . . 0.0 110.224 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.771 ' HA ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -68.61 144.77 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.274 -0.891 . . . . 0.0 109.954 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -97.42 94.74 7.21 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.211 -0.93 . . . . 0.0 109.919 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.709 HG22 ' CD1' ' A' ' 96' ' ' PHE . 16.4 t -112.51 137.84 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.445 -0.784 . . . . 0.0 110.191 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -168.2 150.63 5.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.412 -0.805 . . . . 0.0 110.264 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.4 m -103.44 155.38 18.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 93' ' ' ARG . 5.3 t -117.96 -165.59 1.12 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.21 -0.931 . . . . 0.0 111.004 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.4 mttm -41.34 -48.03 3.61 Favored 'General case' 0 N--CA 1.499 2.014 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -154.31 47.07 0.59 Allowed 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.516 -1.365 . . . . 0.0 111.954 -179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.772 ' O ' HG22 ' A' ' 90' ' ' THR . 4.7 ptp180 -177.79 119.75 0.1 Allowed 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -0.951 . . . . 0.0 110.312 178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.861 ' HB3' HG11 ' A' ' 41' ' ' VAL . 84.0 p -74.24 124.93 27.33 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.521 -0.737 . . . . 0.0 110.412 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.74 HD11 ' OD2' ' A' ' 30' ' ' ASP . 0.5 OUTLIER -111.77 130.51 65.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.419 -0.801 . . . . 0.0 109.74 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.709 ' CD1' HG22 ' A' ' 87' ' ' VAL . 1.2 t80 -114.41 95.85 5.47 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.31 -0.869 . . . . 0.0 109.595 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -119.85 121.83 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.437 -0.79 . . . . 0.0 109.599 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.771 HG23 ' HA ' ' A' ' 85' ' ' VAL . 3.0 p -131.52 135.04 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.405 -0.81 . . . . 0.0 110.423 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -101.06 45.51 0.97 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.367 -0.833 . . . . 0.0 109.773 179.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.454 ' H ' HG22 ' A' ' 98' ' ' VAL . . . -177.82 31.53 0.07 OUTLIER Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 1.021 ' HB3' HG11 ' A' ' 21' ' ' VAL . . . -70.23 83.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.333 -1.098 . . . . 0.0 109.699 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.454 ' O ' HG21 ' A' ' 128' ' ' VAL . 2.7 mt-10 -92.51 -169.57 2.25 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.261 -0.899 . . . . 0.0 110.519 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 2.2 mmtt -52.76 -34.35 52.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.432 -0.793 . . . . 0.0 110.198 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 47' ' ' ILE . 10.0 mm-40 -60.29 -25.0 65.4 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.361 -0.837 . . . . 0.0 109.799 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -91.27 -32.17 15.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.434 -0.791 . . . . 0.0 109.824 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -52.32 166.34 0.18 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.366 -0.834 . . . . 0.0 110.359 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' O ' HG12 ' A' ' 126' ' ' VAL . . . 125.52 -124.2 5.18 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 71.3 t -142.14 156.83 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -1.035 . . . . 0.0 110.233 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.627 ' HE1' HG11 ' A' ' 126' ' ' VAL . 52.2 m-85 -138.11 152.19 48.51 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.438 -0.789 . . . . 0.0 110.558 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 44' ' ' GLN . 6.9 m -132.66 101.69 5.39 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.897 ' CG1' HG13 ' A' ' 122' ' ' VAL . 4.2 p -85.59 131.49 34.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.144 -0.972 . . . . 0.0 110.75 -178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' THR . . . . . . . . . . . . . 15.5 m -115.98 122.64 45.86 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.427 -0.796 . . . . 0.0 110.831 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.526 HG11 ' CD1' ' A' ' 7' ' ' ILE . 6.6 m -95.4 128.52 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.452 -0.78 . . . . 0.0 108.93 178.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.72 165.47 22.82 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.016 -1.053 . . . . 0.0 111.297 -179.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.519 ' HB2' ' HG3' ' A' ' 5' ' ' PRO . 1.3 t-20 -172.36 172.1 1.86 Allowed Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.596 -0.69 . . . . 0.0 109.149 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.26 -5.09 15.71 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 123.551 1.29 . . . . 0.0 111.636 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.556 ' HB ' ' HA ' ' A' ' 4' ' ' PRO . 27.5 t -105.32 -35.84 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.878 -1.139 . . . . 0.0 110.549 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.417 ' C ' ' HG2' ' A' ' 5' ' ' PRO . . . -169.4 -151.42 7.28 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.521 -1.323 . . . . 0.0 109.858 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -169.22 148.1 3.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.397 -1.061 . . . . 0.0 110.365 179.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' CB ' ' CG2' ' A' ' 113' ' ' VAL . 1.1 t0 -133.77 172.46 12.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.321 -0.862 . . . . 0.0 109.84 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -146.12 155.47 42.77 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.211 -0.931 . . . . 0.0 110.843 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . 0.897 HG13 ' CG1' ' A' ' 111' ' ' VAL . 0.2 OUTLIER -159.7 160.61 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 179.536 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -108.06 140.26 41.49 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.305 -0.872 . . . . 0.0 110.509 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.975 HD13 ' CZ3' ' A' ' 43' ' ' TRP . 0.4 OUTLIER -116.43 119.39 35.47 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.562 -0.711 . . . . 0.0 109.682 179.655 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' THR . . . . . . . . . . . . . 3.7 m -82.39 144.05 30.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.398 -0.813 . . . . 0.0 110.376 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.739 HG23 HG23 ' A' ' 19' ' ' ILE . 7.4 p -129.37 159.64 41.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.347 -0.845 . . . . 0.0 110.138 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -168.1 112.68 0.64 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.283 -0.885 . . . . 0.0 110.315 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 102' ' ' GLU . 64.2 t -92.33 119.43 39.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.339 -0.851 . . . . 0.0 110.021 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 130' ' ' ASP . 37.9 mm -92.96 163.23 2.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.385 -0.822 . . . . 0.0 109.441 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 129' ' ' ILE . 1.4 t0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.253 -179.913 . . . . . . . . 1 1 . 1 stop_ save_